Technological University Dublin

ARROW@TU Dublin
Doctoral

Science

2020-5

Novel Therapeutic Approaches to Treat Brain Cancer Combining
Cold Atmospheric Plasma, Therapeutic Prodrugs and Gold
Nanoparticles
Zhonglei He
Technological University Dublin

Follow this and additional works at: https://arrow.tudublin.ie/sciendoc
Part of the Medical Education Commons

Recommended Citation
Zhonglei, H. (2020) Novel Therapeutic Approaches to Treat Brain Cancer Combining Cold Atmospheric
Plasma, Therapeutic Prodrugs and Gold Nanoparticles, Doctoral Thesis, Technological University Dublin.
doi:10.21427/4661-1k23

This Theses, Ph.D is brought to you for free and open
access by the Science at ARROW@TU Dublin. It has been
accepted for inclusion in Doctoral by an authorized
administrator of ARROW@TU Dublin. For more
information, please contact arrow.admin@tudublin.ie,
aisling.coyne@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Novel Therapeutic Approaches to Treat Brain
Cancer Combining Cold Atmospheric Plasma,
Therapeutic Prodrugs and Gold Nanoparticles

Submitted by
Zhonglei He, B.Sc.
PhD

School of Food Science and Environmental Health
Technological University Dublin

Supervisors:
Prof. James F. Curtin, Dr. Furong Tian, Prof. Patrick J. Cullen

May 2020
i

Abstract
Glioblastoma Multiforme (GBM) makes up approximately 45% of all primary brain
tumours. State of the art treatment at present involves concurrent and adjuvant
temozolomide (TMZ) with radical radiotherapy which extends median survival from 12.1
months (radical radiotherapy alone) to 14.6 months according to the study of the
European Organization for Research and Treatment of Cancer (EORTC) Brain Tumour
and Radiotherapy Groups and the National Cancer Institute of Canada (NCIC) Clinical
Trials Group. Meanwhile, National Cancer Registry Ireland presented that GBM
represents over 40% of all malignant brain tumours and had the worst five-year net
survival (4%) compared to overall malignant brain cancer (five-year net survival, 19%)
in Ireland. Long term survival of patients with GBM has not been significantly improved
in the last 20 years. GBM tumours also have presented high level of resistance to normal
treatments. Therefore, novel therapies to treat GBM are urgently needed. This study
aimed to investigate efficient therapeutic methods by combining novel interventions,
including cold atmospheric plasma (CAP), gold nanoparticles (AuNPs) and specific
chemotherapeutic compounds to overcome the barriers of GBM treatment. Over the past
decade CAP has emerged as a novel approach in health care area, especially cancer
therapy. CAP generates chemically active species such as reactive oxygen species (ROS)
and reactive nitrogen species (RNS) and has been demonstrated to act in synergy with a
selection of traditional chemotherapeutic compounds which could reduce the effective
concentrations of drugs needed at the tumour and may allow for targeted toxicity at sites
exposed to the plasma field. AuNPs, well known as biocompatible drug delivery and
diagnosis agents for cancer therapy, have been demonstrated to have synergistic anticancer effects in combination with CAP treatment.
In this project, for the first time, we investigated and described the detailed mechanism
ii

behind the synergistic anti-cancer effects between AuNPs and CAP treatment. Chapter 2
and Chapter 3 demonstrated that low dose treatment of CAP treatment was capable of
promoting the uptake of AuNPs into glioblastoma U373MG cells via stimulated
membrane repair clathrin-dependent endocytosis. The intracellular accumulation of
AuNPs was tracked using atomic absorbance spectrometry (AAS) and simulated with
numerical modelling to identify the enhanced uptake routine. AuNPs were tracked into
early endosomes, late endosomes and finally lysosomes using specific fluorescent probes
and confocal microscope. The lipid oxidation of cancer cells induced by CAP treatment
was confirmed by various methods, including confocal microscopy, Thiobarbituric Acid
Reactive Substances (TBARS) assay and flow cytometry. Meanwhile, the related
endocytosis pathway was determined to be clathrin dependent using multiple clathrin and
caveola specific inhibitors and clathrin siRNA.
In Chapter 4, we performed the screening of 47 prodrug candidates for their cytotoxicity
against U373MG cells in combination with CAP treatment. The selection of
chemotherapeutic compounds provided by collaborators have been tested to determine
dose response curves with or without CAP treatment using Alamar Blue assay, thus, to
characterise their synergistic potential in combination with CAP. Two leading candidates
which showed significant cytotoxicity with CAP, have been identified from 47
compounds. Furthermore, the mechanism behind the synergistic cytotoxicity between
one of the leading candidates, JW-04-061, and CAP treatment has been investigated. It
has been demonstrated that reactive species, especially short-lived species, generated in
culture medium may play a main role in the oxidation and activation of the prodrug during
CAP treatment.
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1.1

Brain Cancer

As technology improves, the survival rates of certain types of cancer, such as lung and
breast cancer, have changed dramatically during recent years. However, only small
improvements were made in brain cancer treatment. Brain cancers are divided in two
types, primary brain cancer and secondary brain cancer (Young et al., 2015). Primary
brain cancer originates in brain cells, forms in the central nervous system (CNS) and
usually does not metastasize to the outside of the CNS. Secondary brain malignancy is
formed by tumours cells metastasized from outside of CNS, such as lung cancer and
breast cancer (Young et al., 2015). Although secondary brain cancer is more common,
primary brain cancer is more deadly, which is the third leading cause of cancer deaths in
age 15-34 adults and the most common cause of neoplasm deaths in children (Mladenov
et al., 2007). Primary brain cancer can be classified as gliomas and nongliomas according
to the origination (as described in Table 1 below).
Table 1. Main types of primary brain cancer
Gliomas

Astrocytomas, Oligodendrogliomas, Ependymomas

Nongliomas

Menigiomas, Medulloblastomas

Gliomas are developed from glial cells, including astrocytes, oligodendrocytes and
ependymal cells or mixed of the above (Parsons et al., 2008). Glial cells are non-neuronal
cells in CNS and the peripheral nervous system which mainly provide protection and
support for neurons (Jessen and Mirsky, 1980). Most common types of nongliomas
include meningiomas, tumours that are developed in the meninges (Marta, Correa and
Teixeira, 2011), and medulloblastomas, primitive neuroectodermal tumour that is raised
in the cerebellum and commonly represents in childhood brain tumours (Schroeder and
Gururangan, 2014).
9

Astrocytomas are the most common type (representing approximately 50%) in the above
primary brain cancer. According to the World Health Organization (WHO), astrocytomas
are classified into 4 types, including pilocytic astrocytoma (Grade 1), low-grade
astrocytoma (Grade 2), anaplastic astrocytoma (Grade 3), glioblastoma (Grade 4) (Young
et al., 2015). Grade 1 pilocytic astrocytomas glow slowing and typically can be cured by
surgical excision (Louis et al., 2016). Low-grade astrocytomas, also known as diffuse
astrocytomas, have higher possibility to recur and may further progress to higher grade
astrocytomas, thus regarded as malignant tumours (Louis et al., 2016). WHO grade 3
and 4 astrocytomas grow much faster compared to the previous tumours mentioned above,
when surgical excision is more difficult to be performed completely (Young et al., 2015).
Thus, radiation therapy and chemotherapy are typically applied to control the progress of
malignancy and extend survival.

1.2

Glioblastoma Multiforme

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most invasive brain
malignancy and the most common primary brain cancer among the previous tumours
mentioned in section 1.1, accounts for 60-75% of astrocytic tumours and 15% of
intracranial tumours in adults (Young et al., 2015). The term glioblastoma multiforme
was first defined by Harvey Cushing and Percival Bailey in 1926, as the name implies,
GBM is developed from glial cells, and presents highly various morphologies, as well as
variable levels of cellular and nuclear polymorphism, which also is able to induce
multiple symptoms, including cysts, haemorrhage and necrosis (Møller et al., 2013).
Even “multiforme” is currently not used in WHO classification, GBM is still commonly
accepted in the literature as abbreviation synonymous with glioblastoma.
The most common symptoms of GBM include changes to personality, headaches,
localized neurological problems, memory loss, mood or concentration, nausea, seizure
10

and vomiting (Alifieris and Trafalis, 2015). However, the type of symptoms induced has
no specificity and mainly depends on the location of the neoplasm. Computed
tomography (CT), Magnetic resonance imaging (MRI), Magnetic resonance spectroscopy
(MRS) are commonly used to view suspected GBM. Craniotomy with tumour resection,
stereotactic biopsy and pathology are typically required for definitive diagnosis.
Furthermore, based on histological confirmation and genetic analysis, GBM can be
divided into primary and secondary subtype. Primary GBM directly originates from glial
cells (de novo), and develops faster, presenting much worse prognosis compared to
secondary GBM. Secondary GBM is progressed from lower-grade (WHO Grade 2)
astrocytoma which has been previously clinical identified. It should be noted that, as
mentioned in section 1.1, all primary and secondary subtypes of GBM originate in brain
cells, which are all primary brain cancer. Due to the difference between primary and
secondary GBM, it is crucial to distinguish these two subtypes, especially identify
primary glioblastoma to determine tumour therapy and prognosis. Although, primary and
secondary GBM cannot be differentiate morphologically, clinical statistic presented that
primary GBM was frequently diagnosed in patients older than 60 years, whereas
secondary GBM more commonly occurred in patients younger than 45 years. The genetic
make-up of primary and secondary GBM can be distinguished. The genetic alternation in
primary GBM more commonly (40-50%) presents as over expression of Epidermal
Growth Factor Receptor (EGFR), whereas tumour suppressor protein (TP53) mutations
were usually (~60%) identified in secondary GBM (Riemenschneider et al., 2010).
However, the current common chemotherapy agents showed little efficacy in the
treatment of primary GBM which develops faster and has worse prognosis compared to
secondary GBM (Clarke, Butowski and Chang, 2010; Tabunoki et al., 2012). Therefore,
efficient novel therapy for primary GBM is urgently needed. The following sections will
11

focus on primary GBM treatment. U373MG glioma cell line was used for investigation
of the treatment against primary GBM in this project. In the following sections, the term
‘GBM’ was used to present primary GBM.
Surgery typically is applied after diagnosis of GBM to remove the tumour as much as
possible, followed by aggressive treatment, including radiotherapy or chemotherapy or
combining of them (Gallego, 2015). TMZ is commonly used in chemotherapy, which is
considered having relatively efficient killing effect to GBM cells compared with other
drugs, therefore is used in standard treatment following maximal surgical resection (75
mg/m2 TMZ daily, together with 60 Gy radiotherapy for 6 weeks) (Hart et al., 2013;
Khosla, 2016). However, even when aggressive treatment was applied after operation,
the neoplasm usually will recur and the prognosis is very dismal (Gallego, 2015). The
length of survival is 12-15 month following diagnosis in most cases, and only less than
3%-5% of patients survived longer than 5 years. The median survival without treatment
is merely 3-4 months (Omuro and DeAngelis, 2013; Gallego, 2015).
The largest cause of treatment failure is the strong resistance of GBM tumours to
conventional therapies, including radiotherapy and chemotherapy. Tumour hypoxia is
that tumour cells alter their metabolism to survival under oxygen deficit situation. As
tumours grow, the insufficient blood supply and rapid proliferating of tumour cells limit
the oxygen diffusing further into core area of the tumour. Therefore, to survive and
proliferate under low oxygen condition, those hypoxic tumour cells dramatically changed
their signalling pathway and following behaviour, which can lead to the resistance to
radiotherapy compared to well-oxygenated cells (Gilkes, Semenza and Wirtz, 2014).
Hypoxia is well known to exhibit in portions of GBM tumours. Spontaneous necrosis was
frequently found in GBM tumours and considered as result of hypoxia (Brat et al., 2004).
In 1994, Rampling et al. proved that hypoxic regions are present in glioblastomas via
12

directly measuring the oxygen level (varies from 9.5% to 68.5%, pO2) in tumours from
10 patients (Rampling et al., 1994). Oxygen plays the key role in the cytotoxicity of
ionizing radiation. The free electron of the free radical in DNA caused by ionizing
radiation, can aggressively react with oxygen then causes covalent modification of DNA
leading to damage of tumour cells and alteration of the sensitivity of tumour cells to other
DNA damaging agents.
However, under hypoxic conditions, the radical in DNA can be ‘neutralized’ when
obtained hydrogen from non-protein sulfhydryls in tumour cells, which gives
glioblastomas strong resistance to ionizing radiation (Brown, 1999). The alteration of
signalling pathways in the absence of oxygen, such as hypoxia-inducible factor (HIF-1)
and following pathways, also have been indicated that induce resistance to radiotherapy.
At present, TMZ has been approved by the US Food and Drug Administration (FDA) and
used as standard chemotherapy in GBM treatment. TMZ can alkylate the guanine base of
DNA, thus leading to cell damage (Figure 1). Meanwhile, this alkylating agent can be
effectively transported through the blood brain barrier (BBB) and get into GBM cells. As
seen in Figure 1, TMZ acts a prodrug which is stable at acidic pH but labile above pH 7
and spontaneously breaks down to form monomethyl triazene 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) (Zhang et al., 2011). MTIC then reacts with water to
release

5-aminoimidazole-4-carboxamide

(AIC)

and

the

highly

reactive

methyldiazonium cation which methylates DNA (Tisdale, 1987; Zhang et al., 2011).
Although the extracellular pH level in the environment of cancer cells is lower than that
around normal cells whereas the acidic products/protons generated during rapid
metabolism of cancer cells are actively transported to the extracellular space via Na+/H+
exchangers, Na+HCO3– transporters, Cl–/HCO3– exchangers and monocarboxylate
transporters (MCT), etc. (Hjelmeland et al., 2011). The average intracellular pH level of
13

brain tumours was found to be 7.31, slightly higher than normal brain cells (7.24) (Hao,
Xu and Li, 2018). In this case, GBM cells possess a more alkaline pH compared with
healthy tissue, therefore favouring TMZ activation preferentially within tumour tissue
DNA (Rottenberg et al., 1984; Zhang et al., 2011).

Figure 1. Structure and activation route of prodrug temozolomide (Zhang et al., 2011).
However, it has been demonstrated that glioblastomas also present resistance to TMZ
treatment (Mirimanoff et al., 2007; Hegi et al., 2008). The enzyme, methylguanine
methyltransferase (MGMT), can attach to damaged DNA and obtain the alkyl group from
guanine. The alkylated MGMT then will be detached and finally be degraded via
ubiquitin/proteasomal system (Zhang et al., 2011). The expression level of MGMT is
increased in GBM cells, thus resulting in resistance to TMZ treatment. Meanwhile, it has
been found that TMZ has little or no effect on prognosis in up to half GBM
(FERNANDES et al., 2017).
Various radiosensitizers, such as oxygen diffusion-enhancing compound trans sodium
crocetinate, have been investigated in preclinical and clinical trials with limited success
(Gainer et al., 2017). More powerful techniques, molecular targeted therapy (such as HIF1 inhibitors) and hypoxia-selective drugs, etc. were investigated to beat glioblastomas
(HARADA, 2011). However, the limitations of conventional treatment in GMB therapy
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haven’t been overcome and novel efficient therapeutic methods with low side effects are
still urgently needed.

1.3

Plasma

Plasma is one of the four fundamental states of matter which is a form of ionized gas,
usually, and accounts for most of the known Universe’s matter. Its early stage of
biomedical applications is focus on the heat and high temperature of thermal plasma for
the purpose of tissue removal, sterilization, and cauterization (Fridman et al., 2008).
1.3.1 Clinical Application of Hot Plasmas
Hot plasmas, also known as high temperature/thermal plasmas, have been widely used
for sterilization, blood coagulation, tissue ablation and tumour therapy, etc. The high
temperature and kinetic energy generated by thermal plasmas device are utilized to
coagulate, cut or ablate tissue surfaces (Heinlin et al., 2010; Gibson and Suslov, 2012).
In the mid-1970s, Glover et al. first reported a convenient thermal plasma device with a
nozzle that was capable of generating high power density of plasma flow by a low gas
flow, which was able to both coagulate and cut tissue and showed that plasma scalpel is
effective in cauterizing blood vessels and causes less damage compared with
steel/electrosurgical scalpels (Link, Incropera and Glover, 1976). This design rapidly
gained ground in surgical operation and has been developed further to invent the
PlasmaJet system.
The PlasmaJet system has been used in clinical surgery since 2004, using small scale,
high-thermal and high-kinetic argon plasma jet to effectively ablate, coagulate a tissue
surface (Roman et al., 2013). The PlasmaJet causes slight thermal tissue damage (seldom
more than 600 μm) with the formation of a filmy coagulum (Deb et al., 2010). It has
shown safety and high performance in plastic surgery, hepatic surgery, gastroenterology,
orthopedics and thoracic surgery (Nezhat and Kho, 2009). More recently, PlasmaJet and
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other thermal plasma devices have been investigated as safe and effective modalities for
treatment of tumours which are untreatable by surgery (Sagawa et al., 2003; Roman et
al., 2013). For instance, using PlasmaJet in ablation of endometrioma showed
encouraging recurrence and pregnancy rates compared with the best reported results of
endometrioma cystectomy, may be due to the fact that the surgeon can select appropriate
degree of completeness of treatment and keep enough normal endometrial tissues by the
plasma operation (Roman et al., 2013). Meanwhile, electrically neutral thermal argon
plasma technology has been demonstrated that can maximize cancer cell killing effects
and decrease tumour burden in several cases of epithelial ovarian cancer (Renaud and
Sebastianelli, 2013). In gynecological oncology cases, PlasmaJet also is used to minimize
the damage to the underlying tissue when removing secondary tumour from the sensitive
or vital structures, such as ureter, bowel and liver (Madhuri et al., 2010).
1.3.2 Cold Atmospheric Plasma
Technological advances have allowed researchers to generate cold atmospheric plasma
which possesses ambient temperatures and approximately 1.0 atmospheric pressure,
compared to hot plasma. Even though hot and cold plasma are both generated by adding
energy to a gas, releasing electrons from nuclei of atoms, electrons in cold plasma can be
at several million K whereas the nucleus of atoms are at room temperature
(thermodynamic disequilibrium state). These are known as cold (or non-thermal/low
temperature) atmospheric plasmas. The application of cold atmospheric plasma allows
direct treatment of cells or live tissues with ionised gases without risking thermal injury.
Cold atmospheric plasma (CAP) has been investigated as a promising technique for
therapies in various fields. Known biomedical applications of CAP include cancer
therapy (Keidar et al., 2011), sterilization (Zelzer et al., 2012), wound healing (Isbary et
al., 2012) blood coagulation (Kalghatgi et al., 2007) and viral destruction (Shi et al.,
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2012). CAP has also been investigated as a novel method to enhance cell transfection
(Leduc et al., 2009) and promote cell proliferation (Kalghatgi et al., 2010).
CAP generates a unique physical and chemical environment activating short- and longlived reactive nitrogen species (RNS, e.g. peroxinitrite (ONOO-), nitric oxide radicals
(NO)) and reactive oxygen species (ROS, e.g. hydroxyl radicals (OH), oxygen atoms (O),
oxygen negative ions (O2-)), photons as well as generation of heat, pressure gradients,
charged particles, and electrostatic and electromagnetic fields (Stoffels, Kieft and Sladek,
2003; Kong, Keidar and Ostrikov, 2011; Babington et al., 2015), many of which are
known to induce biological effects. For example, peroxinitrite (ONOO-), which also
occurs naturally (Babington et al., 2015), can initiate lipid peroxidation reactions and help
to protect against infection during inflammation (Patel et al., 1999) whereas ROS can
cause damage to DNA and induce apoptosis by activating the cell death receptors in the
TNF/NGF-family (Stoffels, Sakiyama and Graves, 2008). These high flux of ROS also
have significant effect in inactivating fungi, virus and bacteria (Fridman et al., 2008;
Kong et al., 2009; Park et al., 2014).

Figure 2. The dielectric barrier discharge (DBD) plasma source (Lu et al., 2014).
CAP can be generated by several different principles such as dielectric barrier discharge
(DBD) plasma sources, atmospheric pressure plasma jet and corona discharge plasma
sources (Weltmann et al., 2008; Hähnel, Von Woedtke and Weltmann, 2010; Ehlbeck et
al., 2011; Wu et al., 2011; Park et al., 2012; Haertel et al., 2014; Babington et al., 2015).
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Different gases such as air, argon, helium, oxygen and nitrogen can be used which alter
the physical and chemical properties of the CAP (Babington et al., 2015). Cold
atmospheric plasmas can be divided into three types in accordance with the interaction
with target cells / tissues: direct plasmas, indirect plasmas and hybrid plasmas (Kong et
al., 2009).
The dielectric barrier discharge (DBD) plasma source is known as the most widely used
direct plasma. The electrical discharge is generated between two electrodes separated by
a dielectric barrier. The dielectric cannot pass direct current and prevents the rise of arcing
after breakdown (Kuchenbecker et al., 2009). The prototype DIT-120, DBD plasma
source used in this project, consists of two circular aluminium plate electrodes over
perspex dielectric layers, a high voltage transformer and a voltage variac (Figure 2). The
applied voltage to the electrode is obtained from the voltage transformer (Lu et al., 2014;
Pankaj et al., 2014). The two electrodes are separated by a dielectric barrier and the
discharge is generated between these two electrodes to ionize gas and create plasma
(Babington et al., 2015). The treated sample has direct contact with all agents in DBD.
The main difference between indirect plasmas and direct plasma is that the plasmas
generated between two electrodes are then mixed into a gas flow to treat samples remotely
in indirect plasmas devices. This technology is also called the atmospheric pressure
plasma jet, Figure 3 (Cullen and Milosavljević, 2015), and has developed various devices
from large ‘plasma torches’ to very narrow ‘micro plasma jet’ (Laroussi, 2002; Kieft,
Laan and Stoffels, 2004; Sladek and Stoffels, 2005; H. W. Lee et al., 2009; Kong et al.,
2009; Babington et al., 2015) . Corona discharge plasma source is also known as ‘barrier
coronal discharges (BCD)’, BCD introduce a grounded wire mesh electrode and combine
the current-free property of indirect plasmas and the production technique of direct
plasmas (Morfill et al., 2009). As seen in Figure 4, the BCD device can be safely applied
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on human body for disinfection.

Figure 3. kINPen® MEDTM plasma source.
Photograph of kINPen® MEDTM plasma source (right) with the schematic of the entire
system (left). It’s a commercially available plasma jet with pure argon as a carrier gas
(Cullen and Milosavljević, 2015).

Figure 4. ‘HandPlaSter’, a prototype of corona discharge plasma source (Morfill et al.,
2009).
Cold atmospheric plasmas have been proved to have various effects on mammalian cells,
such as stimulating proliferation or inducing proliferation arrest, necrosis and apoptosis.
All these responses are dependent on the type and dose of CAP and the type of cell being
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treated (Kim et al., 2010; Kalghatgi et al., 2011). At present, it is promising that there are
a great variety of CAP generating prototypes and commercial cold atmospheric plasma
devices. With different devices, by alternation of gas types, voltage, frequent and current
of energy input, etc., the dose and location of applied CAP can be precisely and easily
controlled to induce specific reaction to targeted area (Adhikari et al., 2020). Most
importantly, cancer cells are generally sensitive to low doses of CAP and can
subsequently undergo apoptosis. These doses often do not produce any measurable
cytotoxic effect on corresponding normal cells (Ahn et al., 2011; Keidar et al., 2011; Siu
et al., 2015). As described above, the wide range and high amounts of reactive oxygen
species and reactive nitrogen species (ROS/RNS) generated by plasma were proposed to
play the major role in the selective cytotoxicity (Walk et al., 2013). It also showed that
CAP can likely induce cancer cells to produce more of their own ROS/RNS (Keidar et
al., 2011). However, the exact mechanism of CAP is not fully understood. Previous
research has proposed several mechanisms for the selective toxicity of cold atmospheric
plasmas, including membrane disruption, mitochondrial dysfunction, DNA damage,
deregulation of signal pathways, protein up/down regulation, cell cycle arrest and finally
apoptosis/necrosis/ autophagy.
CAP have been demonstrated to induce the S-nitrosylation of SH-groups in proteins and
thereby cause inactivation of proteins function (Ishaq, Evans and Ostrikov, 2014). In
addition, ROS can cause lipid peroxidation by interacting with unsaturated fatty acid. It
has been found that CAP treatment could cause the loss of cancer cell membrane integrity,
induce the leakage of cellular content (Siu et al., 2015) and promote the transmission of
ROS/RNS into cells by S-nitrosylation, lipid peroxidation and creating rifts in the
membrane (Halliwell, 1991; Rao, Hale and Ormrod, 1995; Bestwick et al., 2001;
Babington et al., 2015). Nina Recek et. al have studied the differential effects of CAP on
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cell membrane of normal human astrocytes and human glioblastoma cells by atomic force
microscopy (Recek et al., 2015). CAP didn’t harm E6/E7 cells but only caused temporary
disappearance of microvilli structure on cell membrane, whereas plasma treatment
caused selective apoptotic effect on the GBM cells along with granular elevations and
bigger clusters were observed on the surface of GBM cells (Recek et al., 2015). These
different effects on cell membrane may indicate the potential mechanisms of selective
toxicity of CAP (Recek et al., 2015). In the meantime, the cold atmospheric plasma
treatment has been shown to cause enhanced mitochondrial transmembrane permeability
and possible release of proapoptotic factors by depolarizing the mitochondrial membrane
potential via generation of free radicals. And the plasma-induced cell apoptosis has been
proved to be mediated partially by mitochondria-dependent caspase cascade (Ahn et al.,
2011).
After CAP treatment, it was found that cellular DNA was damaged with increasing
intracellular levels of ROS (Babington et al., 2015). In addition, plasma treatment has
been proved to selectively induce the deregulation of several genes in cancer cells. These
genes are intimately associated with multiple pathways, including cell adhesion, cell
proliferation, growth regulation and cell death. Some of these pathways are involved in
cancer processes and their deregulation may be the potential reason of tumour ablation
while treating CAP. Notably, the genes related with oxidative stress and apoptotic
pathways were significantly deregulated in tumour cells by plasma treatment, which
could potentially help explain the plasma-induced apoptosis mechanism (Keidar et al.,
2011).
At present stage, the short-lived and long-lived reactive species generated by cold
atmospheric plasma are considered playing key role in selective cytotoxicity to cancer
cells. In the following section, the interaction between reactive species and tumour cells
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will be detailed introduced.

1.4

The Intracellular Reactive Species and Signalling Pathway

Affected by CAP
Reactive oxygen species (ROS) are a group of highly reactive molecules that have been
identified as important regulators of many signaling pathway. Moderate levels of ROS
are generated during normal cellular metabolism progress and participate in cellular
signalling and several cellular functions by reversibly oxidizing/modifying protein
structure (Ray, Huang and Tsuji, 2012; Perillo et al., 2020). Meanwhile, uncontrolled
ROS have long been known as initiating tumourigenesis, which can cause oxidative
damage to lipid, proteins and DNA or disrupt oxidative signalling to promote cancercausing mutations and cell proliferation (Perillo et al., 2020). Some epidemiological
evidence exists for this, including the observation that a diet high in natural anti-oxidants
is generally associated with lower incidence of various cancers. Thereby, antioxidant food
and supplements have been considered as weapon to prevent cancer for a long term.
As understanding deepens, ROS were found to be a double-edged sword to cancer cells.
Evidence shows that higher level of ROS were generated in cancer cells, compared to
normal cells, due to higher metabolic activities and more rapid proliferation of
transformed cells (Schumacker, 2006). Hence, the cellular antioxidant system works
under heavier load to protect tumour cells from oxidative stress, suggesting it may be
possible to selectively eliminate them with inducers of tumour ROS (Trachootham,
Alexandre and Huang, 2009).
One hypothesis for the increased production of ROS in tumour cells is the difference in
metabolism between normal and cancer cells. Cancer cells require more biomass
synthesis per unit time due to the unregulated and relatively rapid cell growth and
proliferation (Harris et al., 2015). It has been found a phenomenon called “the Warburg
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effect” that cancer cells rely primarily on glycolysis and lactic acid fermentation to
generate energy, whereas most other nucleated cells generate adenosine triphosphate
(ATP) by oxidative phosphorylation (Vander Heiden, Cantley and Thompson, 2009). To
deal with higher intracellular ROS levels, tumour cells synthesise nicotinamide adenine
dinucleotide phosphate (NADPH). NADPH is utilized as a reducing equivalent to reduce
thioredoxins (TRX), peptides that in turn reduce oxidized proteins such as peroxiredoxins,
a family of hydrogen peroxide-scavenging enzymes (Sabharwal and Schumacker, 2014).
NADPH is also involved in the generation of the antioxidant glutathione (GSH), an
important tripeptide in antioxidant systems (Harris et al., 2015). Despite the increased
expression of antioxidant systems, cancer cells generally have a higher baseline
intracellular ROS which strains the antioxidant capacity of tumour cells to deal with
additional oxidative stressors (Harris et al., 2015). With the excessive intracellular levels
of ROS, lipids, proteins and DNA can be damaged in cancer cells, leading to lipid
peroxidation-initiated oxidative stress, inhibition of phosphatases, alternation of
cytoplasmic and nuclear signaling, disruption of epigenetic modulators, etc., and
eventually apoptosis, autophagy or ferroptosis of cancer cells (Perillo et al., 2020).
Therefore, the reactive species generated by CAP can be selective toxic to tumour cells
which can be exploited for efficient, specific and low side effects anticancer strategies. It
has been shown that CAP treatment regulates possible signalling cascades implicated in
cancer cell death, such as stress kinases pathways and growth signalling pathways, etc.
Meanwhile, it also has been found that the interaction of CAP with proteins and
interrupting of cell cycle play important roles in CAP-induced selective cell death, as
detailed below.
1.4.1 Stress Kinase Pathways
Mitogen-activated protein kinase (MAPK or MAP kinase) is involved in the regulation
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of various cellular functions, including apoptosis, differentiation, gene expression,
mitosis and proliferation. c-Jun N-terminal kinase (JNK) is also involved in multiple
pathways which are responsive to apoptosis, differentiation and stress stimulation,
including ROS, ultraviolet radiation, heat and osmotic shock. (Tobiume et al., 2001).
Elevated accumulation of intracellular ROS was found to activate p38α MAPK/JNK by
the activity of Apoptosis signalling regulating kinase 1 (ASK1) (Elenitoba-Johnson et al.,
2003; S. P. Li et al., 2003). ASK1 is one of the regulators of pathways involving p38α
MAPK and JNK. Then p38α MAPK results in the activation of several tumour
suppressors, including protein 53 (P53) (Bulavin and Fornace, 2004), Cdc25
phosphatases (Manke et al., 2005) and pro-apoptotic members of B-cell lymphoma 2
(Bcl2) family (Ishaq, Evans and Ostrikov, 2014), leading to caspases-dependent
apoptosis of cancer cells (Figure 5). Inhibitory members of Bcl-2 family are capable of
inhibiting the release of cytochrome c from mitochondria and in turn lead to the inhibition
of caspases in the apoptosis pathway (Küpper et al., 2014). P53 is able to downregulate
the production of anti-apoptotic Bcl-2 members

promote phosphorylation of the

inhibitory Bcl-2, then stimulate caspases pathway (Ling et al., 2002) (Figure 5).
Phosphorylation of inhibitory Bcl-2 members has been observed after CAP treatment in
a study using Hela and lung cancer cells (Ahn et al., 2014).

Figure 5. CAP affected stress kinase pathway.
Excessive intracellular ROS generated by plasma can stimulate TNF pathway and inhibit
CBR1 and GSTP1, leading to the activation of downstream JNK or p38α MAPK, which
finally induces caspase-dependent tumour cell apoptosis.
Similarly, the signalling cascade of the stress-activated protein kinase JNK is important
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and involved in cellular environment adaptiveness and several physiological processes,
including inflammation, proliferation and apoptosis (Ishaq, Evans and Ostrikov, 2014).
The augmented level of intracellular ROS also has been indicated that may activate JNKs
by blocking stress-response proteins such as Glutathione S-transferase pi 1 (GSTP1) and
carbonyl reductase 1 (CBR1), leading to tumour cells suppression and growth arrest by
stabilizing p53 and stimulating the caspase cascade (Ishaq, Evans and Ostrikov, 2014)
(Figure 5). There’s evidence that pre-treatment of HeLa cells with antioxidants, JNK and
p38 inhibitors, and JNK and p38 siRNA inhibits mitochondrial membrane depolarization
and reduced plasma-induced cancer cell death (Ahn et al., 2014).
The exact mechanisms for activation of JNK and P38 is not fully clear, although in a
study using melanoma cells, upregulation of TNFR1 and TNFα was observed when
incubated with CAP. This was accompanied by an increase in active caspases and could
be reversed using TNFR1 blocking antibodies. Interestingly, increased expression of
TNFR1 and TNFα was only observed in malignant melanoma cells and not in
melanocytes (Ishaq et al., 2014).
1.4.2 Growth Signalling Pathways
CAP can directly interact with growth signalling pathways. For example, the 21-kDa
protein (p21), known as a tumour suppressor encoded by gene WAF1/CIP1, was found
to inhibit the activities of cyclin-dependent kinase which is required for progression of
the cell cycle (Wade Harper et al., 1993). The expression of p21 provided another
pathway to inhibit tumour growth whilst normal p53 function is lost in half of all tumours.
It has been found that excessive level of intracellular ROS induces the expression of p21
as a consequence of oxidative damage, which is independent of p53 (Russo et al., 1995).
Secondary GBM often shows p53 mutation whereas primary GBM mainly contain EGFR
amplification as the principal mutation and rarely present p53 genetic alteration
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(Watanabe et al., 1996). The EGFRvIII, a ligand-independent constitutively active
mutant of EGFR which is often associated in primary GBM, is keeping activating the
phosphatidylinositol 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homolog
(AKT) signaling pathway, thus promotes the survival of primary GBM cells (Li et al.,
2004; Tabunoki et al., 2012). PI3K/AKT pathway is known as a oncogenic signalling
disturbed in many human tumours, which plays an important role in tumour development
and affect the response of cancer cells to tumour treatment (Fresno Vara et al., 2004).
PI3K binds to the growth factor receptors on cell membrane while the receptor is
activated, and then converted to phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3
induces the activation of several signalling proteins, including PKB/AKT, subsequently
leading to survival, growth and proliferation of cells via various signalling pathways
(Fresno Vara et al., 2004). AKT phosphorylates and inhibits p21 by sequestering it in the
cytoplasm (Zhou et al., 2001). Therefore, excessive intracellular ROS generated by
plasma can potentially activate p21, counteract the PI3K/AKT pathway and control
tumour cell growth (Ishaq, Evans and Ostrikov, 2014) (Figure 6).

Figure 6. Cold plasma affected growth signalling pathway.
The induced generation of ROS can counteract PI3K/AKT pathway and induce growth
arrest of cancer cells via activation of p21, PTEN and INK4a/ARF.
Intracellular ROS is also capable of inhibiting PI3K/AKT by activating several other
tumour suppressors, including phosphatase and tensin homolog (PTEN) and INK4a/ARF
(Ishaq, Evans and Ostrikov, 2014). PTEN downregulates the level of PIP3 by
dephosphorylating it and inhibits the phosphorylation/activity of AKT(Stambolic et al.,
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1998). INK4a/ARF encodes two proteins p16 and p14 respectively, which are required
for the activation of PTEN (Maehama and Dixon, 1999; Uhrbom et al., 2002).
1.4.3 Protein Interactions
CAP can directly modify cellular enzymes and structural proteins. For instance, CAP are
able to enhance lipase activity (Li et al., 2011), inactivate lysozyme in aqueous solution
(Takai et al., 2012), decrease peroxidase (POD) activity in fruits and vegetables (Pankaj,
Misra and Cullen, 2013), and inactivate lactate dehydrogenase (LDH) in the phosphate
buffer solution (PBS) (Zhang et al., 2015). The changes of protein activity could be
mainly due to the interaction between protein and the long-lived reactive species (RS)
generated by CAP. These long-lived RS, such as ozone (O3) and hydrogen peroxide
(H2O2) can modify many amino acids (Cataldo, 2005) and denature proteins by oxidizing
them (Nordberg and Arnér, 2001). Therefore, the modification of amino acids can lead
to the secondary structure changes or protein-protein cross-linkage. The structure changes
in the active centre will significantly affect protein activity and protein-protein crosslinkage may cause the molecular aggregation between proteins and then decrease the
amount of viable exposed active sites (Zhang et al., 2015). Especially, cysteine was found
to be the most sensitive of the 20 amino acids to oxidizer. The oxidation of thiol group
on the cysteine residue can affect the function of proteins, including several antioxidant
small molecules or enzymes, including thioredoxin, peroxiredoxin and glutathione
peroxidase, which further reduces the capacity of the antioxidant system of targeted
cancer cells and facilitates the cytotoxicity of extracellular ROS generated by CAP
treatment (Yan et al., 2015).

1.5

Nanoparticles in Cancer Therapy

Cancer treatment can be affected by a combination of physical, chemical and biological
technologies. Due to the considerable variation between types and status of tumours and
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individual patients, the efficiency of cancer therapy is difficult to guarantee and
commonly associated with side effects and off-target toxicity can be daunting (Chen et
al., 2017). However, recent technological advances have led to the development of new
nanotechnological approaches for cancer therapies, which promise high-precision ways
to beat cancer. Nanotechnology can be combined with chemotherapy to facilitate targeted
delivery into cancer tissue with high specificity and efficacy (Ferrari, 2005).
Nanoplatforms allow more accurate, non-invasive and real-time cancer diagnosis and
monitoring during therapy using magnetic resonance imaging, ultrasonography, etc.
(Alexis et al., 2008; Baetke, Lammers and Kiessling, 2015; Zaimy et al., 2017) Adjuvant
nanotechnological devices are used in cancer interventions such as radiotherapy (Wu et
al., 2016), photodynamic therapy (Clement et al., 2017) and sonodynamic therapy (H.
Xu et al., 2016), which are capable of achieving considerably higher precision of
treatment and reduced side effects. After decades of developing the understanding of
nanotechnology, cancer-related nano-treatments have undergone extensive preclinical
and clinical-trial studies and shown promising results (Chen et al., 2017). Bregoli et al.
have summarised the current state of the art of nanomedicines undergoing clinical trial
and clinically-approved nanomedicines for cancer therapies (Bregoli et al., 2016).
The traditional definition of a nanotechnological device for cancer treatment is that the
essential components of the device or the device itself are artificial, and have at least one
dimension in the 1-100 nm range (Whitesides, 2003; Ferrari, 2005). It has been suggested
that there should be less emphasis on the exact definition of size which could be extended
to a range of 1–1,000 nm, and define the approaches to bionanotechnology according to
their function and purpose (Ferrari, 2005). According this definition, nanotechnologies
used in cancer treatment include drug-delivery, therapeutic nanovectors, nano-sensitizers,
diagnostic agents and macroscopic devices with essential nanocomponents such as
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microarrays/ ‘nanoarrays’, nanocantilever arrays and silicon nanowires for highlyspecific and highly-efficient molecular detection and diagnostic (Ferrari, 2005). The
recent advances and use of these emerging nanotechnological treatments for cancer is
briefly reviewed in this section with an emphasis on nanotechnologies used for drugdelivery.
The applications of nanoparticles in pharmacology have been investigated over the last
three decades and a new generation of vehicles for delivery of biomedical compounds
has emerged (Couvreur and Vauthier, 2006). Nano-scale carriers have been exploited for
drug delivery, drug targeting, histological engineering, tissue targeting and labelling
(Kong, Keidar and Ostrikov, 2011). The evolution of nanotechnology enables researchers
to synthesize a wide variety of nanoparticles with distinct functions and characteristics.
Such nanomaterials can be functionalised with molecular and imaging probes or bioactive
compounds which can be conjugated, linked, coated or adsorbed to them, in order to
implement specific functions (Kong, Keidar and Ostrikov, 2011).
For cancer therapy, nanoparticles have been demonstrated to provide site-specific
delivery by incorporation of various targeted ligands to bind to the desired site or utilizing
stimuli-responsive strategies. Targeted ligands can include various compounds (e.g.
antibodies, peptides, hormones, receptor ligands, nucleic acids and lipid derivatives)
(Eckmann et al., 2014). Functionalized nanoparticles are capable of responding to one or
more physical, chemical, biochemical or environmental stimuli, including osmotic
pressure, hydrodynamic pressure, vapor pressure, mechanical force, magnetics,
sonophoresis, iontophoresis, hydration, electricity, pH, salt concentration, hydrolysis,
enzyme, temperature, light and hypoxia, etc. (Bennet and Kim, 2014) In addition,
nanocarriers can prolong circulation time and are incapable of diffusing across nonfenestrated endothelium, thus enabling accumulation in the tumour tissues, resulting in
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enhanced permeation and retention (EPR). Notably, however, it has been pointed out that
precise prognosis should be based on comprehensive characterisation of an individual
tumour, rather than broadly on the EPR effect (Chen et al., 2017).
The term nanoparticle can encompass a variety of materials, including liposomes,
nanogels and polymer-based nanoparticles, silicon and silica nanoparticles, dendrimers,
metal-based nanoparticles, and combinations of the above. This section reviews the recent
developments of nanoparticles for effective cancer treatment and provides related content
that can be used for reference.
1.5.1 Liposomes
Liposome platforms have attracted considerable attention from the academic and clinical
arenas and have become one of the most studied biomaterial nanoparticles, due to the fact
that liposomes can significantly improve the efficiency of a drug by increasing its
solubility, overcoming resistance, controlling its targeted release and modifying its
biocompatibility, bioavailability and safety profile. There have been several clinically
approved liposome-based nanomedicines for cancer therapies, such as Doxil, Myocet,
Mepact, Dauno Xome, Depocyt, Marqibo and MEPACT (Bregoli et al., 2016). Moreover,
advances in liposome research have led to the emergence of hundreds, even thousands,
of different functional liposomes for various tumours, which have been tested in
preclinical research and clinical trials (Ferrari, 2005; Bregoli et al., 2016). According to
their number of bilayer membranes, liposomes are grouped into unilamellar and
multilamellar vesicles (Zununi Vahed et al., 2017). Unilamellar vesicles have a single
lipid bilayer, while multilamellar vesicles consist of several unilamellar vesicles
surrounded by lipid bilayers. On the another hand, according to the formulation,
liposomes can be grouped into several types, including PEGylated stealth liposomes
(Couvreur and Vauthier, 2006), immunoliposomes (Tila et al., 2015), lipoplexes (Lonez,
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Vandenbranden and Ruysschaert, 2008), fusogenic liposomes (Yuba et al., 2010),
stimuli-responsive liposomes (Zununi Vahed et al., 2017) and combinations of the above.
(Couvreur and Vauthier, 2006)
Nanoparticles, including liposomes, can be rapidly cleared from the bloodstream by the
mononuclear phagocytic system (MPS), significantly decreasing in-vivo circulation halflife and the delivery efficiency of drugs (Bregoli et al., 2016). Therefore, for a longer
circulation time, it is critical to protect liposomes from MPS detection. Doxil, the first
clinical approved nanomedicine for cancer therapy, is made of polyethylene glycolcoated (PEGylated) liposomes containing anti-cancer drug doxorubicin (Bregoli et al.,
2016). Coating liposomes with polyethylene glycol, which is a class of biocompatible,
inert and hydrophilic polymer, results in significant increases of the circulation half-life,
from several hours to around 45 h, achieving sustained and prolonged drug delivery, and
promoting tumour accumulation of liposomes (Couvreur and Vauthier, 2006). PEGylated
stealth liposomes have been widely applied in the clinic and are easily functionalised with
other functional features, such as stimuli-responses and ligand targeting (Tila et al., 2015).
Alternatively, sustained release of a drug from MPS cells, more complex liposomal
formulations (e.g. small size, net neutral charge, incorporation of cholesterols and lipids),
or drug release into specific areas, such as the cerebrospinal fluid, non-PEGylated
liposomes have been demonstrated to result in an increase in the tumour exposure to the
drug (Bregoli et al., 2016).
Attaching targeting ligands to the liposome surface is now a well-established and widely
used feature in liposome design. Liposomes functionalised with antibodies, also known
as immunoliposomes, can carry a drug dose and selectively bind to a chosen tumour site,
whilst antibody fragments, glycoproteins, peptides, vitamins and oligonucleotide
aptamers can also be used as targeting ligands (Zalipsky et al., 1996; Park et al., 1997;
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Mastrobattista, Koning and Storm, 1999; Gunawan and Auguste, 2010; Tila et al., 2015).
Gene therapies have been considered as a novel and promising method for cancer
treatment. Lipoplexes (cationic liposomes) have been investigated as an attractive gene
delivery system that are simple to synthesize and control, have high delivery efficiency
and can enhance the stability of nucleic acid therapeutics (Tila et al., 2015). Cationic
lipids used in lipoplexes are comprised of a cationic head and hydrophobic domain and
have the capacity to form particulate complexes in the liposomal membrane by interacting
with nucleic acids therapeutics (negatively charged), including plasmid DNA (pDNA),
small interfering RNA (siRNA) or micro-RNA (Tila et al., 2015).
Fusogenic liposomes are able to fuse with cellular membranes and directly release
encapsulated drugs into the cytoplasm or targeted cell organelles, significantly enhancing
the cellular uptake of drugs, avoiding lysosomal degradation, and counteracting the drug
resistance of cancer cells (Kunisawa et al., 2005; Tila et al., 2015). Membrane fusion is
achieved by the specific interactions between the membrane receptors and the liposomes
or the membrane-associated proteins or peptides that are contained within the liposomes.
Moreover, negatively charged phospholipids promote the fusion in the presence of
calcium in some types of fusogenic liposomes (Malaekeh-Nikouei et al., 2008; Yuba et
al., 2010; Watarai et al., 2014). The formation of lipid bilayers and incorporation of
special lipids (e.g. dioleoyl phosphatidylethanolamine (DOPE)) also promote the
membrane fusion reaction and enhance the release of the encapsulated drugs (Tila et al.,
2015).
Functional liposomes have been used for the improvement of circulation time and
stability of drugs, specifically targeting cancer cells, and promoting drug delivery. More
recently, the maturation of stimuli-responsive liposome technologies has yielded precise
control of drug release, which provides greater individualised treatment with lower
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undesirable side effects (Deshpande, Biswas and Torchilin, 2013). Several types of drug
release triggers have been used in liposome-based delivery systems, including
temperature, pH level, enzymes, light, ultrasound, electromagnetic waves and magnetic
fields. (Zununi Vahed et al., 2017)
Tumor cells are efficient at maintaining plasmalemmal pH gradients, whereas the protons
generated during the metabolism of cancer cells are exported to the extracellular space
efficiently and the extracellular bicarbonate is taken up by cancer cells, following reexport of CO2, for increasing intracellular pH (Chiche et al., 2012). Therefore, the
extracellular pH level in the environment of cancer cells is lower than that around normal
cells (pH 6.2-6.8 vs pH 7.35-7.45). Additionally, in endosomal vesicles, the pH is lower
than 5 (Moussa, Martins and Husseini, 2015). pH-sensitive liposomes (PSLs) are stable
at the neutral pH of blood and healthy tissues, but are designed to become destabilized
and release encapsulated drugs in the vicinity of cancer cells and/or in endosomes
(Karanth and Murthy, 2007). The most developed class of PSLs are designed to be
triggered after endocytosis and several mechanisms may be involved: direct release of
drugs into the cytosol due to the fusion of the endosome and liposome membranes which
is induced via pH changes; drug leakage into the cytosol because of the pH-induced
destabilization of liposomal membranes which will cause the destabilization of
endosomal membranes; release of drugs inside the endosomes due to the pH-induced
destabilisation of the liposomes, followed by the diffusion of the molecules into the
cytosol (Moussa, Martins and Husseini, 2015). There are several classes of materials used
in the formulation of different PSLs, including polymorphic lipids combined with
amphiphilic compounds that contain an acidic group, lipid derivatives that have pHsensitive chemical bond (e.g. N-acylated aminophospholipid derivatives and
plasmalogens), reconstituted fusion proteins or peptides that are pH-sensitive and able to
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destabilise the membrane of liposomes in acidic environments, and pH-titratable
polymers, which change conformations at low pH, as recently reviewed by Moussa et al.
(Moussa, Martins and Husseini, 2015)
Thermo-sensitive liposomes (TSLs) are sensitive to temperature, due to their specific
chemical composition. For example, some types of liposomes consist of lipids (e.g.
dipalmitoyl phosphatidylcholine) that begin to melt when the temperature exceeds their
thermal threshold, whereupon the surface of the liposomes becomes porous and the
encapsulated drug is released (Moussa, Martins and Husseini, 2015). The increase of local
temperature, known as hyperthermia, can be induced via pathological status or external
triggers such as light, ultrasound, microwave or magnetic fields (Moussa, Martins and
Husseini, 2015; Tila et al., 2015). Optimisation of the hyperthermic effect allows precise
control over the amplitude and location of the temperature rise in targeted cancer tissues.
Therefore, TSLs which are stable at the temperature of the human body (37°C on average),
can be triggered to release the encapsulated molecules at targeted sites by hyperthermia
(about 39-43°C) to achieve greater therapeutic effect and reduced side effects (Ta and
Porter, 2013; Moussa, Martins and Husseini, 2015).
Moreover, liposomes can be designed to be sensitive to certain enzymes that only have
high activity at the tumour site, such as lipases, cancer-associated proteases and
phospholipases (de la Rica, Aili and Stevens, 2012; Arouri et al., 2013; Moussa, Martins
and Husseini, 2015). There are several classes of enzyme-sensitive liposomes, chemically
modified with different molecules (e.g. lipopolymers (Arouri et al., 2013), small peptides
and phosphorylated synthetic estrogen, etc.(Bibi et al., 2012)) that can specifically
respond to certain enzyme levels above a threshold.
Some types of liposomes are capable of absorbing the energy of certain external triggers
(e.g. light, ultrasound, electromagnetic waves or magnetic fields, etc.) and subsequently
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converting it to heat, causing a localised hyperthermia that effects the liposomes and
induces the release of drugs (Moussa, Martins and Husseini, 2015). These external
triggers also can be used to directly affect the liposomes. For instance, light can induce
changes in the form of photosensitive lipids, which are chemically modified, and change
the membrane permeability (Anderson and Thompson, 1992). Ultrasound is able to
induce the rupture of microbubbles at target sites, known as transient cavitation. The
collapse of microbubbles produces enormous localised heat and pressure waves, which
can cause the disruption of the liposomal and/or cell membranes, consequently allowing
the release and permeation of drugs (Hernot and Klibanov, 2008).
Additionally, liposomal platforms which are capable of co-delivering combinatorial
drugs bring a paradigm shift in tumour therapy (Hu, Aryal and Zhang, 2010). Several
classes of liposome-based drug combinations have been reported, including the codelivery of chemotherapeutic drugs, the co-delivery of chemosensitizers and
chemotherapies, and the co-delivery of siRNA and chemotherapies (Mayer et al., 2006;
Saad, Garbuzenko and Minko, 2008; Hu and Zhang, 2010). The combination of drugs
can achieve greater synergistic activity by loading them into liposomes at optimised
molar ratios and selecting appropriate encapsulation schemes (Hu, Aryal and Zhang,
2010). For example, multiple hydrophilic drugs can be encapsulated in liposomes;
lipophilic drugs can be partitioned into the membrane of liposomes; and negatively
charged oligonucleotide drugs (e.g. siRNA) are able to bind to the positively charged
liposomal surface (Hu, Aryal and Zhang, 2010).
1.5.2 Nanogels and Polymeric Nanoparticles
Polymeric nanoparticles are nano-sized colloidal particles and have been extensively
explored for drug delivery for cancer therapies. Among the various materials, designs and
synthesis methods, the polymeric nanoparticles studied most commonly consist of a
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hydrophobic polymer-based core containing anticancer drugs and a hydrophilic outer
shell, which ultimately enabled longer persistence and systemic circulation time in the
bloodstream, leading to further accumulation of nanoparticles in cancer tissue (Masood,
2016). Alternatively, there has also been increasing interest in using nanosized
hydrophilic cross-linked polymer networks, also termed as nanogels, for drug delivery
(Sivaram et al., 2015; Chan and Almutairi, 2016).
Polyhydroxyalkanoates (PHAs) (Li and Loh, 2017), cyclodextrins (CDs) (Duchene,
Cavalli and Gref, 2016) and poly-(lactide-co-glycolic acid) (PLGA) (Katiyar et al., 2016)
are the most commonly used polymer materials for the core fabrication (Masood, 2016).
Meanwhile, nontoxic hydrophilic outer shells provide outstanding blood biocompatibility,
such as , polyvinyl alcohol (PVA), PEG and monomethoxy poly-(ethylene glycol)
(mPEG), which has also been widely applied in surface modification of other kinds of
nanoparticles, such as liposomes and gold nanoparticles (Masood, 2016). The reader is
referred to (Duchene, Cavalli and Gref, 2016; Masood, 2016; Li and Loh, 2017) for an
in-depth investigation and discussion of recent advanced PHAs, CDs and PLGA-based
polymeric nanoparticles used for cancer treatment.
Nanogels are hydrophilic nanosized cross-linked polymer networks, also called hydrogel
nanoparticles (Lux et al., 2013; Sivaram et al., 2015; Chan and Almutairi, 2016). In the
last decade, there has been increasing interest in the applications of nanogels as drug
carriers and imaging agents (Maya et al., 2013; Sultana et al., 2013; Sivaram et al., 2015).
Nanogels have unique utilities and properties including:
1. high biocompatibility on account of the high water content and living tissue-like
physical properties and they are easily biodistributed by intravenous injection (Chan
and Almutairi, 2016; Soni and Yadav, 2016).
2. the ability to selectively respond to stimulation, including changes of pH, ionic
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content, biomolecules, magnetic field, light and temperature, which is important in
specific drug delivery and responsive imaging (Stuart et al., 2010; Eckmann et al.,
2014).
3. highly efficient loading capacity of a wide range of drugs due to the prolonged
residence time provided by muco-adhesive polymers (Sivaram et al., 2015).
The release of the drugs and other molecules is easy to control by varying the nanogel
properties, for example by incorporating stimulus-responsive crosslinkers or changing
crosslinking density (Sivaram et al., 2015).
Nanogels are capable of generating appropriately sized complexes with molecules and
keeping their configuration and activity, and even encapsulating fragile compounds to
increase their stability (Bae et al., 2008; Sasaki et al., 2010; Singh, Gill and Gill, 2013;
Sivaram et al., 2015). Like other nanomaterials, nanogels have nanoscale physical
properties, such as size (20~200 nm) and large surface area (Maya et al., 2013; Soni and
Yadav, 2016). Meanwhile, the production of nanogels enables versatile formulation and
it is facile to chemically modify nanogels for specific purposes, including triggered drug
release and targeted drug delivery (Vinogradov, Bronich and Kabanov, 2002; Maya et al.,
2013). These properties of nanogels make them promising for applications in anti-skin
disease, anti-inflammatory, ocular, transdermal and protein/peptide drug delivery and
therapy, cancer drug delivery and imaging (Sivaram et al., 2015).
For cancer therapy, nanogels demonstrate site-specific delivery by incorporating various
targeted ligands to bind to a desired site, or utilising the stimuli-responsive ability
(Eckmann et al., 2014). Targeting ligands can include various compounds, such as
antibodies, peptides, hormones, receptor ligands, nucleic acids and lipid derivatives, etc.
In addition, nanogel carriers have prolonged circulation time and are incapable of
diffusing across non-fenestrated endothelium, and thus are able to accumulate in tumour
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tissues. For instance, Liang et, al. described a novel self-assembled nanogel consisting of
hyaluronic acid-epigallocatechin gallate conjugates (HA–EGCG), cytotoxic protein
Granzyme B (GzmB) and linear polyethylenimine (PEI) (Liang et al., 2016). HA is
known to have the ability of targeting CD44, which is overexpressed in many cancer cells
types and EGCG is used to facilitate the formation of stable nanogels. After endocytosis,
PEI is able to change the pH in endosomes and rupture the membrane to release drugs
into the cytosol (Boussif et al., 1995). It has been observed that this nanogel efficiently
kills CD44-overexpressing cancer cells and shows little toxic effect to normal cells (Liang
et al., 2016).
After accumulating in tumour tissues via the EPR effect, pH-responsive nanogels are
triggered to release drugs either in the extracellular fluids (pH 6.8) or, after cellular uptake,
in the acidic endosomes and lysosomes (pH 4.5-6.5) in cancer cells (Manchun, Dass and
Sriamornsak, 2012; Manchun et al., 2015). In recent research, hybrid nanogels have been
applied to photothermal cancer therapy. Hui Wang et al. fabricated drug loaded core-shell
hybrid nanogels that have the function of both tumour imaging, local hyperthermia,
temperature sensing and triggered drug release (Wang et al., 2014). These multifunctional
nanoparticles

have

high

photoluminescence, photostability,

magnetic/NIR-heat

conversion ability and drug accumulation potential due to the composite structure
consisting of fluorescent carbon dots, a porous carbon shell and superparamagnetic iron
oxide nanocrystals. Meanwhile, the hydrogel shell can control the release of drug and
fluorescence intensity by varying environmental temperature, which is based on the
thermo-responsive poly (N-isopropylacrylamide-co-acrylamide) (Wang et al., 2014).
Therefore, NIR light and magnetic field are able to induce localised heating and trigger
the release of drugs. In addition, they demonstrated that these hybrid nanogels are capable
of overcoming cellular barriers to exert effects in mouse melanoma B16-F10 cells (Wang
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et al., 2014).
1.5.3 Silicon and Silica Nanoparticles
As emerging nanomaterials, nanosized porous silicon (silicon-based nanoparticles) and
silicon oxide (silica)-based nanoparticles have attracted great attention for cancer
treatment applications. Compared to other types of nanoparticles, silicon and silica based
nanoparticles have uniquely mesoporous structures, strong hydrophobicity and other
distinct material characteristics which make them a promising nanomaterial for cancer
therapy applications (Feng et al., 2016). Due to the biocompatibility, porous
structures/volume and high active surface area of silicon-based nanoparticles, they have
been demonstrated to be one of the outstanding candidate nanovectors for targeted drug
delivery, diagnosis and sensitisations of sonodynamic, photodynamic and thermal
therapies, etc. (Ferrari, 2005; Stojanovic et al., 2016) Silicon is one of the most
fundamental trace materials in the human body, and silicon-based nanoparticles are
completely degradable in the living organism. The generated free silicon atoms can be
converted to a nontoxic bioavailable form and be excreted efficiently, which illustrates
the biocompatibility of silicon-based nanoparticle (Stojanovic et al., 2016). It was
observed using Raman spectroscopy that silicon nanoparticles can be completely
biodegraded in breast cancer cells after 13-days incubation (Tolstik et al., 2016). The
surface modifications of silicon-based nanoparticles for stabilisation, targeted delivery,
controlled drug release or immunotherapy can be accomplished due to the porous
structures/volume and high surface area (Stojanovic et al., 2016). Meanwhile, the pores
inside silicon-based nanoparticles and their structure allow high-efficiency loading of
varied compounds for cancer treatment, including both hydrophilic and hydrophobic
compounds (Salonen et al., 2005; Kinsella et al., 2011; Kaasalainen et al., 2015;
Stojanovic et al., 2016).
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Coating silicon nanoparticles with PEG (Putnam, 2008) or serum albumin (Xia et al.,
2013) is capable of increasing the solubility and stability of silicon nanoparticles in
aqueous environments and results in a much longer circulation time and EPR, similar to
other nanoparticles. Simultaneously, silicon nanoparticles can target tumour tissue and
enter cancer cells by recognising the receptors on the cell membrane and anchoring via
multiple functionalised components, such as carbohydrates, antibodies and peptides
(Godin et al., 2011; Secret et al., 2014; Stojanovic et al., 2016). A variety of silicon
nanoparticle-delivered drugs have been examined, such as methotrexate, SFN (Wang et
al., 2015), indomethacin (Liu et al., 2013), PTX (Liu et al., 2015), DOX (Xu et al., 2015)
and siRNA (Osminkina et al., 2012), etc.
Silicon oxide, also known as silica, is well-known as a bio-safe and widely applied natural
material. Due to the large internal surface area, controllable porous structure and other
material properties of silica-based nanoparticles, they have been investigated as imaging
agents, drug vectors and sensitisers as well as silicon-based nanoparticles (Feng et al.,
2016). The most commonly studied structures of silica nanoparticles for drug delivery
are mesoporous silica based nanoparticles based on Mobil Composition of Matter No. 41
(MCM-41) and/or Santa Barbara Amorphous-15 (SBA-15) (Feng et al., 2016). By
altering the temperature, solution composition and concentrations of the synthesis system,
the size, shape, surface area and pore size of the hexagonal porous MCM-41 structure can
be easily controlled. SBA-15 type silica nanoparticles are synthesized using a polymeric
template, which is able to provide mesostructural ordering properties for silica
nanoparticles (Zhao et al., 1998). MCM-41 type and SBA-15 type have both been
extensively explored for targeted drug delivery (Feng et al., 2016). Controlled-release
drug delivery systems based on silica nanoparticles have also attracted increasing
attention. The stimuli used for triggered drug release from silica nanoparticles include pH
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(Casasús et al., 2004), temperature (Yang et al., 2014), redox potential (Giri et al., 2005),
enzyme (Radhakrishnan et al., 2015) and light (Tang et al., 2015), etc. For instance,
Chang et al. fabricated a pH-sensitive drug delivery system by modifying the surface of
silica nanoparticles with polydopamine. The anti-cancer drug desipramine contained in
pH-triggered silica nanoparticles can be released in low-pH cellular conditions (Chang et
al., 2016). Compared to free desipramine, pH-sensitive silica nanoparticles showed
significantly higher toxicity and inhibitory effects to cancer cells. Lipid-coated silica
nanoparticles, a lipid bilayer surrounding silica nanoparticles containing anti-cancer
drugs, have been investigated recently, and less drug leakage, slower rate of drug release,
and more substantial in vivo therapeutic effects where observed (Meng et al., 2015; Choi
et al., 2016; Liu et al., 2016) .
1.5.4 Dendrimers
Dendrimers

are

3-dimensional,

highly

branched

monodispersed

nanoscale

macromolecules (Sharma et al., 2017). Generally, dendrimers consist of an initiator core,
branches which emanate from the core and functional end groups on the outermost layer
(Gupta et al., 2010). Dendrimers have been considered as a promising nanomaterial for
targeted delivery and diagnostic imaging agents, due to their unique properties, such as
the monodispersity, internal cavities and modifiable functional end groups (Sharma et al.,
2017). The cavity in the hydrophobic core and the multivalent surface allow dendrimers
to effectively load hydrophobic and hydrophilic compounds, respectively (Hu, Aryal and
Zhang, 2010). Varied dendrimer-based MRI, X-ray and CT contrast agents have been
developed by linking contrast agents to dendrimers with design formulations (Sharma et
al., 2017). In addition to diagnostic agents, functionalized and ligand-anchored
dendrimers have shown outstanding ability to target drug delivery. The ligands that have
been used with dendrimers include folic acid (Hilgenbrink and Low, 2005), biotin (Yang
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et al., 2009), N-acetyl-glucosamine (Vannucci et al., 2014) and riboflavin, etc. (Sharma
et al., 2017) Due to the definition of dendrimers, the formulations of dendrimers are
various, such as PAMAM (Buczkowski et al., 2011), polyglycerol (Lee and Ooya, 2012),
PPI (Jain et al., 2015), polyester (Morgan et al., 2006) and nucleic acid (Taghdisi et al.,
2016), etc. (Sharma et al., 2017) For instance, Taghdisi et al. fabricated an aptamer-base
DNA dendrimer containing the anti-cancer drug epirubicin, and targeted drug delivery
and considerable in vivo tumour inhibiting effects were observed (Taghdisi et al., 2016).
Several major types of nanovectors, including liposomes, polymeric, metal-based, silicon
and silica-based nanoparticles, and dendrimers which have been applied in clinical or
preclinical trials for targeted delivery of anti-cancer drugs, have been briefly introduced
above. Moreover, oceans of novel nanoparticles are currently under study and the
systematically combination of varied nanomaterial will provide a very large number of
options for selecting highly specific and highly efficient therapeutic nanovectors
according to individual patient. On the other hands, to develop more selective and less
toxic cancer therapies, nanoparticles have been applied to combine several therapeutic
interventions, including photodynamic (Chatterjee, Fong and Zhang, 2008; RobleroBartolon and Ramon-Gallegos, 2015; Agostinis P, Berg K, Cengel K., 2017),
sonodynamic (H. Xu et al., 2016; Rengeng et al., 2017) and radiotherapy (Hainfeld et al.,
2010), etc., as sensitisers or imaging agent or both. The following sections will review
the recent advance in the combination of nanoparticles with existing anti-cancer
interventions.
1.5.5 Metal-based Nanoparticles
Metal-based nanoparticles used for drug delivery include gold (Cooper, Bekah and
Nadeau, 2014), iron oxide (Sharma et al., 2015), zinc oxide (Rasmussen et al., 2010) and
titanium oxide (Bakhshizadeh et al., 2017) based nanoparticles. For instance, Sun et al.
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fabricated iron oxide nanoparticles conjugated with anti-cancer drug methotrexate and
targeting ligand chlorotoxin, and enhanced cytotoxicity was observed both in vitro and in
vivo (Sun et al., 2008). Meanwhile, due to the superparamagnetic properties of iron oxide
nanoparticles, they can also be used as MRI contrast agents for diagnosing and
monitoring the effects of tumour treatment at the same time (Sun et al., 2008). To enhance
the loading capacity of metal-based nanoparticles, polymer (Bakhshizadeh et al., 2017),
lipid (Kong et al., 2012) or other customized shells have been used to coat the metal cores,
which also provide high stability and biocompatibility. For instance, Bakhshizadeh et al.
assembled core-shell molecularly imprinted polymer for drug delivery by coating
titanium oxide nano-cores with diacrylated polycaprolctone as cross-linkers and
methacrylic acid or 4-vinylpyridin as the functional modification, and superior loading
capacity, higher amount of drug release and considerable cytotoxicity in vitro were
observed (Bakhshizadeh et al., 2017).
On the other hand, metal-based nanoparticles, including copper, copper oxide (Studer et
al., 2010; Akhtar et al., 2016), titanium oxide (Park et al., 2008), silver (Foldbjerg et al.,
2009) have been demonstrated to be able to induce the generation of reactive oxygen
species inside cells and ultimately lead to oxidative stress, DNA damage and apoptosis
of targeted cells, which provide the therapeutic potential as anti-cancer agents themselves.
Among those nanoparticles, gold nanoparticles (AuNPs) are the most studied metal-based
nanoparticles for anti-cancer drug delivery and have been demonstrated to be promising
and effective imaging labels and contrast agents on account of their strong surface
plasmon resonance (SPR) effect. Electromagnetic radiation of specific resonant
frequencies can induce a coherent oscillation of the free electrons on the nanoparticle
surface, when the diameter (1-100 nm) of the metal nanoparticles is less than the
wavelength of light. The oscillation is called the SPR. The SPR can cause an intensely
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enhanced absorption and scattering of electromagnetic radiation in resonance with the
metal nanoparticles (Jain, ElSayed and El-Sayed, 2007). Furthermore, AuNPs have high
stability and can be easily manufactured in controllable size, shape and functionalised by
bioconjugations and biomodifications, which make them an outstanding nanomaterial for
drug delivery. AuNPs are facile to be bio-conjugated and bio-modified on account of the
strong binding affinity towards amines, disulphides and thiols of their surface. This strong
affinity allows AuNPs to conjugate a variety of peptides, proteins, DNA and other
biomedical compounds (Niemeyer, 2001; Katz and Willner, 2004; Jain, ElSayed and ElSayed, 2007). Cancer specific antibodies (such as anti-FAK antibody and anti-EGFR
antibody), biomolecules (which can be eagerly taken up by cancer cells) and viruses etc.
can be conjugated to AuNPs to selectively target cancer cells (El-Sayed, Huang and ElSayed, 2005; Jain, ElSayed and El-Sayed, 2007; Kim et al., 2008; Cheng et al., 2014).
Therefore, antibody-conjugated gold nanoparticles are widely used in cancer diagnosis
and therapy. It is also known that AuNPs with strong surface-plasmon-enhanced
absorption can convert the absorbed light into localized heat expeditiously and therefore
can be utilised for selective photothermal cancer therapy (El-Sayed, Huang and El-Sayed,
2006).
AuNPs are generally considered relatively nontoxic to normal cells (Connor et al., 2005;
Shukla et al., 2005; Alkilany and Murphy, 2010; Villiers et al., 2010), but nonfunctionalized AuNPs have been reported to show selective cytotoxicity to certain cell
lines, especially cancer cells. Hirak K. Patra and colleagues found that citrate-capped
AuNPs (13 nm in diameter) can specifically induce death in the human carcinoma lung
cell line (A549), while leaving two other cell lines, baby hamster kidney and human
hepatocellular liver carcinoma, unaffected at the same dosage (Patra et al., 2007). AuNPs
have been implicated in detrimental effects on various important cellular components,
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such as mitochondria and membrane, damage to DNA, generation of reactive chemical
species, hindrance of cell function and ultimately induction of cell death (Alkilany and
Murphy, 2010). Triphenylphosphine monosulfonate (TPPMS) capped AuNPs (1.4 nm in
diameter) were found to be toxic to HeLa cervical carcinoma epithelial cells (IC50 = 48
μM）as a result of oxidative stress and mitochondrial damage leading to necrosis (Pan et
al., 2009). Metal nanoparticles can capture electrons from O2, owing to their high
surface/volume ratio and the specific electronic configuration of surface atoms (Nel et al.,
2006). Jia et Al. reported that AuNPs (13 nm in diameter) can catalyse the production of
nitric oxide (NO) from endogenous S-nitroso adducts with thiol groups (RSNOs) in blood
serum, resulting in the formation of Au-thiolate on the surface. It is known that NO can
effectively interact with superoxide to generate a toxic peroxinitrite (ONOO-) (Jia et al.,
2009).
Cellular responses to AuNPs depend on their chemical/physical properties, such as
surface charge, size and shape (Alkilany and Murphy, 2010). For instance, Goodman and
colleagues found that cationic (aminated) AuNPs (size 2 nm) are able to cause membrane
disruption and cell death, while anionic (carboxylated) AuNPs with similar size and shape
show no toxicity to cells. It suggests that the binding of the AuNPs to the negatively
charged cell membrane can be a potential mechanism of the cytotoxicity of cationic
AuNPs (Goodman et al., 2004).
Recent nanoparticles-cancer research has led to the development of special functional
nanosized gold-based particles that conjugate drugs, antibodies or bioactive ligands
which are designed to target or kill cancer cell (Service, 2005; Kong, Keidar and Ostrikov,
2011; Cheng et al., 2014). Branch et al. reported aurimmune CYT-6091, constructed by
concurrently binding polyethylene glycol (PEG) and recombinant human Tumour
Necrosis Factor (rhTNF) to AuNPs. It was tested in a phase I dose escalation clinical trial.
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It was demonstrated that the rhTNF plays a role in targeting and killing cancer cells
(Libutti et al., 2010). Anil Kumar et al. successfully investigated a kind of peptide
functionalized AuNPs which consists of a therapeutic peptide, PMI and neuropilin1(Nrp-1) receptor-targeted peptide on ultrasmall AuNPs (2 nm). Since nrp-1 is highly
expressed by a variety of human cancer cell lines and PMI is a potent inhibitor of
suppressive protein, p53, these AuNPs can target cancer cells and show strong anti-cancer
activity (Kumar et al., 2012).
1.5.6 Combination of Gold Nanoparticles and CAP Treatment
The combination of CAP treatment and nanoparticles, especially gold nanoparticles, has
been a new approach in the therapies of cancer. There are few studies reported that CAP
treatment has anti-cancer synergy with various types of nanoparticles, including iron
nanoparticles (Jalili, Irani and Mirfakhraie, 2016), iron oxide-based magnetic
nanoparticles (Li et al., 2019), silver nanoparticles (Manaloto et al., 2020), paclitaxel
loaded core-shell magnetic nanoparticles (Yu et al., 2018). However, the related studies
were mainly focused on the combination therapy between CAP treatment and AuNPs due
to the unique properties and various advantages of AuNPs.
Kim et al. first reported their study about synergistic effect between CAP and antibodyconjugated AuNPs on G361 human melanoma skin cell (Kim et al., 2008). The authors
achieved five-fold enhancement in G361 cell death over the case of the CAP alone by
using CAP with AuNPs conjugated to anti-phospho-focal adhesion kinase (FAK)
antibodies (Kim et al., 2008). In this study, melanoma cancer cells were placed 2 mm
from the touch-safe CAP source and treated for 40s. The CAP temperature remained less
than 38℃ even after radiating for 10 min (Kim et al., 2008). FAK was more expressed
in melanoma cells than in normal cells and crucial for melanoma cells’ survival, growth
and metastasis. So anti-FAK antibody-conjugated AuNPs (FAK-AuNPs) can target
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melanoma cells and enter into cytoplasm to bind to FAK (Kim et al., 2008). In the
research, there were three groups cultured in: (1) only medium (control); (2) medium
containing AuNPs; (3) medium containing FAK-AuNPs. FAK-AuNPs (30 nm) and
AuNPs (30 nm) did not show to toxicity to G361 compared with the control group. After
these groups of cells were exposed to CAP for 40s, the cell death rate was 74% (FAKAuNPs), 36% (AuNPs) and 14% (control) (Kim et al., 2008). It seems that CAP
stimulated nanoparticles induced deactivation of FAK and led to increased cell death rate.
This study first demonstrated that a low-dose CAP treatment can combine AuNPs located
inside cells to effectively kill cancer cells. The synergy of CAP and AuNPs suggested a
promising novel method to against cancer which is low-dose, safe, selective and effective
(Kim et al., 2008).
More recently, using CAP plus various cancer specific antibody-conjugated AuNPs has
been reported that has significant cancer selective lethal effect, such as anti-epidermal
growth factor receptor (EGFR) antibody conjugated AuNPs (AuNPs-EGFR). EGFR has
been demonstrated to be overexpressed in multiple cancer types and can promote solid
tumor growth (Nicholson, Gee and Harper, 2001). It was shown that AuNPs coated with
EGFR binding immunoglobulins can bind selectively to EGFR on cancer cells membrane
and inactivate them with CAP stimulating, consequently causing the destruction of cancer
cell membrane and cell death while leaving normal cells significantly less affected (Choi
et al., 2012).
A similar approach was taken by the same authors (Choi BB et al.) using anti-human
epidermal growth factor receptor 2 (NEU) antibody labelled AuNPs and CAP to treat
melanoma cells. The NEU protein is usually over-expressed in melanoma cells and the
anti-NEU antibody labelled AuNPs can preferentially target melanoma cells rather than
other normal cells (Choi et al., 2015). It was shown that the NEU protein was selectively
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destroyed, leading a downstream effector after the synergistic treatment. These effects
finally caused significantly higher death rate of melanoma cells compared with other
control groups (Choi et al., 2015).
Unconjugated AuNPs also display synergistic effects when used in combination with
CAP against cancer. Chen et al. studied the synergistic effect of non-attached AuNPs and
CAP on human brain glioblastoma U87 cell line, which takes a larger CAP lethal dose
than other brain glioblastoma cancer cell lines and is resistant to AuNPs (Cheng et al.,
2014). The synergy can induce up to 30% more cell death with an optimal concentration
of AuNPs compared to control groups (Cheng et al., 2014). The unconjugated AuNPs in
the cell culture medium may potentially promote the absorption of extracellular ROS and
RNS generated by CAP into cells (Cheng et al., 2014). The absorption may help
accumulation of intracellular ROS and RNS and theoretically leads to oxidative stress,
which further affects the cellular pathways and causes damage to the DNA, lipids and
proteins. This strengthened effect on CAP treatment varies with the concentration,
incubation time of AuNPs and cancer cell lines (Cheng et al., 2014). The exact
mechanism has yet to be studied further.
In the study by Irani S et al. higher concentration of AuNPs showed stronger cytotoxicity
to Human colorectal cancer cells (HCT-116). The authors used highest concentration of
AuNPs (375 ppm) and CAP (exposure time: 60, 90, 120 and 180 s) to treat HCT-116
cells, longer CAP treatment time led to more apoptotic cell death synergistically
combined with AuNPs treatment (Irani et al., 2015). The endocytosis of AuNPs plays an
important role in their application, and indicated that CAP may promote the uptake of
AuNPs into cancer cells. X. Cheng et al. found that CAP induced the formation of small
pores on cell membrane of Glioblastoma cells (U87) and made the membrane become
uneven, while leaving immortalized normal human astrocytes (E6/E7) unaffected. The
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cancer cell morphology was changed by CAP treatment which may explain the
accelerated uptake of AuNPs by CAP (Cheng et al., 2015).
The combination of low doses of AuNPs and CAP was indicated to inhibit PI3K/AKT
pathway in cancer cells (Kaushik et al., 2016). AKT activation has been demonstrated to
obstruct the function of p53 protein and inhibit the activity of caspase-9 (Cardone et al.,
1998; Jeong et al., 2005). Caspase cleavage plays a crucial role in apoptosis (Jia et al.,
2015) and is known as reliable marker of apoptotic cell death with PARP cleavage
together (Kaushik et al., 2016). Moreover, CASP9, p53, and CASP3 mRNA expression
were observed that were enhanced by the co-treatment with AuNPs and CAP (Kaushik
et al., 2016). Epithelial-mesenchymal transition (EMT) is known as a cellular mechanism
that contributes to normal embryonic development and generally is responsible for the
initiation of metastasis in solid tumors (Roizen, 2012; Kaushik et al., 2016). It has also
been indicated that EMT can stimulate the cancer stem cells (CSCs) potential of cancer
cells. CSCs are the only cells that can initiate and drive tumor growth, resulting metastasis,
tumor recurrence and clinical relapse (Mani et al., 2008; Morel et al., 2008). A growing
amount of evidence indicates that these cells are resistant to radiation therapy and
chemotherapy. Hence, it is highly promising that co-treatment with AuNPs and CAP can
effectively block EMT and inhibit CSCs. It has also been found that low dose of AuNPs
combined with CAP induce the increase of epithelial markers, such as E-cadherin, with
decrease in mesenchymal markers, such as N-cadherin (Kaushik et al., 2016). Cotreatment also can enhance the expression levels of some EMT-associated transcription
proteins, such as N-Cad, Zeb-1 and Slug which can block cell cycle and are related with
the loss of N-Cadherin (Kajita, McClinic and Wade, 2004; Vega et al., 2004; Kaushik et
al., 2016). Besides, it has been shown that co-treatment with AuNPs and CAP can
significantly reduce the population of glioma stem-like cells (GSCs) in vivo and vitro
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model and thus avoid drug resistance, recurrence and metastasis (Kaushik et al., 2016).
However, the effects of combination therapy of CAP treatment and AuNPs can vary due
to the wide range of different AuNPs, CAP-generating devices and cell lines. More
importantly, the exact and detailed mechanism behind the synergistic cytotoxicity,
especially, accelerated uptake of AuNPs into cancer cells by CAP, has yet been to be
discovered. Therefore, considering all the advantage of AuNPs and the unsolved research
questions, this project used AuNPs to investigate the synergistic anti-cancer effects
combined with CAP treatment.

1.6

Combination of Chemotherapy with CAP Treatment

A number of studies have investigated the possible additive, or synergic effect of CAP
with traditional chemotherapeutic agents. The chemical and physical effects (i.e.
production of reactive oxygen and nitrogen species, generation of heat and
electromagnetic fields) of CAP treatment induced cell permeability (Leduc et al., 2009),
disruption of cell membrane (Chen, Cheng and Cheng, 2018), enhanced endocytosis (He
et al., 2018) and cell apoptosis (Tanaka et al., 2015). Therefore, the cancer cells treated
by CAP could increase their uptake of chemotherapeutic agents and present higher
sensitivity to chemotherapy. Additive or synergic effects have been described in a number
of studies and several mechanisms of action are beginning to emerge (Brulléet al., 2012;
Kaushik et al., 2015; Conway et al., 2016; Zhu et al., 2016). For instance, Conway GE
et. al first reported the enhanced ROS-, JNK-, and caspase-independent mechanism of
cell inactivation in human glioma cell line U373MG by the combination of CAP with
TMZ (Conway et al., 2016). CAP was observed to overcome chemoresistance of the
GBM cell line LN18 which has unfavourable MGMT status and displays resistance to
TMZ. Pre-treatment with CAP induced cytotoxicity and restored cell cycle arrest in G2/M
Phase when co-treated with TMZ (Köritzer et al., 2013). In a myeloma cell line model,
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CAP was found to increase bortezomib sensitivity and induce myeloma cell apoptosis (D.
Xu et al., 2016). Interestingly, low frequency, low intensity alternating current electrical
stimulation has also been shown to enhance chemotherapeutic efficacy in MDR1 drug
resistant brain, lung, prostate, ovary, fibrosarcoma and tumour cells (Janigro et al., 2006).
Due to the alterations of metabolism of cancer cells, a specific microenvironment with
high reactive species level is created both inside of cancer cells and in the tumour tissues.
The increased reactive species level provide an attractive target for developing anticancer
therapy, especially as it seems a common feature among various types of cancer
(Marzenell et al., 2013). Several anticancer drugs targeting this feature have been
developed to further increase reactive species level in cancer cells beyond their tolerable
allowance to trigger cancer cell death, including fenretinide (Sun et al., 1999), nitric
oxide-donating aspirin (Gao, Liu and Rigas, 2005), imexone (Hersh et al., 1992),
motexafin gadolinium (Evens et al., 2005), menadione (Beck et al., 2009), β-lapachone
(Y. Li et al., 2003) and others (Trachootham, Alexandre and Huang, 2009). However,
those drugs also can increase the reactive species level in healthy cells, which may induce
secondary malignancies as a dangerous side effect (Marzenell et al., 2013). Therefore,
prodrugs, which were developed in an alternative strategy against the specific high
reactive species level in tumours, are only activated to be cytotoxic after exposure to rich
reactive species, which should lack this side effect and be more specific.
The majority of prodrugs were developed to be activated in cells by oxidation induced by
ROS. CAP has been demonstrated to generate ROS and RNS in specific area and treat
tumour tissues with controllable dose (Welz et al., 2015), therefore it can be a promising
intervention for combination therapy with ROS-activated pro-drugs, especially,
increasing the therapeutic efficiency of pro-drugs.
In this project, we have acquired four types of prodrug candidates, including ferrocene51

based prodrugs provided by Prof. Andriy Mokhir (Marzenell et al., 2013) and Prof.
Gérard Jaouen (Jaouen, Vessières and Top, 2015), matrix metalloproteinase proinhibitors and thiazolidinone-based prodrugs provided by Prof. Seth M. Cohen (Perez et
al., 2015), and pyrazolopyrimidines derivatives provided by Prof. John Stephens (Kelada
et al., 2018).
As seen from Appendix V Supplementary Table S1 and S3, ferrocene (C5H5FeC5H5)
consists of two cyclopentadienyl rings and a central iron atom. Ferrocene itself has high
stability but reacts with reactive oxygen species which induces alternations of their
derivatives. Prof. Gérard Jaouen and his group have investigated and reported a series of
compounds based on ferrocene derivatives, [3] ferrocenophane and ferrocifen derivatives.
[3] ferrocenophane consists of a central iron atom and two cyclopentadienyl rings linked
by a three-carbon atom bridge. Ferrocifen is also known as ferrocene derivative
hydroxyferrocifen. So, based on those ferrocene derivatives and analogues, Prof.
Jaouen’s group has developed a series of compounds which are capable of being activated
in cancer cells by their relative high ROS level with the formation of alkylating agents
and other cytotoxic agents, which inhibit the cellular antioxidative system and induce
antiproliferative effects against cancer cells (Plazuk et al., 2009; Görmen et al., 2010;
Top et al., 2013; Jaouen, Vessières and Top, 2015). A series of compounds that have been
tested and approved to be antiproliferative against MDA‐MB‐231 breast cancer cell line
were provided to us for investigating the combination treatment with CAP against GBM
U373MG cell line. Meanwhile, we also received two aminoferrocene-based prodrugs
from Prof. Andriy Mokhir which are active against primary chronic lymphocytic
leukemia cells and found to not affect mononuclear cells and representative bacterial cells
(Marzenell et al., 2013). And those aminoferrocene-based prodrugs also contain boronic
acid ester residue, which has been well-developed as oxidation trigger group, therefore
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will be cleaved in the presence of ROS, leading to the formation of two types of anticancer agents: redox-active iron-containing species (aminoferrocenes and iron(II) ions)
that induce the catalytic generation of ROS and a quinone methide that inhibits the
cellular antioxidative system (Marzenell et al., 2013).
The matrix metalloproteinase pro-inhibitors provided by Prof. Cohen contain boronic
acid esters or benzylic ether as ROS trigger groups which can liberate the active
compounds while being oxidised by high level of ROS (Rouffet and Cohen, 2011). The
pro-inhibitors were designed to inhibit matrix metalloproteinase at high ROS level
therefore could apply for the treatment of ischemic injury whereas increasing level of
ROS and ROS activated matrix metalloproteinases break down the blood brain barrier
(Major Jourden and Cohen, 2010; Rouffet and Cohen, 2011). Therefore, they were not
designed for cancer treatment, but it is interesting to treat brain cancer cells with those
matrix metalloproteinase pro-inhibitors in combination with CAP treatment. Meanwhile,
Prof. Cohen provided few thiazolidinone-based prodrugs, in which thiazolidinone group
can reveal carboxylic acid groups after activation by hydrogen peroxide (Perez et al.,
2015).
The last group of compounds were provided by Prof. John Stephens, which are
pyrazolopyrimidine derivates, not usually considered as prodrugs, but have found use as
various bioactive molecules in the battle against cancer, infections, obesity and cystic
fibrosis (Kelada et al., 2018). It also has been reported that pyrazolopyrimidines
derivatives present notable inhibiting effects to the activity or function of several kinases,
including the PI3 kinase, glycogen synthase kinase -3 (GSK-3) and others, which are
involved in and even play key roles in a variety of cellular activities including cell
differentiation, motility, cell growth, proliferation, survival and intracellular trafficking,
and therefore involved in cancer cells (Peat et al., 2004; Folkes et al., 2008; Venkatesan
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et al., 2010; Martina Ferrari et al., 2015). Therefore, it is promising to find novel drugs
in pyrazolopyrimidine derivates for cancer treatment which may possess synergistic anticancer effects in combination with CAP treatment.

1.7

Aims & Objectives

GBM neoplasms usually recur and the prognosis is highly dismal. The length of survival
is commonly 12-15 month, whereas 5-year survival rate is only less than 3%-5% (Gallego,
2015). Meanwhile, even with aggressive treatment, application of radiosensitizer or many
chemotherapeutic agents, high amount of GBM tumours present high resistance to
conventional therapies, and the therapeutic effects of chemotherapeutics are limited when
they are blocked by the blood-brain barrier. Novel therapies are urgently needed and the
understanding of molecular signalling processes of GBM also needs to be further
investigated. The aim of this project is to investigate novel therapies for glioblastomas by
combining cold atmospheric plasma, gold nanoparticles and chemotherapy, to enhance
the knowledge of the reaction of GBM to cold atmospheric plasma and provide the basis
to further develop efficient novel clinical treatment for GBM tumour. More specifically,
we aimed to investigate the synergistic anti-cancer effects between low dose CAP
treatment, AuNPs and discover new prodrug candidates that possess strong synergy with
CAP treatment. Our research questions are ‘How does low dose CAP treatment accelerate
the uptake of non-toxic AuNPs into GBM U373MG cells and lead to synergistic
cytotoxicity?’ and ‘Identify potential leading prodrug candidates that can be activated and
induce synergistic anti-cancer effects in combination with low dose CAP treatment.’
There are 4 Chapters in this PhD thesis. In Chapter 1, the objective is completing a
literature review, which has been presented above in section 1.1-1.6, to introduce brain
cancer, especially GBM, therapeutic cold and hot plasma, the intracellular reactive
species and related signalling pathways, nanoparticles in cancer therapy and
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chemotherapy agents, especially, prodrugs that have potential synergistic anti-cancer
effects combined with CAP treatment. The literature review has been published as a book
chapter. In Chapter 2, the objective was identifying the synergistic cytotoxicity of CAP
treatment and AuNPs against U373MG cells and investigating the mechanism of CAPaccelerated uptake of AuNPs, which leads to the synergistic cytotoxicity. For deliverables:
(1) The study was published (He et al., 2018); (2) We preliminary determined the
mechanism of the synergistic effects between CAP and AuNPs. The further studies about
signalling pathway and detailed mechanism of CAP-accelerated uptake is being carrying
out and is presented in Chapter 3. In Chapter 3, the objective was determining the possible
endocytosis pathways activated by low dose CAP treatment. For deliverables: (1) The
study described above was published (He et al., 2020); (2) For the first time, we
discovered the membrane repairing clathrin-dependent endocytosis was activated after
being treated with CAP, whereas it increases the accumulation of AuNPs inside cells and
eventually leads to cell death. This mechanism of RONS-induced endocytosis will also
be of relevance to other cancer therapies that induce an increase in extracellular RONS.
In Chapter 4, the objective was screening all prodrug candidates and identify possible
leading candidates that have significant synergy with CAP treatment. For deliverables:
(1) Screening of all 47 prodrug candidates was carried out and the alamar blue assay was
used for all compounds to determin their dose response curves against U373MG cells
with or with CAP treatment; (2) The manuscript is in preparation and will be submitted
for publication soon; (3) We have indentified two leading candidates and the possible
mechanism of the activation of prodrug JW-04-061 by CAP treatment.
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CHAPTER 2. COLD ATMOSPHERIC PLASMA
PROMOTE THE UPTAKE AND ACCUMULATION
OF GOLD NANOPARTICLES IN U373MG CELLS

Part of this Chapter has been published.
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ATP-dependent endocytosis of nanoparticles and synergistic u373mg cancer cell
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2.1

Introduction

Gold nanoparticles (AuNPs) can be used as diagnostic agents, radiosensitizers and drug
delivery vehicles, due to their specific physical and chemical properties, such as strong
surface plasmon resonance effect, high stability and low cytotoxicity (Jain, ElSayed and
El-Sayed, 2007; Cheng et al., 2011; Joh et al., 2013). AuNPs can be readily manufactured
in various controllable shapes, sizes and monodispersity. Though non-functionalized
AuNPs can show selective cytotoxicity to certain cell lines, especially cancer cells (Patra
et al., 2007), AuNPs are generally considered nontoxic to normal cells (Connor et al.,
2005; Alkilany and Murphy, 2010). Cytotoxicity of AuNPs is size dependent, small
AuNPs elicit higher cytotoxicity than larger AuNP. AuNPs of ~20 nm diameter elicit
relatively low cytotoxicity in both normal and cancer cells (Pan et al., 2007) and are
optimal for traversing the blood brain barrier to enter the brain (Shilo et al., 2015). The
surface chemistry of AuNPs enables bio-conjugation and bio-modification, for example,
conjugation of antibodies to assist in targeting or conjugation of chemotherapeutic or
detection agents (Cheng et al., 2011; Joh et al., 2013). These properties underpin the
emergence of gold nanoparticles as promising therapeutic and diagnostic administration
systems to treat neoplasms.
Plasma, a form of ionized gas, is one of the four fundamental states of matter and by far
the most common form of matter in the universe. Initially, biomedical applications of
plasma concentrated on heat and high temperature, i.e. thermal plasmas, for tissue
removal, sterilization, and cauterization (Fridman et al., 2008). Technological advances
have allowed researchers to generate plasmas at ambient temperatures and at
approximately 1.0 atmospheric pressure, allowing safer application to biological samples
and tissues without risking thermal injury. These are known as non-thermal atmospheric
plasma (NTAP) or Cold Atmospheric Plasma (CAP). CAP has been investigated as a
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promising technique for various biomedical applications including tumour therapies,
sterilization, wound healing and local viral and microbial infection control (Isbary et al.,
2012; Shi et al., 2012; Zelzer et al., 2012; Yan et al., 2015). CAP generates a unique
physical and chemical environment for exposure of biological tissues, eliciting effects
such as activation of short and long lived reactive nitrogen species (RNS, e.g. N2+, NO3
and NO, etc.) and reactive oxygen species (ROS, e.g. OH•, O and O2•, etc.), photons as
well as generation of heat, pressure gradients, charged particles, and electrostatic and
electromagnetic fields (Kong, Keidar and Ostrikov, 2011; Babington et al., 2015), many
of which are known to induce effective death pathways in cancer cells (Yan et al., 2015).
Synergistic anti-cancer effects between AuNPs and CAP have emerged as a promising
potential approach in cancer therapy studies. Kim et al. first reported that cytotoxicity of
CAP to melanoma cells was significantly increased (near five-fold) by combining with
antibody-conjugated AuNPs (Kim et al., 2008). Zhu et al. showed that CAP coupled with
drug loaded core-shell AuNPs led to a significant enhancement in growth inhibition of
breast cancer cells compared with control groups (Zhu et al., 2016). Other studies have
also suggested that AuNPs have synergistic cytotoxicity when combined with CAP in
cancer treatment (Cheng et al., 2014; Irani et al., 2015). However, the effects of CAP and
AuNPs can vary due to the wide range of different AuNP, CAP-generating devices and
cell lines.
The current research uses an experimental dielectric barrier discharge (DBD) plasma
device, DIT 120, with a maximum voltage output of 120 kV at 50 Hz generated between
two 15 cm diameter aluminium disk electrodes (Figure 7a, b) (Ziuzina et al., 2013;
Patange et al., 2017). We have previously characterised biological activities in cancer
cells that are dependent and independent of reactive species generation using this system
(Boehm et al., 2016; Conway et al., 2016). We wished to explore the mechanism of CAP
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and AuNPs induced cytotoxicity in cancer cells using our system. Using various
analytical chemistry, biochemistry and microscopy to characterise the effects of CAP on
AuNP, we provide evidence that direct exposure to CAP induces increased AuNPs
endocytosis and trafficking to lysosomes, which could be the mechanism of the
synergistic cytotoxic effects observed in GBM U373MG cells.

Figure 7. CAP demonstrates no significant effect on AuNPs (≤100μg/ml) within
culture medium or water.
(a) Schematic of the DIT120 Plasma Device used in this study. (b) A photograph showing
plasma generation (blue) and treatment on cell samples. (c) 20nm AuNPs were diluted to
different concentrations with cell culture medium or water. The mixed solutions were
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treated with CAP (75 kV, 30 s), incubated for 24h, then measured the sizes by Zetasizer.
(d) AuNPs were diluted in cell culture medium or water to 100μg/ml and treated with
CAP at 75 kV for 0, 30 s. Zeta potential was then measured by Zetasizer. (e) STEM of
AuNP, from left to right: mixed with water; mixed with culture media; mixed with culture
medium then exposed to CAP for 75 kV, 30 s, AuNPs concentrations are 100μg/ml. For
Fig. 1c and d, Zetasizer measurements were repeated in six replicates. Statistical analysis
was carried out using one-way ANOVA with Bonferroni’s multiple comparisons post-test.

2.2

Materials &Methods

2.2.1 Cell Culture.
The human brain glioblastoma cancer cell line U-251 MG (formerly known as U-373
MG) (ECACC 09063001) were obtained from Dr Michael Carty (Trinity College Dublin).
The stock held as U-373MG in ECACC was found to be identical by STR-PCR profiling
to U-251, so now has been re-named as ‘U-251 MG (formerly known as U-373 MG)’.
The new deposit of U-373 MG is named as U-373 MG (Uppsala) (ECACC catalogue
number 08061901). However, the U-373MG cell line used in this project is considered
as a subclone of U-251 and has been demonstrated to display variations in phenotypic
marker expression as well as differences in growth characteristics, which may explain
that various laboratories reported different results from U-373MG and U251 cell lines
(Torsvik et al., 2014). Therefore, we used term U373MG in this thesis and only added
explanation in all Method Sections to distinguish it from the U-251 and U-373MG
(Uppsala) cell lines. Cells were cultured in Dulbecco’s Modified Eagle’s Media-high
glucose (Sigma-Aldrich) supplemented with 10% foetal bovine serum (Sigma-Aldrich)
and 1% penicillin and streptomycin mixture (Thermo Fisher Scientific) in TC flask T25,
standard for adherent cells (Sarstedt). The cultures were maintained under a condition of
5% (v/v) CO2 and 37 ℃ in a humidified incubator. Culture medium was changed every
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2 days until reaching around 80% confluency. Cells were then brought into suspension
using 0.25% trypsin solution (Thermo Fisher Scientific) and subcultured in new flasks.
2.2.2 CAP Configuration and Treatment.
The CAP-DBD device used (Figure 7a, b) is an experimental atmospheric low
temperature plasma generator (Conway et al., 2016). It consists of two aluminium discelectrodes (diameter 15 cm) with a polypropylene sheet in the middle, which is used as
dielectric barrier and holder for the reactor and cell samples. The thickness of the
dielectric barrier is 1.2mm, and the distance between the two electrodes was 26.6 mm.
Samples were placed in a sealed reactor and treated inside or outside the plasma
discharging area. The CAP was generated between two disc-electrodes when the high
voltage was applied. Voltage was monitored using an InfiniVision 2000 X-Series
Oscilloscope (Agilent Technologies Inc., Santa Clara, CA, USA). TC dish 35 standard
(35x10mm, Sarstedt) was used as the cell container for CAP treatment. U373MG cells
were seeded into the dishes at a density of 1×105 cells/ml and incubated overnight to
allow a proper adherence (70-80% confluency). For direct treatment, culture medium was
removed from the dishes before the CAP treatment, then the cell culture dishes were put
between the two electrodes and treated at 75 kV for 0-40 s. The fresh culture medium
containing 100 μg/ml AuNPs or inhibitors was added after exposing to CAP. For CAPactivated culture medium, the fresh culture medium were contained in TC dish 35,
standard and treated with CAP at 75 kV for 30 s and stored overnight to remove shortlived reactive species. AuNPs were added into CAP-activated medium to 100 μg/ml. The
CAP-untreated cells were then incubated with CAP-activated medium containing AuNPs
for 24 and 48 h. The indirect CAP treatment was used to determine the role of direct
physical effects. To indirectly treat cells with CAP, the sample was treated in the reactor
without the dish lid on it, and culture medium was removed before the treatment. The cell
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culture dish was placed on the corner of the reactor, outside the plasma discharging area.
During the treatment (75 kV, 30 s), the reactor was sealed in a high barrier polypropylene
bag (B2630; Cryovac Sealed Air Ltd, Dunkan, SC, USA) to keep the CAP inside the
reactor, and to make sure the cells were only affected by the short-lived and long-lived
reactive species generated in air (Han et al., 2016). Fresh culture medium containing 100
μg/ml AuNPs was then added after indirect CAP treatment.
2.2.3 Gold Nanoparticles Synthesis and Characterization.
20 nm AuNPs used in this study are synthesised by trisodium citrate (Na3C6H5O)
reduction of auric acid (HAuCl4). The typical method of AuNPs synthesis as follows.
HAuCl4 was dissolved in water at a concentration of 0.25 mM in a clean glass flask and
heated with magnetic stirring and brought to boiling. The corresponding amount of 5%
(w/v) sodium citrate solution was quickly added to final 3.5:1 molar ratio of citrate to
Au3+ while being keep heating and stirring. The reaction was completed until the colour
of solution was changed from dark purple to wine red and keep stable. The gold colloid
was then centrifuged at 10000 g for 10 min to concentrate the AuNPs stock solution to
2500 μg/ml. The size, absorbance curve and zeta potential of AuNPs was then determined
by UV-Vis spectrometer (Shimadzu, UV-1800), Zetasizer (Malvern, Nano ZS) and
scanning transmission electron microscopy (STEM). The AuNPs stock solution was
diluted in water or culture medium to corresponding concentration as indicated in the
relevant figures.
2.2.4 Cell Viability Assays.
Cell viability was analysed using the Alamar blue assay (Thermo Fisher Scientific),
which used a redox indicator that can generate fluorescent signal by the metabolic
reduction. U373MG cells were plated into 96-well plates (Sarstedt) at a density of 1×104
cells/well (100 μl culture medium per well) and were incubated overnight to allow a
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proper adherence. The cells were then directly treated with CAP at 75 kV for 0- 30 s at
70-80% confluency, and culture medium containing 0-100 μg/ml AuNPs was added post
CAP treatment. Forty-eight hours late, the cells were rinsed once with phosphate buffered
saline (Sigma-Aldrich), incubated for 3 h at 37 ℃ with a 10% Alamar blue/90% culture
medium solution. The fluorescence was then measured (excitation, 530 nm; emission,
595 nm) by a Victor 3V 1420 microplate reader (Perkin Elmer).
2.2.5 Atomic Absorption Spectroscopy.
U373MG cells were seeded into 60 mm dishes (Sarstedt) at a density of 1×105 cells/ml
and incubated for 2 days to achieving 90-100% confluency. The culture medium was
removed, and cells were directly exposed to CAP at 75 kV for corresponding time. The
fresh culture medium containing 100 μg/ml AuNPs or 0.1% (w/v) NaN3 was then
replaced and incubated for 0.5-48 h at 37 ℃ or 4 ℃ as indicated. After treatment, cells
were washed thrice with phosphate buffered saline to remove the AuNPs outside cells.
Cells were then dissociated and collected from the culture dish using prewarmed (37 ℃)
0.25% trypsin solution. The cell suspension was counted using hemocytometer, then
transferred to 15 ml tube (Sarstedt) to measure the gold atomic absorbance in AAS. To
verify the Au amount of the samples, five-point standard curve were first established
using 1-5 ppm standard gold colloid. The concentrations of AuNPs in samples were then
calibrated by the standard curve as described elsewhere (Trono et al., 2009).
2.2.6 Inhibitor Studies.
To determine the uptake of AuNPs, NaN3 was used as metabolic inhibitor to inhibit the
energy-dependent endocytosis. 20% (w/v) NaN3 stock solution was prepared in
phosphate buffered saline. The cells were pre-incubated with 0.1% (w/v) NaN3 in
prewarmed (37 ℃) culture medium for 1h. The culture medium was then removed during
CAP treatment, then fresh medium containing 0.1% (w/v) NaN3 and 100 μg/ml AuNPs
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was added into the cell culture and incubated at 37 ℃ as indicated. 4 ℃ incubation was
used to inhibit endocytosis as a standard experiment. Cells were incubated at 4 ℃ for 1h
before the CAP treatment, pre-chilled culture medium containing 100 μg/ml AuNPs was
then replaced post CAP treatment and incubated at 4 ℃ for 0.5-6 h as indicated. N-Acetyl
Cysteine (NAC) was used as antioxidant to remove long-lived reactive species. 4 M NAC
stock solution was prepared in water. The cells were pre-incubated with 4 mM NAC in
culture medium for 1 h at 37 ℃. The culture medium was then removed during CAP
treatment. Afterward, cells were incubated in fresh medium with 4 mM NAC and 100
μg/ml AuNPs for 24 and 48 h.
2.2.7 Fluorescent Dyes and Cell Imaging.
Lysosomes was demonstrated using the LysoTracker™ Green DND-26 (Thermo Fisher
Scientific). Cells were seeded in 35 mm glass-bottom dishes (Greiner Bio-One) at a
density of 1×105 cells/ml overnight and treated with CAP for 0-40 s at 70-80% confluency,
the fresh medium containing 0-100 μg/ml AuNPs was then replaced and incubated for
24h or 48 h at 37 ℃ as indicated. After treatment, the cells were rinsed thrice with
phosphate buffered saline and incubated with prewarmed (37 ℃) LysoTrackercontaining (50 nM) medium for 5 min at 37 ℃. Cells were then washed once with
phosphate buffered saline and loaded with fresh phosphate buffered saline and observed
using Zeiss LSM 510 confocal laser scanning microscope fitted with the corresponding
filter settings as follows. LysoTracker™ Green DND-26, excitation wavelength: 488 nm,
emission filter: 505-530 nm; AuNPs, excitation wavelength: 633 nm, reflection filter:
649-799 nm. Plan-Apochromat 63x/1.4 Oil Ph3 was used as objective for all samples. To
determine the level of AuNPs reflection, around 50 cells were randomly imaged for each
treatment condition and the levels of reflection was analysed using the ImageJ and
compared with other groups.
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2.2.8 Statistical Analysis.
All data points were from at least triplicate independent samples and are presented and/or
pooled as mean ±S.E.M unless indicated otherwise. Curve fitting and statistical analysis
were carried out using Prism 6 (GraphPad Software). The Alpha for all tests is 0.05 and
two-tailed P values were used. One-way ANOVA and two-way ANOVA was used to
verify the significance between data points as indicated in figures (*P<0.05, **P<0.01,
***P<0.001, ****p<0.0001).

2.3

Results

2.3.1 The effects of CAP on the physical properties of AuNP.
CAP has been used to fabricate metal nanoparticles (e.g. gold and silver) without adding
reducing agents (Tseng et al., 2009). Moreover, AuNPs are known to agglomerate upon
stresses such as repeated centrifugation, dilution, dialysis, and upon contact with
biological medium (Articles and Results, 2012). We first explored whether exposure of
20 nm AuNPs to our experimental plasma device DIT 120 altered their physical
parameters (size, shape, surface (zeta) potential, or extent of agglomeration) in water and
biological cell culture medium. A concentration range of AuNPs (20 nm, 50-200 μg/ml)
in water or culture medium was treated with CAP (75 kV, 30s), or untreated and incubated
for 24 hours prior to analysis. As evident in Figure 7c, agglomeration was evident at
higher concentrations (>100 μg/ml) in culture medium and no agglomeration of AuNPs
was evident even at 200 μg/ml in water. CAP did not induce any significant change in
particle size and there is no evidence of agglomeration either in water or in culture
medium (Figure 7c, P=0.1160 in medium group, >0.9999 in water group). We also
confirmed that dilution of AuNPs in culture medium to 100 μg/ml and exposure to CAP
(75 kV, 30 s) has no significant change in relation to other physical properties such as
zeta potential (Figure 7d, P>0.05) or optical absorption (see Figure S1 in the Appendix
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III). Moreover, no discernible change in physical parameters was evident using Scanning
Transmission Electron Microscopy, nanoparticles remaining spherical with an average
diameter of 20 nm and displaying similar degrees of dispersion across the surface of the
gird (Figure 7e). As AuNPs were not observed to agglomerate in culture medium for
concentrations AuNPs ≤ 100 μg/ml and no changes in physical parameters were detected
in response to CAP, culture medium containing up to 100 μg/ml AuNPs were used in
subsequent experiments exploring uptake kinetics of AuNP.
2.3.2 Synergistic cytotoxicity when CAP and AuNPs are combined.

Figure 8. Cytotoxic synergy observed between CAP and AuNP.
(a) U373MG cells were treated with different concentrations of AuNPs (0-800 μg/ml).
After incubation for 48 h, cell viability was analysed using the Alamar Blue assay. The
cell viabilities were divided into two phases (red and green) and non-linear regression
was carried out. The 95% confidence bands are displayed using dotted lines. Significant
differences in the slope (p<0.05) are evident using non-toxic AuNPs concentrations (012.5 μg/ml) which was further confirmed using Pearson’s Correlation test (p<0.05). All
experiments were repeated in five replicates. (b) After CAP treatment (75 kV, 0, 30s)
U373MG cells were incubated with 100 μg/ml AuNPs for 24 h, 48 h, then observed under
optical microscope.
In our previous study, U373MG cells were exposed to CAP for between 3 and 300 s at
75 kV and the IC50 value of CAP treatment was determined to be 74.26 s (95% confidence
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range of 47.24–116.8 s) (Conway et al., 2016). The toxicity measured in U373MG cells
exposed to 30 s CAP is low (18.52%, SEM=5.41%) (see Table S1 in the Appendix III).
Figure 8a shows the results of non-linear regression analysis used to calculate IC50 values
and confidence ranges for cells treated with AuNPs alone and AuNPs combined with
CAP (75 kV, 30 s) (see Table S1 in the Appendix III). The IC50 value for AuNPs alone
was 2125 μg/ml (95% confidence range: 1294-3491 μg/ml) (Inverse IC50=~0.471 μl/μg),
which is in agreement with other reports that ~20 nm spherical gold nanoparticles have
very low cytotoxicity to healthy or cancerous cells (Connor et al., 2005; Pan et al., 2007).
The IC50 value for AuNPs combined with CAP was 81.71 μg/ml (95% confidence range:
53.83-124.16 μg/ml) (Inverse IC50=~12.238 μl/μg), ~26 times more toxic by comparing
their inverse IC50. The dose response curve was divided into two phases of toxicity
(Figure 8a) to demonstrate synergy between CAP and AuNP. In the first phase, using low
concentrations of AuNPs (0-12.5 μg/ml), a sharp and significant drop in viability was
observed only when cells were incubated with both CAP and increasing AuNPs
concentrations. The 95% confidence intervals of the slope of CAP and AuNPs treated
cells during first phase (-63.57 to -33.43) was significantly different to AuNPs only
treated cells (-5.573 to 12.71). We believe this provides evidence that CAP and AuNPs
have a synergistic cytotoxicity to U373MG cells and the uptake of AuNPs could reach to
a threshold with increase concentration of AuNP.
Morphological assessment using bright-field microscopy confirmed the accumulation of
AuNPs in cells, but this was significantly greater when cells were pretreated with CAP
(Figure 8b). We therefore hypothesised that CAP can accelerate the uptake and
accumulation of AuNPs into U373MG cells, thereby causing higher cytotoxicity. To
explore the mechanism of synergistic cytotoxicity of CAP and AuNPs, we used 100 μg/ml
AuNPs which is close to the IC50 value, at which no discernible physical changes to
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AuNPs was observed.
2.3.3 Role of active (ATP-dependent) and passive (ATP-independent) transport
mechanisms.
To confirm the hypothesis that CAP affects enhanced AuNPs uptake, and to investigate
the mechanisms, Atomic Absorption Spectroscopy (AAS) was used to quantify the total
amount of gold in cells. Intracellular AuNPs accumulated over time and followed a
similar overall non-linear relationship for cells with or without exposure to CAP. We
observed that CAP significantly increased both the initial rate of uptake and total amount
of AuNPs accumulated in cells (Figure 9a).
To confirm whether active transport or passive diffusion mechanisms were involved, we
used the mitochondrial decoupler, NaN3, to identify endocytosis, in which ATP is the rate
limiting component. Meanwhile, cold temperature incubation (4 ℃) was used to inhibit
all energy-dependent uptake in cells. NaN3 inhibited AuNPs uptake by about 50% when
compared with controls (Figure 9a). Interestingly, NaN3 treatment inhibited the uptake of
AuNPs in both CAP-treated cells and untreated cells. No significant difference was
observed between these two groups between 4 and 48 hours (Figure 9a), indicating that
CAP-stimulated uptake of AuNPs is mainly ATP-dependent. On the other hand, NaN3
can act as a RONS scavenger, which may lead to different conclusions. In Chapter 3,
AuNPs have been demonstrated to be uptake into cells mainly via endocytosis when the
cell membrane remains intact. We have demonstrated that the membrane lipids were
partly peroxidised by the membrane got repaired rapidly and remains intact. Therefore,
we can confirm that NaN3 mainly inhibited the ATP-dependent endocytosis pathway.
Cells were then incubated at 4 ℃ for 0.5, 1, 4, 6 h (cell viability was affected at longer
time points). As expected, uptake of AuNPs was significantly inhibited compared with
controls (Figure 9a). Together, we believe this provides evidence that an active transport
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mechanism, most likely endocytosis, is the major route of uptake of AuNPs in cells,
which occurred between 0 and 16 hours after incubation with AuNP, and which was
stimulated by CAP exposure. We could not rule out other transport mechanisms playing
a minor role. For example, we observed a small fraction (i.e. 10%) of CAP-stimulated
AuNPs accumulation in cells that was not inhibited in either NaN3 or 4 ℃-incubated cells.
This second, minor CAP-dependent uptake mechanism occurs within 1-hour exposure to
NaN3 (Figure 9b) and 4 hours of exposure to 4 ℃-incubated cells (Figure 9c). Plasmaactivated culture medium (PAM) containing AuNPs was used to treat cells to determine
the role of long-lived reactive species (Judée et al., 2016). As seen in Figure 9d, the uptake
of AuNPs in PAM showed no significant difference when compared with the control after
24 and 48 h incubation.

Figure 9. AAS analysis demonstrate the accelerated uptake of AuNPs into cells.
(a) After CAP treatment (75 kV, 0, 30s), U373MG cells were treated with 100 μg/ml
AuNPs together with 1% NaN3 or without to inhibit endocytosis, then incubated at 37 ℃
or 4 ℃ as indicated before calculating the average amount of Au per cell using AAS. The
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uptake curves were assessed by non-linear regression analyses. All experiments were
repeated in six replicates. (b) The short-time effects of CAP with or without 1% NaN3
were compared. (c) The uptake of AuNPs incubated at 4 ℃ for 0.5, 1, 4, 6 h. (d) The role
of long-lived ROS generated by CAP on endocytosis in U373MG cells was determined by
using Plasma activated medium (PAM; 75 kV, 30 s, stored overnight) in place of CAP.
For Figure 9b-d, all experiments were repeated in six replicates. The statistical
significances were assessed by two-way ANOVA with Tukey’s multiple comparison posttest (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
2.3.4 Subcellular localization of AuNPs endocytosed in response to CAP treatment.
Despite the accuracy of using AAS to quantify to total amount of Au in a sample, one
limitation with the technique is the difficulty in differentiating between AuNPs that are
loosely associated with the plasma membrane compared with intracellular AuNP. To
verify the uptake of intracellular AuNP, investigate the subcellular location and quantify
the rate of uptake, we used confocal microscopy (Figure 10). Unlabelled, citrate-capped
AuNPs were visualised using reflection of laser light from the colloid gold (red dots) and
lysosomes were counterstained using LysoTracker Green, as shown in Figure 10a. The
absorption spectrum of 20nm AuNPs confirmed that the absorption peak is around 520
nm, and that there is minimal absorbance above 600 nm (see Figure S1 in the Appendix
III). The reflection filter setting for AuNPs was set at 649-799 nm and the emission filter
for LysoTracker Green was set at 505-530 nm. This allowed us to confirm that the green
fluorescence signal is from LysoTracker Green (excited with argon laser) and red
reflection is from AuNPs (reflected light from HeNe laser). A significant fraction of
intracellular colocalization was evident (yellow), indicating that the lysosomal
compartment was the major destination of AuNPs following CAP-stimulated uptake
(Figure 10a). Interestingly, some AuNPs were not located in lysosomes, suggesting that
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these AuNPs remained in early endosomes or had entered the cytosol, either by passive
diffusion, transport mechanisms through the cell membrane or released from lysosomes
subsequent to endocytosis. Significantly higher levels of intracellular AuNPs in cells
were observed following CAP treatment (Figure 10b), in agreement with our AAS data.
Moreover, varying the dose of CAP confirmed a significant, strong and positive
correlation exists between exposure to CAP and subsequent AuNPs uptake (Figure 10c),
Pearson’s correlation, r=0.9359, P=0.0193.
Z-stacked images were obtained to ensure that only intracellular AuNPs were quantified.
Stacked, deconvoluted confocal images were next reconstructed using rendering software
(Imaris 8.0. Bitplane) to generate 3 dimensional reconstructions of individual cells. The
presence of AuNPs (red) inside lysosomes (green) was confirmed by rotating and
sectioning the cells around the three spatial axes and projecting sections from the x, y and
z planes of the reconstructions (Figure 11a, b. Taken together, our data confirm that CAP
induces synergistic cytotoxicity while-stimulating the uptake of citrate capped 20nm
AuNPs through a predominantly endocytic mechanism, leading to trafficking of the
AuNPs into acidic (lysosomal) compartments of U373MG cells.

71

Figure 10. Uptake and subcellular localization of AuNPs observed by confocal
microscopy.
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(a) After CAP treatment (75 kV, 0, 30 s), U373MG cells were incubated with 100 μg/ml
AuNPs for 24 h. Cell lysosomes were stained using 50 nM LysoTracker™ Green DND26. The reflection of AuNPs was measured by confocal microscopy. (b) After CAP
treatment (75 kV, 0, 30 s), U373MG cells were incubated with 100 μg/ml AuNPs for 24
h, 48 h. Cells were then measured by confocal microscopy, the level of reflection of
AuNPs was quantified using ImageJ. The statistical significance was assessed by twoway ANOVA with Tukey’s multiple comparison post-test (*P<0.05, **P<0.01,
***P<0.001, ****p<0.0001), n≥20. (c) After exposure to CAP for increasing time (75
kV, 0-40 s), U373MG cells were incubated with 100 μg/ml AuNPs for 24 h. Cells were
then measured by confocal microscopy, the level (Integrated Density) of reflection of
AuNPs was quantified using the software, ImageJ. Statistical analysis was carried out
using Pearson’s correlation, r=0.9359, *P (two-tailed) =0.0193, n≥20.
2.3.5 Role of physical and chemical effects of CAP on AuNPs uptake.
Our data indicated that long-lived reactive species present in plasma activated medium
(PAM) did not play a major role in enhanced uptake of AuNPs (Figure 9d). We wished
to further investigate effects of CAP on AuNPs endocytosis. Due to the set-up of the DBD
plasma device, samples can either be placed directly in the plasma discharging area
(direct exposure) or outside the plasma-discharging area (indirect exposure). Plasma
sources for direct or indirect plasma treatment were previously distinguished by Fridman
et, al. (Fridman et al., 2008) and more recently by Von Woedtke et, al. (2013) (von
Woedtke et al., 2013). In indirect plasma treatment, the electrodes are part of the plasmagenerating device, only and there is no significant electrical contact to the targeted
structures, whereas in direct plasma treatment, the biological samples serve as one of the
two electrodes. In both cases, samples are contained within a sealed reactor. Direct
exposure results in direct interaction with UV, electric fields, electron beams, charged
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particles, whereas indirect exposure does not result in any interaction with these physical
species. However, the sealed reactor system still allows the exposure of reactive species
to cells. It has been demonstrated that ozone concentration and reactive oxygen species
generated are not significantly different during direct or indirect CAP exposure (Ziuzina
et al., 2013; Han et al., 2016). We investigated the difference between direct and indirect
CAP treatment on AuNPs uptake to differentiate between direct physical effects and
chemical (oxidation) effects. Our results demonstrated that AuNPs uptake was
significantly higher when cells were treated with indirect CAP exposure compared with
untreated cells, suggesting that chemical effects were important in promoting endocytosis
(Figure 11c, d). The enhanced AuNPs uptake was consistently slightly lower compared
with direct CAP exposure although we were not able to determine a significant difference,
suggesting that any physical effects only play a minor role in the increased uptake of
AuNP. We used N-Acetyl Cysteine (NAC), a synthetic precursor of intracellular cysteine
and glutathione (GSH) that replenishes intracellular GSH and scavenges reactive species
as a redox buffer (Deneke, 2001) to remove long-lived ROS in situ during CAP treatment.
This was ineffective in significantly reducing AuNPs uptake enhanced by CAP (Figure
11c, d), suggesting that either the oxidising environment generated by CAP overwhelms
GSH and other intracellular anti-oxidant defences, or that NAC-insensitive chemicals
produced by both direct and indirect contained CAP fields are the primary cause of
enhanced AuNPs uptake.
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Figure 11. AuNPs are incorporated within lysosomes in glioma cells.
(a) 3D reconstruction of the CAP-treated glioma cells visualized with dichroic channel
(grey), incorporating AuNPs (red) within lysosomes (LysoTracker green). U373MG cells
were incubated with 100 μg/ml AuNPs for 24 h, after CAP treatment (75 kV, 0, 30 s) and
a significant increase of AuNPs was observed in the entire cells but being part located
inside lysosomes. High magnifications in bottom panel show lysosomes evidenced with
green isosurface. Vertical and horizontal clipping planes reveal red AuNPs nanoparticles
inside lysosomes. Boxes at the bottom indicate the orientation of the clipping planes (b)
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Analogous 3D reconstruction of CAP-untreated cells, demonstrated low incorporation of
AuNPs inside the cells. High magnification at the bottom panel shows lysosomes rendered
with green isosurface. Horizontal clipping plane revealed no red material inside
lysosomes. (c, d) The role of short and long-lived reactive species generated by CAP on
endocytosis in U373MG cells was determined by pretreating cells with 4 mM anti-oxidant
N-Acetyl Cysteine (NAC) for 1 h before CAP treatment (75 kV, 30 s) or by indirect CAP
treatment (see detail in Method). The level of reflection of AuNPs was quantified using
the ImageJ after incubated for 24 (c) or 48 hours (d). The statistical significance was
assessed by two-way ANOVA with Tukey ’ s multiple comparison post-test (*P<0.05,
**P<0.01, ***P<0.001), n≥20..

2.4

Discussion

AuNPs have been developed as promising theranostic agents for brain cancer therapy in
diverse applications, such as in vivo tumour imaging, inducing radiosensitization and
targeted delivery of chemotherapeutics across blood-brain barrier (BBB) to brain cancer
cells (Joh et al., 2013; Setua et al., 2014). As an emerging platform for drug delivery, the
toxic effect of AuNPs to normal cells can be minimized or eliminated by altering the size.
(Pan et al., 2007) However, the proportion of AuNPs that penetrate the BBB is usually
no more than 1% (Dykman and Khlebtsov, 2012). To date, efforts to enhance AuNPs
crossing of the BBB have been mainly focused on targeting AuNPs to the surface
receptors of endothelial cells (Kumar, Zhang and Liang, 2013) and the limited success
means that there is still need for further studying the mechanisms of crossing BBB and
blood-tumour barriers, etc. The permeability, targeting capacity and uptake of AuNPs
into targeted cancer cells are the key to successful clinical application of AuNP. CAP
treatment has been extensively investigated in cancer therapy, due to its promising
selective capacity of killing a wide range of cancer cells (Yan et al., 2015), such as
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carcinomas, glioblastomas, melanomas and hematopoietic malignancies (Kim et al., 2008;
H. J. Lee et al., 2009; Yan et al., 2012). In recent years, CAP has been successfully and
safely used in a prospective clinical trial for head and neck cancer treatment and chronic
wound healing, demonstrating significant benefits and no side-effects. Meanwhile, the
synergistic anti-cancer effects between AuNPs and CAP were reported in several
previous studies (Kim et al., 2008; Cheng et al., 2014; Irani et al., 2015; Kaushik et al.,
2016; Zhu et al., 2016).
Although cancer cells are generally reported to be favourably sensitive to CAP induced
cytotoxicity when compared with normal cells or tissues (Babington et al., 2015),
U373MG GBM cells have significantly higher resistance to CAP treatment compared to
other cancer cell lines (Conway et al., 2016). GBM cells also show high aggressiveness
and resistance to radiation therapy and most chemotherapies (Candolfi et al., 2007). There
is evidence in the literature that AuNPs have synergistic cytotoxicity combined with CAP,
although the mechanisms remain to be elucidated. Therefore, we chose to study the
mechanism of CAP, combined with AuNP, as a possible future chemotherapy delivery
vehicle. In this study, we confirmed that combining CAP with AuNPs increased around
25-fold of U373MG cell death compared to AuNPs only. We also demonstrated that CAP
treatments accelerate the endocytosis of U373MG cells by temporarily increaseing
membrane permeabilisation or turnover, thereby increasing uptake and cytotoxicity of
AuNP. These effects will be useful to induce higher selective cytotoxicity against cancer
cells while increasing drug delivery efficiency and/or imaging diagnostics for cancer
therapy.
In this study, we used 20 nm citrate capped AuNPs, which not only have optimal BBB
permeability and low toxicity, but also can rapidly enter cells, mostly by receptormediated endocytosis (Gao, Shi and Freund, 2005; Pan et al., 2007; Shilo et al., 2015).
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Therefore, 20 nm AuNPs can be the optimal candidate for drug delivery across BBB. We
were able to confirm that the observation of the uptake of 20 nm citrate capped AuNPs
are consistent with endocytosis and a large proportion of them were trapped in lysosomes
in both CAP-treated and untreated U373MG cells (Figure 9, 4 and 5). We confirmed that
CAP did not discernibly alter the physical properties of AuNP, although we did see
evidence that CAP could stimulate low levels of non-active uptake through an ATPindependent mechanism, which may indicate some level of surface modification or other
physical change to AuNPs and/or cell membranes. Although we were unable to detect
physical changes to AuNPs exposed to CAP, significant alterations in cell membranes
after exposure to CAP were previously observed by others (Recek et al., 2015). Our
observation that synergistic cytotoxicity occurs in parallel with enhanced uptake suggests
the two processes are linked in U373MG cells. Although, there have been no studies
reported to date on the relative sensitivity of normal and GBM cells to CAP-induced
endocytosis, it has been demonstrated that the significant alterations in cell membrane of
GBM cells induced by CAP treatment is maintained, whereas the membrane alteration in
normal human astrocytes E6/E7 is weaker and reversible (Recek et al., 2015). More
detailed mechanisms regulating the uptake of nanoparticles in normal and GBM cells will
be investigated in a follow-on study. A controllable, directable CAP treatment, which is
directly applied to diseased tissue, also is expected to be included to present the in vivo
experiment in the follow-on study. At this stage, we provided a likely hypothesis as
follows.
It is possible that enhanced uptake of AuNPs may underpin the synergistic cytotoxicity
observed, in combination with other effects such as the higher load of reactive species
carried by CAP-treated AuNP. For example, it has been reported that AuNPs are capable
of trapping reactive species and extending their half-life, and thus helping the delivery of
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CAP generated reactive species into cancer cells (Kong, Keidar and Ostrikov, 2011). It
is also likely that the enhanced accumulation of AuNPs is caused by one of three effects
attributed to CAP, i.e. reactive species, direct physical effects and cellular mechanism
(mainly endocytosis).
Considering the potential role of reactive species, hydrogen peroxide (H2O2) was found
to be capable of facilitating the endocytosis of polyethylenimine /oligonucleotide
(PEI/ON) complexes, involving a cytoplasmic [Ca2+]-independent activation of
calcium/calmodulin-dependent

protein

kinase

II

(CaMKII),

which

stimulates

cytoskeleton contractions and transportation (Ma, Sun and Wang, 2014). It was also
found that the ROS generated in mitochondria mediate the hypoxia-induced endocytosis
in alveolar epithelial cells (Dada et al., 2003). It is considered that CAP is capable of
influencing cell behaviour by generating intracellular ROS and RNS (Conway et al.,
2016). These studies imply that the CAP-generated intracellular ROS could have an
impact on the enhanced endocytosis. Meanwhile, reactive species are capable of inducing
membrane damage and increasing the permeability of cell membrane (Djordjević, 2004).
The reactive species generated in the cytoplasm or in the medium can induce lipid
peroxidation in membranes by oxidizing the polyunsaturated fatty acids. Reactive species
are also able to attack membrane proteins, causing the membrane damage (Djordjević,
2004). It has been found that the membrane lesions are capable of activating rapid
endocytosis to remove damage parts and preserve and repair the integrity of cell
membrane (Idone et al., 2008). Therefore, it is possible that the chemical and physical
membrane damage caused by CAP could activate the membrane repair response, thus
accelerating the endocytosis of AuNPs. Although we found that long-lived reactive
species have little effect on the uptake of AuNPs (Figure 9d), the short-lived, highly
reactive species may play a role in the stimulated uptake, which will need to be further
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elucidated.
Considering the direct physical effects, which are mainly electrical factors in DBD CAP
treatment, Jinno, M et, al. has described the roles of chemical (reactive species) and
electrical effects of CAP in the CAP gene transfection in L-929, mouse fibroblast cells
(Jinno et al., 2016). It was found that reactive species alone do not work, but need to be
combined with electrical effects. Electroporation effects, which can last for a few minutes,
were also found to play a role in gene transfection (Jinno et al., 2016). Computational
modelling was used to determine that large pore formation in spherical cell membranes
(i.e. 15-25 nm) can be induced in strong electric fields in silico (Krassowska and Filev,
2007), a notion which has since been confirmed for 20 nm AuNPs in vitro (Zu et al.,
2014). Meanwhile, it was observed that the treatment of CAP in GBM cells results in an
uneven membrane and development of membrane pores (Cheng et al., 2015). Nina Recek
et. al. have studied the differential effects of CAP on cell membranes of normal human
astrocytes (E6/E7) and GBM cells by atomic force microscopy. CAP treatment causes a
temporary disappearance of microvilli in E6/E7, and unrecoverable partial cell
membranes and cell components damage of GBM cells. The temporary pores created in
membranes and membrane damage could be the ATP-independent mechanism that
stimulates low levels of non-active uptake of AuNPs during the first few hours after
treatment with NaN3 or under low-temperature incubation (Figure 9b, c). Moreover, it is
also known that CAP is capable of temporarily changing the polarity/potential of the
membrane, which also could play a role in stimulating endocytosis (Dong, Liu and Xiong,
2017). As seen in Figure 11c, d, the indirect treatment, which removes the direct physical
effects caused by CAP, showed only slightly decreased accumulation of AuNPs and no
significant difference evident compared with direct treatment. It confirmed that the
temporary direct physical influence caused by DBD CAP treatment plays only a minor
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role in the increased uptake of AuNP.
It is considered that the endocyosis of cells can be stimulated by CAP via reactive species
and other mechanisms such as membrane damage, as indicated above (Idone et al., 2008;
Ma, Sun and Wang, 2014; Jinno et al., 2016). In gene transfection, the clathrin-dependent
endocytosis stimulated by CAP was found to be dominant in the uptake, while
synergistically combining with electrical effects (Jinno et al., 2016). We observed two
phases to the enhanced uptake of AuNP. Over the first one hour, we observed both
increased endocytosis and possibly also increased passive diffusion through damaged or
otherwise permeable membranes (Figure 9b, c). We then observed a second phase,
between 4 and 18 hours, where AuNPs uptake was further accelerated by CAP primarily
though endocytosis with no evidence for further passive mechanisms before reaching a
maximum accumulated threshold (Figure 9a).
Taken together, we report that the synergistic cytotoxicity of AuNPs and CAP is a result
of enhanced endocytosis and trafficking to the lysosomal compartment as well as
temporarily increased membrane permeability, due to CAP treatment. This contributes
understanding to the mechanisms of synergistic cytotoxic effects between CAP and
nanotechnologies and identifies strategies that may be employed for the release of drugs
when used in a drug-delivery capacity.
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CHAPTER 3. COLD ATMOSPHERIC PLASMA
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3.1

Introduction

Cold atmospheric plasma (CAP) is increasingly studied in a growing number of clinical
trials for cancer treatment (Fridman et al., 2008; Guerrero-Preston et al., 2014) and
research is ongoing to explore the combination of CAP with other therapies, including
nanoparticles, radiotherapy and chemotherapy (Kim et al., 2008; Collet et al., 2014; He
et al., 2020).
Gold nanoparticles (AuNPs) are known to be weakly-toxic to human cells and be readily
manufactured and designed for targeting delivery of various therapeutic compounds into
cells. Citrate-capped cationic AuNPs may adsorb serum proteins onto their surface and
thereby stimulate receptor-mediated endocytosis(Alkilany and Murphy, 2010). Without
special surface functionalisation, AuNPs enter cells and become trapped in vesicles
(Chithrani, Ghazani and Chan, 2006; Alkilany and Murphy, 2010; Freese et al., 2012) or
enter the nucleus, depending on their size/shape (Tsoli et al., 2005; Ryan et al., 2007).
Meanwhile, AuNPs with functionalised surface chemistries/ligands can directly penetrate
the membrane and enter the cytoplasm (Verma et al., 2008).
Recently, AuNPs have emerged as a promising reagent, combined with CAP, for anticancer therapy (Kim et al., 2008; Irani et al., 2015; Zhu et al., 2016). CAP generates a
unique physical and chemical environment, including generating short- and long-lived
reactive nitrogen species (RNS, e.g. excited N2, N2+, ONOO- and NO•, etc.) and reactive
oxygen species (ROS, e.g. •OH, O, •O2- and O3, etc.), photons as well as heat, pressure
gradients, charged particles, and electrostatic and electromagnetic fields, many of which
are known to induce biological effects (Stoffels, Kieft and Sladek, 2003; Kong, Keidar
and Ostrikov, 2011; Babington et al., 2015). Parallels to this can be found in phagocytes
of the immune system. Enzymatic production of RONS along with various hypohalous
acids, especially hypochlorite, play a significant role in respiratory bursts, also known as
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oxidative bursts, which are used in the clearance of tumour cells by phagocytic immune
cells including neutrophils, macrophages and monocytes (Reuter et al., 2010). Anticancer cytotoxicity induced by respiratory bursts has been shown to induce spontaneous
regression in mouse tumour models (Chao et al., 1994; Hicks et al., 2006; Zivkovic et al.,
2007).
Reactive species can induce a free radical chain reaction in membrane lipids leading to
lipid peroxidation, oxidative degradation of the lipids, disruption of membrane function
and induced injury and disorder in cells. Peroxidated lipid products can induce further
propagation of free radical reactions (Halliwell et al., 1992). Several ROS and RNS
generated by CAP can induce cell injures via lipid peroxidation (Leopold and Loscalzo,
2009), for instance, hydroxyl radicals (•OH) react with various cellular components,
including membrane lipid (Adibhatla and Hatcher, 2008) while superoxide (•O2- ) can
form peroxynitrite (ONOO-), which is able to initiate lipid peroxidation, after reacting
with nitric oxide (NO) (Adibhatla and Hatcher, 2008). RNS, such as NO2 and ONOOH,
also interact with lipids to form nitrated lipids, which have been demonstrated to play
roles in vascular and inflammatory cellular signalling pathways (Leopold and Loscalzo,
2009).
Independent application of AuNPs and CAP for cancer therapy has been widely
investigated. Recent studies have shown that combination of AuNPs and CAP is
emerging as a novel and promising therapeutic approach against malignant tumours,
resulting in synergistic anti-cancer effects. Synergistic cytotoxicity has been
demonstrated for various AuNPs when combined with CAP against several cancer cell
lines including melanoma (Kim et al., 2008), breast cancer (Zhu et al., 2016),
glioblastoma (Cheng et al., 2014), alveolar basal epithelial cancer (Kim et al., 2017) and
colorectal cancer cells (Irani et al., 2015).
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In our previous study, we demonstrated CAP in combination with AuNPs shows
promising synergistic cytotoxicity to U373MG Glioblastoma multiforme (GBM) cells
and ATP-dependent uptake mechanism (He et al., 2018). Kim et al. demonstrated that
epidermal growth factor-conjugated AuNPs combined with CAP induced DNA damage
and selective apoptosis of A549 human cancer cells after uptake via receptor-mediated
endocytosis (Kim et al., 2017). Shi et al found that CAP treatment can induce irondependent oxidative stress to stimulate fluid-phase endocytosis in in mesothelioma cells
(Shi et al., 2017).
However, the precise route of uptake requires further investigation. Herein, we
demonstrate, for the first time, that synergistic effects of nonfunctionalised AuNPs
combined with CAP is via clathrin-mediated endocytosis pathway and is triggered as part
of the CAP-induced membrane repair process in GBM cells. Numerical modelling of the
uptake of AuNPs, confirmed that CAP treatment stimulated a new uptake route separate
from normal cellular processes and in response to lipid peroxidation. Meanwhile, our use
of CAP as an alternative novel tool to trigger and understand membrane oxidative damage
and repair mechanisms is outlined.

3.2

Methods

3.2.1 Cell Culture and Gold Nanoparticle Treatment.
U-251 MG (formerly known as U-373 MG) (ECACC 09063001), human brain
glioblastoma cancer cells (Obtained from Dr Michael Carty, Trinity College Dublin) were
cultured in DMEM-high glucose medium (Merck, Arklow, Ireland) supplemented with
10% FBS (Merck) and maintained in a 37 ℃ incubator within a humidified 5% (v/v) CO2
atmosphere. Gold nanoparticles were synthesised by trisodium citrate reduction of auric
acid. 20nm sphere citrate-capped AuNPs were used to treat cells whose properties were
determined in a previous study (He et al., 2018). The gold colloid was concentrated to
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2500 μg/ml then diluted in culture medium to 100 μg/ml.
3.2.2 CAP Configuration and Treatment.
The current research uses an experimental atmospheric dielectric barrier discharge (DBD)
plasma reactor, which has been described and characterised in detail (Moiseev et al., 2014;
Conway et al., 2016). Unless otherwise stated, all U373MG cells were treated within
containers, which were placed in between two electrodes, at a voltage level of 75 kV for
30 s. The culture medium was removed prior to CAP treatment then replaced with fresh
culture medium afterwards.
3.2.3 H2DCFDA Assay and Optical Emission Spectroscopy (OES) and Ozone
measurement.
H2DCFDA (Thermo Fisher Scientific, Ballycoolin, Ireland) was used to detect ROS
induced by CAP treatment. U373MG cells were seeded into the TC dish 35 standard
(Sarstedt, Belfast, UK) at a density of 2×105 cells/ml and incubated overnight to allow
adherence. After washing twice with PBS, cells were incubated with 25 μM H2DCFDA
in serum-free medium for 30 min at 37 ℃. Cells were then washed with PBS twice,
culture medium once and treated with CAP at 75 kV for 30s. The fluorescence of
H2DCFDA was measured using flow cytometry 30 minutes later.
Optical emission spectroscopy was carried out using an Edmund Optics CCD
spectrometer with a spectral resolution of between 0.6 nm to 1.8 nm. The spectra was
measured using BWSpecTM software with a spectral range between 200 and 850 nm and
was acquired every 7.5 s with an integration time of 1500 ms. Total relative intensity of
each emission line was calculated using the integral of the area under each peak. EEDF
was calculated using a line ratio method (N2 at 337 nm and N2+ at 391 nm) (Begum,
Laroussi and Pervez, 2013). O3 was sampled using a standard Gastec sampling pump in
conjunction with a Gastec detection tubes immediately after plasma discharge had ceased.
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3.2.4 Measurement of Hydrogen Peroxide, Nitrite and Nitrate Concentrations.
The concentrations of hydrogen peroxide, nitrite and nitrate were quantitatively measured
in CAP-treated culture medium without phenol red. Concentrations of hydrogen peroxide,
nitrite and nitrate were determined employing the TiSO4 assay, Griess reagent and 2,6dimethylphenol assay, respectively. The quantitative methods have been described in
detail elsewhere (Lu et al., 2017). To eliminate the effect of the culture medium on
photometrical measurements, the results of CAP-treated groups were standardised with
untreated culture medium.
3.2.5 Lipid Peroxidation.
For TBARS assay, thiobarbituric acid (TBA), trichloroacetic acid, MDA were purchased
from Merck. U373MG cells were seeded into TC Dish 150 (Sarstedt) at a density of 1×105
cells/ml and incubated until confluence. After CAP treatment, cells were further
incubated for 24 h, and collected by trypsinisation, centrifuged (100 g for 5 min), and
homogenized by sonication. 100 μl homogenate was mixed with 200 μl ice cold 10%
trichloroacetic acid and incubated on ice for 15 min to precipitate protein, then
centrifuged (2200 g for 15 min at 4 ℃). 200 μl of each supernatant was then mixed with
200 μl 0.67% (w/v) TBA and incubate at 100 ℃ for 10 min. After cooling, samples were
measured at 532 nm for MDA.
Lipid peroxidation sensor, C11-BODIPY (581/591) (Thermo Fisher Scientific) was used
for in-situ detection and localization of the lipid peroxidation induced by CAP treatment.
Cells were incubated in fresh culture medium containing 5 μM of the probe at 37 ℃ for
30 min in advance. Then the cells were washed with PBS twice and culture medium once.
After CAP treatment, cells were further incubated with fresh medium for 30 min at 37 ℃
and observed using flow cytometry and confocal microscope as described later.
3.2.6 Flow Cytometry.
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BD Accuri™ C6 Plus flow cytometry (BD Bioscience, Allschwil, Switzerland) was used
in this study. Cells were loaded with C11-BODIPY and treated with CAP as described
above (Lipid peroxidation). To prepare aliquots, all floating and attaching cells were
collected by trypsinisation and then washed twice with PBS. For the measurement, a 488
nm laser was used for excitation, and 10,000 gated events were collected. Green
fluorescence (oxidised dye) and red fluorescence (non-oxidised dye) was measured using
an FL1 standard filter (533/30 nm) and FL2 standard filter (585/40 nm), respectively.
For Propidium iodide (PI) staining, cells were exposed to CAP 75kV for 30s and
incubated at 37 ℃ for 30 minutes afterwards, then collected by trypsinisation,
resuspended into 1ml PBS. Resuspended cells were stained with 1µg/ml PI for 5 minutes.
The fluorescence of PI was then measured at FL2 (585/40nm) standard filter.
3.2.7 Inhibitor Studies.
To inhibit various endocytic pathways, cells were pre-incubated with Pitstop (12.5 μM,
5 min) chlorpromazine (10 μg/ml, 10 min), filipin (5 μg/ml, 30 min), genistein (200 μM,
30 min), amiloride (50 μM, 30 min) and methyl-β-cyclodextrin (10 mM, 30 min) in
culture medium for the time indicated, at 37 ℃. After inhibiting treatment, the culture
medium was removed during CAP treatment, prewarmed fresh culture medium
containing 100 μg/ml AuNPs was then added immediately to the dishes and incubated
for 3 h before observing using a Zeiss LSM 510 confocal laser scanning microscope.
Transferrin conjugated with Alexa Fluor™ 546 was used to determine the change of early
endosomes induced by CAP combining various endocytosis inhibitors. After the
inhibiting and CAP treatments indicated above, the cells were incubated in prewarmed
fresh medium for 0 or 3 h, then incubated with 25 μg/ml transferrin in medium for 5 min.
Afterwards, cells were fixed with 4% PFA and then observed using confocal microscopy.
The details of the confocal microscope are described in following section.
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3.2.8 Clathrin Silencing.
MISSION® esiRNA (human CLTC) and MISSION® siRNA transfection reagents were
purchase from Merck. 50,000 U373MG cells were seeded into each 35 mm glass-bottom
dishes (Greiner Bio-One, Lörrach, Germany) and incubated overnight. 1.2 ul esiRNA
stock was mixed with 20 ul of transfection reagent in 400 μl serum-free medium and
incubated for 15 minutes at room temperature. In glass-bottom dishes, previous medium
was replaced with 1 ml of prewarmed fresh medium with serum. The siRNA/transfection
reagent solution was then added onto the cells and homogenized to final volume of 1.2
ml. Afterwards, U373MG cells were incubated at 37 ℃ for 24 h and then incubated with
fresh medium containing 100 μg/ml AuNPs for 3 h before observing using confocal
microscopy.
3.2.9 Endocytosis Tracking and Cell Imaging.
Early endosomes, late endosomes, lysosomes were demonstrated using the CellLight™
Early Endosomes-RFP, BacMam 2.0, the CellLight™ Late Endosomes-RFP, BacMam
2.0 and the LysoTracker™ Green DND-26, respectively (Thermo Fisher Scientific). 35
mm glass-bottom dishes (Greiner Bio-One) were used as containers for confocal imaging.
For early and late endosome marker, 2 μl of BacMan 2.0 reagent per 10,000 cells was
added in fresh medium and incubated with cells at 37 ℃ for 16 h. Then the cells were
treated with CAP for 30s and incubated with fresh medium containing 100 μg/ml AuNPs
for 3 h at 37 ℃. Before observing under a Zeiss LSM 510 confocal laser scanning
microscope, cells were washed twice with PBS and incubated with fresh medium
containing 50 nM LysoTracker for 5 min at 37 ℃. The corresponding filter settings were
as follows. AuNPs, excitation 633 nm, reflection 649-799 nm; Transferrin conjugated
with Alexa Fluor™ 546, excitation 568 nm, emission 580-630 nm; CellLight™ Early
Endosomes-RFP, BacMam 2.0, excitation 568 nm, emission 580-630 nm; CellLight™
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Late Endosomes-RFP, BacMam 2.0, excitation 568 nm, emission 580-630 nm;
LysoTracker™ Green DND-26, excitation 488 nm, emission 505-530 nm; C11-BODIPY
(581/591), excitation 1: 488 nm, emission 1: 500-560 nm; excitation 2: 568 nm, emission
2: 560-620 nm. Plan-Apochromat 63x/1.4 Oil Ph3 was used as objective for all samples.
The integrated density of fluorescence in the confocal images was quantified using
ImageJ software. The confocal images were unscaled, the quantified integrated density
being the sum of the pixel values in the selection, which is the selected fluorescent area.
3.2.10 Statistical Analysis.
At least triplicate independent tests were carried out for each data point, unless indicated
otherwise. Error bars of all figures are presented using the standard error of the mean
(S.E.M). Prism 6 (GraphPad Software) was used to carry out curve fitting and statistical
analysis. Two-tailed P values were used and the Alpha for all experiments is 0.05. The
significance between data points was verified using one-way ANOVA and two-way
ANOVA with Tukey’s multiple comparison post-test, as indicated in figures (*P<0.05,
**P<0.01, ***P<0.001, ****p<0.0001).

90

3.3

Results

3.3.1 Numerical Modelling of the Uptake of AuNPs by GBM Cells

Figure 12. Modelling uptake of AuNPs.
Numerical modelling of experimental data from our previous uptake study (He et al.,
2018) (shown with open circles and dashed lines) was carried out for simulated AuNPs
uptake (green solid line), AuNPs uptake quenched by incubation of the cells with NaN3
(blue solid line), AuNPs uptake on application of low dose CAP (red solid line). The
simulated uptake of AuNPs has been normalised to the maximum calculated value.
The accumulation of AuNPs inside U373MG cells was monitored using atomic
absorption spectroscopy and the dose response curve of AuNPs with or without CAP
treatment has been presented in previous study (He et al., 2018). The experimental results
reproduced in Figure 12 (open circles/dashed lines) were further analysed according to a
simulated uptake model to better understand the possible mechanism of CAP-stimulated
AuNPs uptake. Uptake of nanoparticles by cell populations in vitro has previously been
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modelled according to a phenomenological rate equation approach (Maher et al., 2014;
Souto et al., 2016; Byrne and Maher, 2019), which was extended here to further
investigate the role of CAP in AuNPs uptake.
The rate of uptake of AuNPs into a cell can be described by the equation:
dNAuNP/dt= (D-NAuNP) *(1+kdoub) *(N1*R1+N2*R2+N3*R3)

(1)

where NAuNPs is the number of internalised AuNPs, D is the initial dose of AuNPs, (DNAuNP) allows for the depletion of the applied AuNPs dose, and kdoub is the doubling time
of the cells. N1/R1, N2/R2and N3/R3 allow for three different principle uptake pathways,
with respective limiting capacities of N and rates R. The first two terms describe
independent active and passive uptake mechanisms, respectively, with limiting cellular
capacities N1(0) = N1max and N2(0) = N2max, such that:
dN1dt= -N1*(D-NAuNP) *R1

(2)

dN2dt= -N2*(D-NAuNP) *R2

(3)

Figure 12 (solid green line) shows the simulated uptake of AuNPs, normalised to the
maximum uptake observed for AuNPs + CAP, for the case of R1 = 3 x 10-3 hr-1, R2 = 2.5
x 10-5 hr-1, R3 =0, which faithfully reproduces the experimentally observed behaviour.
Quenching of the active uptake of AuNPs by NaN3 is best simulated by addition of a
further term in equation 2, such that
dN1dt= -N1*(D-NAuNP) *R1-N1*NaN3*R4

(4)

where NaN3 is the effective dose of sodium azide, and R4 allows for the rapid depletion
of the active uptake pathway. The experimentally observed uptake was well simulated
(solid blue line) by a value of R4 = 3 x 10-5 hr-1, keeping all other rates as before.
In simulating the increased uptake of AuNPs upon CAP treatment, it was noted that the
enhancement of a single pathway described by equations (2-4) by CAP treatment, by
increasing a single uptake rate, did not faithfully reproduce the experimentally observed
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behaviour, as the uptakes were limited by the parameters N1max and N2max. Rather, faithful
reproduction of the observed behaviour required the introduction of independent uptake
mechanisms for untreated and CAP treated AuNPs uptake, an observation which was
critical to the interpretation of the effects of CAP treatment on the cells. Such a pathway
can be represented by:
dN3/dt = -N3*(D-NAuNP) *R3

(5)

such that N3(0) = N3max. Upon the application of CAP, the enhanced uptake was well
fitted (solid red line) by R3 = 2.5 x 10-4 hr-1, keeping all other rates as before.
The modelling process indicates that CAP treatment increases the capacity of the
U373MG cells to uptake AuNPs by introducing a third uptake route distinct from passive
uptake and normal active uptake processes. The modelling parameters employed are
detailed in Table 1. Note that the parameters relating to the limiting cell uptake, Nnmax,
were determined by the definition of the dose as 100 mg/mL. Furthermore, the process
was one of simulation, rather than a mathematical fitting, so the parameters should be
considered within ~10% confidence.
Table 2: The modelling parameters employed in Figure 12.
N1max

N2max

N3max

NaN3

R1 hr-1

R2 hr-1

R3 hr-1

R4 hr-1

75

150

400

8500

3 x 10-3

2.5 x 10-5

0

0

+

75

150

400

8500

3 x 10-3

2.5 x 10-5

0

3 x 10-5

AuNPs + CAP

75

150

400

8500

3 x 10-3

2.5 x 10-5

2.5 x 10-4

0

AuNP
AuNPs
NaN3

3.3.2 Reactive Species Generated by CAP Treatment.
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To identify the possible uptake pathways implicated by the numerical modelling of our
data, ROS generation of 30 s, 75 kV CAP treatment was first investigated. Several RONS
were measured using optical emission spectroscopy (OES) and Gastec gas detector tubes,
including N2, N2+, •OH, and O3. OES emission intensities from the N2 second positive
system (SPS) were measured at 315, 337, 357, and 377 nm, the N2+ first negative system
(FNS) at 391 nm, and •OH at 310 nm were measured. The data demonstrated a relatively
constant RONS production throughout the 30 s treatment (Figure 13a).

Figure 13. Measurement of reactive species generated by CAP treatment by OES and
H2DCFDA, TBARS assay and PI staining.
(a) Emission intensities of excited N2 molecules, N2+ and •OH. (b) Concentration of O3
measured during CAP treatment. (c) The concentrations of hydrogen peroxide, nitrite
and nitrate were measured in CAP-treated culture medium. (d) Fluorescence level of
intracellular oxidised H2DCFDA was measured via Flow cytometry, left curve (green,
untreated cells), right curve (red, CAP-treated cells). (e) U373MG cells were incubated
for 24 hours after CAP treatment (0-30 s, 75 kV) and then collected and analysed to detect
cellular MDA level using TABARS assay. (f) 30 mins after CAP treatment, cells were
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stained with PI for 5 min, then measured with Flow cytometry.
The electron energy distribution function (EEDF) of the plasma was also determined. As
seen in Appendix IV Supplementary Figure S1a, EEDF remained close to a ratio of 7
during CAP treatment, which indicated that the electron energies were distributed more
so on the lower end of the energy scale (11 - 12 eV) than the higher energy levels (18.8
eV). The low variability of the EEDF indicated that the electric field was stable, and that
the formation of the reactive species was in a steady state manner. Using Gastec ozone
detector tubes, the concentrations of generated O3 in the extracted gas were measured
post-discharge of CAP treatment (Figure 13b), revealing significantly increasing levels
of O3 recorded over the discharge time, which became saturated at the maximum labelled
value of O3 detection tube after 15 s. High levels of ozone generation may give
explanation why no detectable or low emission of NO, O, NOx (NO2, NO3, N2O2, N2O3,
and N2O4), •OH and N2+ were measured in air using OES (Schmidt-Bleker et al., 2015)
(Appendix IV Supplementary Table S1).
Hydrogen peroxide (H2O2), nitrite (NO-2) and nitrate (NO-3) were measured and detected
in culture medium (Figure 13c). Comparing with previous results (Tsoukou, Bourke and
Boehm, 2018), CAP treatment of culture medium for 30 s generated very low amounts
of H2O2 (~20 μM), NO2-(~5 μM), and NO3-(~30 μM) which are at least 15-fold and 200fold lower than the IC50 cytotoxicity values we measured previously for U373MG cells
(315 µM, >1200 µM and >600 µM respectively) and therefore are essentially non-toxic
(Lu et al., 2017). Intracellular H2O2 was significantly elevated 30 minutes after CAP
treatment when measured using H2DCFDA by flow cytometry (Figure 13d). Mean
fluorescence was observed to significantly increase by 4-5-fold above untreated controls
(Appendix IV Supplementary Figure S1b).
3.3.3 CAP Treatment Induces Lipid Peroxidation.
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ROS induces lipid peroxidation of the cell membrane (Leutner, Eckert and Müller, 2001;
Schuessel et al., 2006). The level of the lipid peroxidation indicator malondialdehyde
(MDA), measured using the Thiobarbituric acid reactive substances (TBARS) assay, was
significantly higher in U373MG cells 24 h after CAP treatment compared with the control
group (Figure 13e), indicating a high level of lipid peroxidation is induced by CAP
treatment. In our previous study, the IC50 of CAP treatment (75 kV) was determined to
be 74.26 s (95% confidence range of 47.24–116.8 s) for U373MG cells (Conway et al.,
2016) and we demonstrated that 60 s CAP treatment induces rapid permeabilisation of
U373MG cell membranes (Conway et al., 2019). Here, we confirm that no significant
increase of PI uptake is evident following 30 s CAP treatment compared to the control
(Figure 13f), indicating that membrane integrity was not significantly affected by 30 s
CAP treatment and CAP-induce lipid peroxidation. This is in agreement with our
previous findings, where 30 s CAP treatment induces very low, non-significant levels of
toxicity in U373MG cells 48 hours post treatment (18.52%, SEM=5.41%)(He et al.,
2018).
CAP induced lipid peroxidation was further analysed and visualised using the lipid
peroxidation fluorescent sensor C11-BODIPY (581/591). C11-BODIPY (581/591) is a
lipophilic fluorescent dye that remains membrane bound, can react with various RONS
and oxidation leads to a shift of the emission peak from around 590 nm (Orange) to
around 510 nm (Green) (Drummen et al., 2004). To determine the level of lipid
peroxidation, more than 60 cells were analysed using ImageJ software for each group. A
significantly stronger emission of the oxidised green fluorescence was observed in CAPtreated cells compared to the untreated cells (****p<0.0001, Figure 14a, 2nd panel and
Figure 14b), which was accompanied by a significant decrease in the non-oxidised orange
fluorescence (Figure 14a, 1st panel and Appendix IV Supplementary Figure S2).
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Furthermore, Figure 14c demonstrated a 3-fold significantly greater level of the oxidised
green fluorescence in CAP-treated cells (****p<0.0001) with a focus on green
fluorescent vesicle-like structures (Figure 14a, 3rd panel), likely caused by concentrated
oxidised lipid membranes internalised in endosomes or lysosomes. CAP-induced
oxidation of lipid membranes was confirmed using flow cytometry (Figure 14d). When
cells were counterstained with LysoTracker™ Deep Red (red), examples of
colocalization of oxidised membranes and acidic vesicular organelles (such as lysosomes,
late endosomes, etc.) were clearly evident in CAP treated cells (Appendix IV
Supplementary Figure S3, middle& right).

Figure 14. C11-BODIPY (581/591) staining shows lipid peroxidation and membrane
trafficking inside the cell to lysosomes.
(a) Confocal imaging of C11-BODIPY loaded cells, from 1st to 4th panel: Orange,
reduced form of C11-BODIPY; Green, oxidised form of C11-BODIPY; Red, vesicle-like
structures was highlighted from green fluorescence using high threshold setting in
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ImageJ; Merged images (orange and green channels). (b) The total fluorescent
integrated density of oxidised BODIPY was quantified using ImageJ. (c) With high
threshold setting, the fluorescence integrated density of oxidised BODIPY was quantified
with a focus on green fluorescent vesicle-like structures. The statistical significance (b,
c) assessed by unpaired T-test. (*P<0.05, **P<0.01, ***P<0.001, ****p<0.0001), n≥50,
see Appendix IV Supplementary Table S2 for original data. (d) Fluorescence level of
intracellular oxidised BODIPY was measured via Flow cytometry, left curve (green,
untreated cells), right curve (red, CAP-treated cells).
3.3.4 Effects of CAP Treatment on Endocytosis of AuNPs.
A membrane repair mechanism has been described where cells can quickly remove
damaged regions of membranes from the cell surface through rapid endocytosis (Idone,
Tam and Andrews, 2008; Andrews and Corrotte, 2018). These impaired membranes can
be trafficked into endosomes and finally into lysosomes. We wished to determine whether
rapid endocytosis may contribute to the increased uptake of AuNPs and other materials
into cells following CAP treatment. To test this hypothesis, CellLight™ Early
Endosomes-RFP, BacMam 2.0 and CellLight™ Late Endosomes-RFP, BacMam 2.0
were used to further visualise the route of uptake of AuNPs after CAP treatment. Rab5a
and Rab7a chimeras tagged with RFP were transfected and expressed inside cells.
Following overnight incubation, Rab5a-RFP and Rab7a-RFP specifically tracked early
endosomes and late endosomes, respectively (Dolman, Kilgore and Davidson, 2013).
Cells were then incubated with AuNPs for 3 h after CAP treatment. In Appendix IV
Supplementary Figure S4, the white arrows identify examples of co-localisation of
AuNPs (red) with early (left) and late (right) endosomes (orange). Lysosomes (green)
were also counterstained. We have previously demonstrated that AuNPs accumulate in
lysosomes 24 hours after 30 s, 75 kV CAP treatment using confocal imaging and 3D98

image construction (He et al., 2018). We demonstrate here that that AuNPs enter CAPtreated U373MG cells mainly through endocytosis and colocalise with Rab5a and Rab7a
chimeras corresponding to early and late endosomes respectively, eventually
accumulating in lysosomes (Appendix IV Supplementary Figure S4).
Transferrin conjugated with Alexa Fluor™ 546, is used as an early endosome marker. To
investigate the immediate uptake route, CAP treated U373MG cells were incubated with
Alexa546-Transferrin for 5 min, then fixed with 4% PFA. As seen from confocal imaging,
within 5 mins after CAP treatment, the number of transferrin-containing endosomes was
greater compared to the control group (Figure 15a). Quantification of transferrin uptake
confirmed a significant increase of endosomes 5 min after CAP treatment (Figure 15b,
p<0.0001).
Endocytosis is typically subdivided into four types, including clathrin-mediated
endocytosis (CME), caveolae-mediated endocytosis, macropinocytosis and phagocytosis.
We used a panel of inhibitors (Iversen, Skotland and Sandvig, 2011) to delineate the
specific endocytic pathway activated by CAP (see Table 2). Clathrin-inhibitors and
MβCD-induced cholesterol depletion decreased the number of transferrin labelled
endosomes and AuNP-uptake 3 h following CAP treatment (Figure 15c, d) whereas
caveolae-specific inhibitors and an inhibitor of micropinocytosis did not lead to any
significant inhibition of Transferrin or AuNPs endocytosis in cells 3 h after CAP
treatment (Figure 15e, f). Original data for quantification can be viewed in Appendix IV
Supplementary Table S4.
To further confirm that clathrin-mediated endocytosis played the main role in CAPaccelerated cellular uptake, MISSION® Endoribonuclease-prepared siRNA (esiRNA)
against human Clathrin heavy chain 1 (CLTC) was used to disrupting endocytosis
mediated by clathrin coated pit formation. As seen in Figure 16, AuNPs uptake was much
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lower in clathrin-silenced cells and no increase in AuNPs uptake was observed 3 h after
CAP treatment (p<0.0001, see Appendix IV Supplementary Table S5 for original data).
Together, our data confirms that clathrin-mediated endocytosis played an important role
in AuNPs uptake, and accelerated endocytosis following CAP treatment was clathrin
dependent.
Table 3: Inhibitors used to inhibit endocytosis in this research.
Agent
Pitstop

CPZ
MβCD

Filipin

Genistein

Amiloride

Effect

Targeting endocytosis

Small molecular that target and disfunction clathrin
(Robertson et al., 2014)
Inhibits Rho GTPase.
(Wang, Rothberg and Anderson, 1993)

Clathrin-mediated endocytosis

Clathrin-mediated endocytosis

Extracts cholesterol from membrane. (Iversen,

CME, caveolae and

Skotland and Sandvig, 2011)

micropinocytosis

Interacts with cholesterol

A few caveolae and cholesterol-

(Iversen, Skotland and Sandvig, 2011)

dependent mechanisms

Inhibitor of few tyrosine kinases (Pelkmans,
Püntener and Helenius, 2002)
Lowers the submembraneous pH and blocks Rac1
and Cdc42 signalling (Koivusalo et al., 2010)
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Caveolae pinching

Micropinocytosis

Figure 15. The CAP-induced endocytosis is clathrin-dependent.
(a) After CAP treatment (0, 30 s), cells were loaded with transferrin-conjugated with
Alexa Fluor™ 546 (red) for 5 min and fixed before observing with a confocal microscope.
(b) The fluorescence level of transferrin was quantified using ImageJ, see Appendix IV
Supplementary Table S3 for original data. (c, d, e, f) After incubation with various
inhibitors as indicated, U373MG cells were treated with CAP for 0, 30 s at 75 kV and
then loaded with transferrin for 5 min or 100 μg/ml AuNPs for 3 h respectively before
observing using confocal microscopy, with the fluorescence integrated densities
quantified using ImageJ. The statistical significance in (b, c, d, e, f) was assessed by oneway ANOVA with Tukey’s multiple comparison post-test (*P<0.05, **P<0.01,
***P<0.001, ****p<0.0001), n≥50.
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Figure 16. Clathrin silencing inhibits AuNPs uptake and CAP-induced endocytosis.
After incubation with esiRNA, targeting expression of clathrin heavy chain, U373MG
cells were treated with CAP for 0, 30 s at 75 kV and then loaded with 100 μg/ml AuNPs
for 3 h before observation by confocal microscopy, in comparison with unsilenced groups.
(a) CAP-untreated cells without silencing, (b) CAP-treated cells without silencing, (c)
CAP-untreated cells with silencing of clathrin heavy chain, (d) CAP-treated cells with
silencing of clathrin heavy chain. AuNPs are identifiable as red fluorescence inside cells.
(e) The fluorescence level was quantified using ImageJ and presented as integrated
density. The statistical significance was assessed by one-way ANOVA with Tukey’s
multiple comparison post-test (*P<0.05, **P<0.01, ***P<0.001, ****p<0.0001), n≥50.

3.4

Discussion

The cytoplasmic membrane separates and protects the cellular interior from the exterior
environment and provides specific and efficient exchange channels for the remaining
intracellular balance and cell viability. Therefore, the integrity of the membrane is vital
for all cells. Mammalian cells have developed efficient membrane repair mechanisms that
can recover and reseal an injured cytoplasm membrane quickly to retain cell viability.
Although investigations of the precise membrane repairing mechanisms have been
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limited, four possible mechanisms, including patch, tension reduction and
exocytosis/endocytosis and budding repair mechanisms have been proposed (Andrews
and Corrotte, 2018). The study of cytoplasmic membrane repair usually employs bacterial
pore-forming toxins, such as Streptolysin O, to create mechanical injuries on membranes
(Andrews and Corrotte, 2018). Meanwhile, lipid peroxidation is a complex process that
damages cellular membrane structure and function, which is believed to link to numerous
human diseases and aging, including Alzheimer diseases, dementia, Huntington,
Parkinson, and traumatic injuries, under presence of oxidative stress (Stockwell et al.,
2017; Feng and Stockwell, 2018). Many studies have shown that lipid peroxidation have
various significant effects to cellular membranes, such as increased membrane
permeability (Goldstein and Weissmann, 1977; Chatterjee and Agarwal, 1988; Van Der
Paal et al., 2016), alteration of the lipid order and membrane fluidity (Chatterjee and
Agarwal, 1988; Borchman et al., 1992; Petrescu et al., 2001; Jacob and Mason, 2005)
and activity change of membrane proteins (Mattson, 1998; Mattson et al., 1999; Sevanian
and Ursini, 2000; Jacob and Mason, 2005). However, there remains a paucity of literature
identifying mechanisms of lipid peroxidation-related membrane damage repair, and the
mechanisms of oxidised membrane repair remain unknown.
CAP is known to generate reactive species and thereby cause lipid peroxidation of cells.
In this research, we explored CAP-induced lipid peroxidation using a low, relatively nontoxic dose of CAP and studied the possible mechanisms of accelerated cellular uptake of
AuNPs following CAP-induced oxidative membrane damage.
As seen in Figure 12, the uptake and accumulation of AuNPs into U373MG cells was
first modelled. To faithfully reproduce the experimentally observed results in our
mathematical model, a new independent uptake rate was necessary in the model (equation
5). This numerical model indicates that CAP treatment may introduce a new uptake route.
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Following a detailed experimental analysis, we can confirm this occurs and is due to a
CAP-triggered, membrane repairing, clathrin-dependent, pathway of endocytosis.
As seen in Figure 13, we observed a relatively high level of reactive species generated in
air during CAP treatment such as •OH, ONOO- and O3. This was also evident in medium,
cells, and ultimately in lipid membranes with the detection of RONS including hydrogen
peroxide, nitrite and nitrate and detection of peroxidated lipids and by-products.
Interestingly, the low doses of CAP treatment used generate non-toxic levels of RONS
but still are induce significant lipid peroxidation.
CAP treatment has been shown to alter membrane structures, which may be partly due to
the reactive species-caused lipid peroxidation (Adibhatla and Hatcher, 2010; Cheng et al.,
2014; Recek et al., 2015; Conway et al., 2019). However, in our study, cell membranes
remain PI impermeable and therefore intact after exposing to 75 kV CAP for 30 s.
Interestingly, not only did we observe a significant increase in oxidised lipids using C11BODIPY following CAP treatment, but there was also a clear and significant increase in
vesicle-like structures with high levels of oxidised C11-BODIPY, suggesting that
peroxidised membrane lipids were trafficked inside cells via endocytosis (Figure 14a).
An immediate (within 5 minutes) increase in endosomes was also confirmed using
transferrin conjugated with Alexa Fluor™ 546.
Therefore, we propose that low, sub-toxic doses of CAP can cause cytoplasmic
membrane oxidation which triggers a rapid membrane repair system. The increased
endocytosis induced by membrane repair is initiated within 5 minutes and accelerates the
uptake of AuNPs into U373MG cells.
To further explore the route of uptake, AuNPs were tracked in cells counterstained with
Rab5a-RFP, Rab7a-RFP, and LysoTracker™ Green DND-26. Co-localisation of AuNPs
with early and late endosomes and lysosomes were observed. AuNPs uptake displayed a
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tendency to enter the periphery region of the cells through endocytosis, then gather at the
central zone of the cells via endosome trafficking into lysosomes. This demonstrates that
CAP treatment of U373MG cells triggers uptake and trafficking of AuNPs through early
endosomes into late endosomes and ultimately accumulation lysosomes.
Our inhibitor studies and RNA interference studies demonstrate a primary role for
clathrin-dependent endocytosis of AuNPs, and no other routes of endocytosis in CAPtriggered uptake. We compared uptake of AuNPs with Transferrin, an essential ironbinding protein that facilitate iron-uptake in cells via transferrin receptors. Uptake of
Transferrin is well characterised and involves Clathrin-mediated, receptor dependent
endocytosis (Lakadamyali, Rust and Zhuang, 2006). Interestingly, Shi et al found that
CAP treatment decreased transferrin receptor-1 but could induce iron-dependent
oxidative stress to stimulate significant increase in fluid-phase endocytosis, lysosome
biogenesis and autophagy in mesothelioma cells (Shi et al., 2017). In contrast to this, as
seen in Figure 15a, b, our data demonstrates that the uptake of transferrin was
significantly increased just 5 min after CAP treatment, which may due to the diversity of
cell lines or CAP generation devices. Similar to AuNPs, formation of transferrintrafficking endosomes was inhibited in both groups with 0 and 30 s CAP treatment, after
exposure to specific/non-specific clathrin inhibitors, including pitstop, CPZ and MβCD.
Tracking the accumulation of AuNPs demonstrates the long-term CAP-triggered uptake
via a single, clathrin-dependent endocytosis route are retained for at least 24 hours post
CAP treatment. Jinno M et al. demonstrated in a CAP-induced gene transfection model
using mouse fibroblasts that a clathrin specific inhibitor showed 60% decrease in the
gene transfection efficiency and that both clathrin-dependent endocytosis and
electroporation played a role in enhanced transfection efficiency (Jinno et al., 2016). The
work of Jinno M et al. supports our investigation that clathrin may play key roles in CAP105

induced cellular uptake mechanisms in response to different materials.
Our data indicate that oxidised lipids can be seen to colocalise with endosomes and
lysosomes demonstrating the intracellular sites where the repair of peroxidised lipid
membranes is taking place. Further investigation of these mechanisms and sites of
membrane repair following CAP-stimulated oxidative damage is ongoing, to identify
novel therapeutic targets that can augment CAP cytotoxicity and to fully understand the
cellular mechanisms governing oxidative membrane repair.
In summary, we report that the enhanced uptake of AuNPs induced by CAP can be as a
result of ROS-caused lipid peroxidation, leading to rapid plasma membrane repair via
clathrin-dependent endocytosis. This contributes to our understanding of the cellular
effects induced by CAP, especially membrane damage and endocytosis activation, which
can be employed for efficient uptake of nanomaterials and pharmaceuticals into cells
when combining CAP with cancer therapies. This mechanism of RONS-induced
endocytosis will also be of relevance to researchers optimizing other cancer therapies that
induce an increase in extracellular RONS.
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CHAPTER 4. SYNERGISTIC CYTOTOXICITY BETWEEN
PRO-DRUGS AND CAP AGAINST GLIOBLASTOMA
CELLS
Manuscript in preparation.

107

4.1

Introduction

Extensive efforts have been made in the war against cancer in the past decades, however,
the treatment of cancer is challenging due to the tumour heterogeneity and varied patient
characteristics. Widespread application of advanced stage cancer treatment and early
diagnosis of cancer are still the highest aspirations.
Reactive oxygen species (ROS), as natural products generated during normal metabolism
pathways, play key roles in a variety of cellular activities, but also are considered as
carcinogenic factors as high levels of ROS are capable of inducing damage and mutation
of intracellular DNA and therefore cause malignancy (Metelmann et al., 2015). However,
as understanding deepened, ROS were found to be a double-edged sword to cancer cells
(von Woedtke et al., 2013). Evidence showed that higher levels of ROS are generated in
cancer cells by comparison with normal cells, which is attributed to the higher metabolic
activities and more rapid proliferation of transformed cells (von Woedtke et al., 2013).
Hence, the cellular antioxidant system works under heavier load to protect tumour cells
from oxidative stress, which is a common feature in many types of tumours that can be
targeted for development of efficient therapies. There have been reported various
anticancer drugs which can induce extra generation of tumour ROS to kill cancer cells,
however, they also increase the ROS level in healthy cells, which may induce DNA
damage and cause secondary malignancies (Peng and Gandhi, 2012). Cold atmospheric
plasma (CAP) can induce generation of ROS to adjustable levels in controllable area
(Welz et al., 2015). Meanwhile, prodrugs, which only have cytotoxicity after being
activated by high level of ROS, have less side effects and are more specific to cancer cells
(Görmen et al., 2010). Therefore, combining prodrugs with CAP to locally increase
tumour ROS and activate cytotoxicity only in tumour tissue may provide a novel
promising combination therapy against most, if not all, cancers.
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We have acquired in total 47 various types of prodrug candidates from our collaborators,
who are experts in discovery of novel drugs, including aminoferrocene-based prodrugs
provided by Prof. Andriy Mokhir (Marzenell et al., 2013), ferrocene, [3] ferrocenophane
and ferrocifen derivatives provided by Prof. Gérard Jaouen (Jaouen, Vessières and Top,
2015), matrix metalloproteinase pro-inhibitors and thiazolidinone-based prodrugs
provided by Prof. Seth M. Cohen (Perez et al., 2015), and a series of pyrazolopyrimidines
derivatives provided by Prof. John Stephens (Kelada et al., 2018) as described in section
1.6 (Appendix V Supplementary Table S1, S2, S3, S4 and S5).
In this chapter, we have screened those 47 candidates for their potential synergistic anticancer effect combined with CAP treatment and identified two leading prodrug
candidates JW-04-057a and JW-04-061, which were both pyrazolopyrimidine derivates
provided by Prof. John Stephens. In combination with low dose CAP treatment, which
had little or no toxicity on cancer cells, the cytotoxicity of leading prodrug candidates
was synergistically enhanced more than 10 times. The synergistic cytotoxicity between
JW-04-061 and CAP treatment has been further demonstrated and investigated as
described in following sections. The ROS generated in culture medium by CAP treatment
has been determined to play the main role in the activation of prodrug JW-04-061.

4.2

Methods

4.2.1 Cell Culture
U-251 MG (formerly known as U-373 MG) (ECACC 09063001), human brain
glioblastoma cancer cells (Obtained from Dr Michael Carty, Trinity College Dublin) were
cultured in DMEM-high glucose medium containing pyruvate (Merck) supplemented
with 10% FBS (Merck) and maintained in a 37 ℃ incubator within a humidified 5% (v/v)
CO2 atmosphere. For prodrug treatment, DMEM-high glucose medium without pyruvate
(Merck) was used to make up culture medium for all groups to avoid the antioxidant
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effects of pyruvate (O’donnell-Tormey et al., 1987).
4.2.2 H2DCFDA Assay
H2DCFDA (Thermo Fisher Scientific, Ballycoolin, Ireland) was used to detect ROS
induced by CAP treatment. U373MG cells were seeded into the TC dish 35 standard
(Sarstedt, Belfast, UK) (for flow cytometry) at a density of 2×105 cells/ml, or 35 mm
glass-bottom dishes (Greiner Bio-One) (for confocal imaging) at a density of 1×105
cells/ml and incubated overnight to allow adherence. After washing twice with PBS, cells
were incubated with 25 μM H2DCFDA in serum-free medium for 30 min at 37 ℃. 30
minutes before measuring the fluorescence of H2DCFDA using flow cytometry, cells
were then washed with PBS twice, culture medium once and treated with CAP at 75 kV
for 30s. For confocal imagining, cells were washed with PBS twice, culture medium once
and treated with CAP at 75 kV for 30s, then were observed under a Zeiss LSM 510
confocal laser scanning microscope 30 min later (excitation 488 nm, emission 505-530
nm).
4.2.3 CAP Configuration and Prodrug Treatment.
The current research uses an experimental atmospheric dielectric barrier discharge (DBD)
plasma reactor, which has been described and characterised in detail (Moiseev et al., 2014;
Conway et al., 2016). Unless otherwise stated, all U373MG cells were treated within
containers, which were placed in between two electrodes, at a voltage level of 75 kV for
10-40 s. The culture medium was removed prior to CAP treatment then replaced with
fresh culture medium afterwards. An optimized prodrug treatment protocol was
developed and applied in this project as described below. U373MG cells were plated into
96-well plates (Sarstedt) at a density of 1×104 cells/well (100 μl normal culture medium
per well) and were incubated overnight to allow a proper adherence. Unless otherwise
stated, the plating map was 6×10 wells, for 10 different concentrations, negative and
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positive control groups (5 replicates for each group). All pro-drugs were dissolved and
prepared in 100% DMSO (Merck) for stock solution, which were then series diluted in
culture medium to different concentrations as indicated. Afterwards, 10 μl of prodrug
non-pyruvate culture medium solution was added into each well after fully removing
previous medium and the rest of prodrug culture medium solution was added into empty
wells in the plate (300 μl per well). The plate then was treated with CAP at 75 kV for 1040 s as indicated. 90 μl of CAP-treated prodrug culture medium solution was then add to
corresponding wells with cells to final volume 100 μl immediately after CAP treatment.
Cell viability assays were then carried out after incubation for indicated time.
4.2.4 Cell Viability Assays.
Cell viability was analysed using the Alamar blue assay (Thermo Fisher Scientific),
which used a redox indicator that can generate fluorescent signal by the metabolic
reduction. After CAP and prodrug treatment, plates were incubated in a 37 ℃ incubator
within a humidified 5% (v/v) CO2 atmosphere for forty-eight hours. Afterwards, the cells
were rinsed once with phosphate buffered saline (Sigma-Aldrich), incubated for 3 h at
37 ℃ with a 10% Alamar blue/90% culture medium solution. The fluorescence was then
measured (excitation, 530 nm; emission, 595 nm) by a Victor 3V 1420 microplate reader
(Perkin Elmer).
4.2.5 CAP-activated medium/prodrug/cells and Inhibitor Study.
We have investigated the effects of CAP on prodrugs alone to determine the mechanism
of synergistic cytotoxicity to U373MG cells. Prodrugs were treated with CAP at 75 kV
for 10 s to 10 min in DMSO stock solution or culture medium solution using 96-well
plates as container as indicated. The CAP-treated prodrug solution was then added into
96-well plates to incubate with U373MG cells for 48 hours before cell viability assays.
For CAP-activated medium, the culture medium was treated with CAP at 75 kV for 30
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sec in 96-well plate and incubated overnight to remove short-lived reactive species. Then
prodrug stock solution was series-diluted in the overnight storage CAP-activated medium
and incubated with U373MG cells in 96-well plates for 48 hours before cell viability
assays.
For CAP-activated cells, the U373MG cells were treated with CAP for 30 sec in 96-well
plates with 10 µl culture medium without pyruvate covered in each well, while culture
medium was added into empty wells in the plate (300 μl per well). Then the CAP-treated
culture medium was added to each well to 100 µl. Those CAP-activated cells were then
incubated in the CAP-activated medium for 0-5 hours as indicated in the figures.
Afterwards, the previous medium was replaced with fresh medium containing
corresponding concentrations of prodrugs. The U373MG cells were then further
incubated for 48 hours before cell viability assays.
Meanwhile, N-Acetyl Cysteine (NAC) was used as antioxidant to investigate the roles of
reactive species in activation of prodrugs. 4 M NAC stock solution was prepared in water.
4 M NAC solution was then diluted in culture medium till final concentration 4 mM
before adding prodrugs and CAP treatment. The CAP treated culture medium containing
prodrugs and 4 mM NAC was then added into 96-well plates to incubate with U373MG
cells for 48 hours before cell viability assays.
Catalase stock solution (1 mg/ml) was fresh prepared with PBS, then diluted in culture
medium to 0.1mg/ml for inhibition of H2O2 production. 10 µl of culture medium
containing 0.1mg/ml catalase and corresponding concentrations of pro-drugs was added
into each well of 96-well plates to treat U373MG cells with CAP, the rest of culture
medium containing catalase and pro-drugs was treated in the empty wells of the same
plates (300 µl per well). After CAP treatment, 90 µl of CAP-treated culture medium
containing catalase and pro-drugs was added into each well and the U373MG cells were
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then incubated with in total 100 µl of the culture medium containing catalase and prodrugs for 48 hours before cell viability assays.
4.2.6 Statistical Analysis.
At least triplicate independent tests were carried out for each data point, unless indicated
otherwise. Error bars of all figures are presented using the standard error of the mean
(S.E.M). Prism 6 (GraphPad Software) was used to carry out curve fitting and statistical
analysis. The isobologram and synergistic analysis were carried out using CompuSyn
software (Available for free download from www.combosyn.com) according to the detail
mentioned in Figure 25d legend (Chou and Martin, 2005). Two-tailed P values were used
and the Alpha for all experiments is 0.05. The significance between data points was
verified using one-way ANOVA and two-way ANOVA with Tukey’s multiple
comparison post-test, as indicated in figures (*P<0.05, **P<0.01, ***P<0.001,
****p<0.0001).

4.3

Results

The majority of prodrugs were developed to be activated in cells by oxidation induced by
ROS. CAP has been well known as inducing generation of ROS (Babington et al., 2015;
Conway et al., 2016; He et al., 2018). We have demonstrated the generation of ROS by
CAP in Chapter 3. In Chapter 4, besides flow cytometry, we have used confocal
microscope and ROS indicator H2DCFDA to demonstrate the ROS generated by 30 s of
CAP treatment (Figure 17).
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Figure 17. Measurement of reactive species generated by CAP treatment by H2DCFDA.
Confocal imaging of H2DCFDA loaded cells: (a) untreated U373MG cells; (b) 30 s CAP
treated U373MG cells. (c) Fluorescence level of intracellular oxidised H2DCFDA was
measured via Flow cytometry, left curve (green, untreated cells), right curve (red, 30 s
CAP treated cells).
As seen in Figure 13 and 14 in Chapter 3, we have also quantified the ROS generation in
cells and culture medium after 30 s of CAP treatment and measured the level of lipid
peroxidation in CAP-treated U373MG cells as well. Therefore, 30 s of CAP treatment
has been demonstrated to be effective on ROS generation and can be used to test the
synergistic effects with prodrugs. In total four different types of prodrugs have been tested
in this Chapter, including ferrocene-based prodrugs, pyrimidone bicycle family
compounds, matrix metalloproteinase pro-inhibitors and thiazolidinone-based prodrugs.
Due to high amount of work, and to identify leading candidates as soon as possible, all
compounds were preliminarily tested in CAP-treated and control groups once to acquire
dose response curves to determine the synergistic cytotoxicity. The relative IC75 values
of each compounds have been summarised in Figure 18, except low or non-toxic
compounds (Cmpd1, Cmpd2 and MK2, as seen in Figure 22 and 23, and Table 7 and 8).
The IC75 values of control groups were separately normalised to 1 together with
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corresponding CAP-treated groups. The 95% confident ranges were used to present the
error bars. As see in Figure 18, the difference between control and CAP-treated groups,
which presents possible synergistic cytotoxicity, was only significant with compounds 1e,
PY-2-Benzyl, JW-04-057a and JW-04-061. However, according to corresponding dose
response curves (Figure 19 and 22), there was no significant synergy effect between CAP
treatment and compounds 1e, PY-2-Benzyl separately. Therefore, JW-04-057a and JW04-061 have been determined as the only two leading candidates after repeating the dose
response curves for two more times. Furthermore, the investigation of the synergistic
effects between CAP treatment and JW-04-061 and the mechanisms behind it has been
carried out and presented.

Figure 18. Summary of relative IC75 values of all available compounds.
The IC75 values were calculated using IC50 values and corresponding hillslopes, and
then all control groups were normalised to 1 along with corresponding CAP-treated
groups and 95% confident interval as error bar.
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4.3.1 Ferrocene-based Prodrugs.

Figure 19. Dose response curves of compounds 1e and 2a, provided by Prof. Andriy
Mokhir, Friedrich Alexander University, Germany.
We have acquired and received a variety of ferrocene-based prodrugs from Prof. Andriy
Mokhir and Prof. Gérard Jaouen. Two aminoferrocene-based prodrugs were provided by
Prof. Andriy Mokhir. As seen in Figure 19, compounds 1e and 2a had no significant
synergistic cytotoxicity but additive cytotoxicity with 30 s CAP treatment. The CAP
treatment decreased the IC50 values of 1e and 2a (Table 5), but the cell viabilities
decreased nearly 20% in all CAP treated groups therefore same trends were presented in
both dose response curves treated with or without CAP.
Table 4. IC50 values of compounds 1e and 2a, provided by Prof. Andriy Mokhir.

Control
IC50 (μM) 95% Confidence Intervals
1e
153
121.4 to 192.9
2a
80.07
72.40 to 88.55

IC50 (μM)
63.9
44.56

CAP 30s
95% Confidence Intervals
28.42 to 143.7
23.46 to 84.62

Meanwhile, a series of ferrocene, [3] ferrocenophane and ferrocifen derivatives provided
by Prof. Gérard Jaouen were tested with U373MG cells (Figure 20 and 21). There was
no significant synergy observed between those compounds and CAP treatment. Ferrocene,
[3] ferrocenophane and ferrocifen derivatives usually present strong reaction to ROS.
They could be already fully activated by the relatively high ROS level in U373MG cells
instead of CAP treatment, therefore, leading to no synergistic effects with CAP.
As seen in Table 6, there were highly toxic candidates, P257 (IC50: 62.64 nM, 95%
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confidence intervals: 20.05 to 195.7 nM), P286 (IC50: 77.75 nM, 95% confidence
intervals: 39.15 to 154.4 nM), P686 (IC50: 4.1 nM, 95% confidence intervals: 2.134 to
8.116 nM), P722 (IC50: 29.06 nM, 95% confidence intervals: 8.561 to 98.65 nM), which
could be further tested both in cancer cell lines with high ROS levels and health cell lines
with normal ROS levels for drug discovery for GBM treatment as a future project. It is
interesting that P686 presented significantly lowed cytotoxicity when combining with
CAP treatment (Figure 21), which might due to chemical or physical effects generated by
CAP treatment against the structure of P686, thus deactivating the cytotoxicity of P686.
Table 5. IC50 values of compounds provided by Prof. Gérard Jaouen.

CG2
0
DP1
DP6
P15
P208
P228
P240
P256
P257
P258
P283
P284
P286
P292
P316
P388
P5
P53
P581
P686
P721
P722
P85

IC50
(μM)
0.233
0.7197
5.772
3.188
5.746
0.486
1.176
1.626
0.06264
0.5966
5.303
1.396
0.07775
14.56
4.756
21.16
1.739
0.229
6.813
0.00416
2.104
0.02906
5.389

Control
95% Confidence
Intervals
0.1899 to 0.2859

IC50
(μM)
0.1041

CAP 30s
95% Confidence
Intervals
0.08296 to 0.1305

0.5216 to 0.9929
4.220 to 7.894
2.754 to 3.691
4.991 to 6.614
0.3139 to 0.7523
0.8729 to 1.583
1.180 to 2.240
0.02005 to 0.1957
0.4794 to 0.7424
4.802 to 5.857
1.073 to 1.817
0.03915 to 0.1544
11.28 to 18.79
3.796 to 5.957
18.94 to 23.63
1.304 to 2.320
0.1782 to 0.2944
6.099 to 7.611
0.002134 to 0.008116
1.721 to 2.573
0.008561 to 0.09865
4.685 to 6.199

0.8853
6.697
2.376
3.001
0.5175
1.093
1.531
0.09171
0.5094
5.225
1.403
0.07017
18.05
4.491
17.17
2.668
0.2526
8.139
0.3142
0.8811
0.01991
5.773

0.6660 to 1.177
5.556 to 8.071
1.928 to 2.927
1.871 to 4.815
0.3606 to 0.7426
0.8713 to 1.370
1.253 to 1.872
0.03351 to 0.2510
0.4016 to 0.6462
4.679 to 5.835
1.113 to 1.768
0.03573 to 0.1378
13.15 to 24.77
3.268 to 6.170
13.92 to 21.17
2.096 to 3.396
0.1895 to 0.3368
6.512 to 10.17
0.1376 to 0.7175
0.6000 to 1.294
0.005744 to 0.06901
4.893 to 6.810
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Figure 20. Dose response curves of compounds provided by Prof. Gérard Jaouen,
Chimie ParisTech, France, Part 1.
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Figure 21. Dose response curves of compounds provided by Prof. Gérard Jaouen,
Chimie ParisTech, France, Part 2.
4.3.2 Matrix Metalloproteinase Pro-Inhibitors and Thiazolidinone-Based Prodrugs.
Several hydrogen peroxides activated matrix metalloproteinase inhibitors and hydrogen
peroxide responsive thiazolidinone-based compounds were provided by Prof. Seth M.
Cohen. In our previous study, IC50 value of CAP treatment to U373MG cells was
determined to be 74.26 s (95% confidence range of 47.24–116.8 s)(Conway et al., 2016).
The toxicity measured in U373MG cells exposed to 30 s CAP is 18.52%, SEM=5.41%
(He et al., 2018). As seen from Figure 22, the majority of the compounds presented no
synergistic effects with CAP treatment. There was only additive decrease of nearly 20%
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cell viability when U373MG cells were treated with compounds in combination with 30
s CAP treatment.
Table 6. IC50 values of compounds provided by Prof. Seth M. Cohen.

IC50 (μM)
1,2HOPO-2
1,2HOPO-2Boronic
PY-2
PY-2Benzyl
PY-2Boronic
Cmpd1
Cmpd2

118.3

Control
95% Confidence
Intervals
93.12 to 150.3

IC50
(μM)
78.11

CAP 30s
95% Confidence
Intervals
47.32 to 128.9

55.39

49.11 to 62.46

36.67

26.32 to 51.08

1008
51.83

497.0 to 2045
43.88 to 61.21

489.9
17.07

71.38 to 3363
8.523 to 34.18

47.41

40.05 to 56.12

29.19

11.60 to 73.44

Not
converged
Not
converged

Not converged

203.6

141.4 to 293.3

Not converged

4391

195.1 to 98790
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Figure 22. Dose response curves of compounds provided by Prof. Seth M. Cohen,
University of California San Diego, US.
4.3.3 Pyrimidone Bicycle Family Compounds
A series of pyrazolopyrimidines derivatives, also as known as compounds from
pyrimidone bicycle family, provided by Prof. John Stephens were tested using U373MG
cell line. As seen in Figure 24, the majority of pyrazolopyrimidines derivatives had no
synergistic cytotoxicity in combination with CAP treatment, the dose response curves of
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CAP-treated groups presented high comparability and similar trends with untreated
groups. The CAP treatment didn’t change the IC50 values of the majority of tested
compounds (Table 8).
However, the leading candidates of CAP-activated prodrugs were determined in this
pyrimidone bicycle family. As seen in Figure 23, JW-04-061 and JW-04-057a presented
great synergistic cytotoxicity with 30 s of CAP treatment. The CAP treatment induced a
pronounced descent of dose response curves with the increasing of concentrations of
prodrugs. As seen in Table 8, CAP treatment induced significant decreases of IC50 values
of JW-04-061 (from 610.8 μM to 55.37 μM) and JW-04-057a (from 940.6 μM to 62.41
μM) while presenting low cytotoxicity themselves.
Therefore, among all 47 candidates of prodrugs, JW-04-061 and JW-04-057a were
determined as the only two leading candidates of CAP-activated prodrugs. The dose
response curves of JW-04-061 and JW-04-057a with or without 30 s CAP treatment have
been repeated to further confirm the synergistic cytotoxicity (Appendix V Supplementary
Figure S2). JW-04-061 has been chosen to be the research focus to save time and budget
and lay the foundation for future projects.
Table 7. IC50 values of compounds provided by Prof. John Stephens.

JW-01009
JW-01033
JW-01037
JW-01072
JW-04012
JW-04017

IC50
(μM)
25.51

Control
95% Confidence
Intervals (μM)
22.84 to 28.50

IC50
(μM)
12.92

11.32

10.09 to 12.70

11.4

10.34 to 12.57

197

174.3 to 222.7

126.8

113.0 to 142.4

42.9

37.75 to 48.74

19.04

13.75 to 26.38

13372

5733 to 31190

5670

1831 to 17555

77.68

66.55 to 90.67

73.62

60.59 to 89.44
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CAP 30s
95% Confidence
Intervals (μM)
11.53 to 14.48

JW-04037
JW-04039
JW-04057a
JW-04061
MK2
MK6
MK7
MK8
MK9

366.8

306.1 to 439.5

462.1

197.3 to 1082

137.2

120.2 to 156.6

86.27

76.20 to 97.68

940.6

564.2 to 1568

62.41

49.58 to 78.56

610.8

523.0 to 713.4

55.37

44.94 to 68.21

502.2
23.34
74.59
148.1

Not converged
452.4 to 557.4
19.82 to 27.49
67.68 to 82.20
131.7 to 166.6

608.6
38.23
44.42
86.7

Not converged
561.0 to 660.2
34.96 to 41.80
31.39 to 62.85
75.02 to 100.2

Figure 23. Dose response curves of compounds provided by Prof. John Stephens,
Maynooth University, Ireland, part 1.
(a) Dose response curves of JW-04-061 with or without CAP treatment. (b) Dose
response curves of JW-04-057a with or without CAP treatment.
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Figure 24. Dose response curves of compounds provided by Prof. John Stephens,
Maynooth University, Ireland, part 2.
4.3.4 Investigate the Mechanism behind the Synergistic Cytotoxicity Between
Leading Prodrug Candidate JW-04-061 and CAP Treatment.
JW-04-061 has been used to further investigate the synergistic anti-cancer effects in
combination with CAP treatment. To determine the mechanism of CAP activation of JW04-061, JW-04-061 was first dissolved in 100% DMSO and then treated with 30 s and 10
min CAP in DMSO solution. Afterwards, CAP-treated JW-04-061 DMSO solution was
diluted in culture medium to 1000 μM (DMSO final concentration 1%) and series diluted
to lower concentrations to incubate with U373MG cells for 48 h before Alamar Blue
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assay. As seen from Figure 25c, CAP-10 min treated DMSO (series diluted
concentrations starting from 1%) had no significant cytotoxicity on U373MG cells, and
untreated JW-04-061, CAP 30s treated JW-04-061 in DMSO, CAP 10 min treated JW04-061 in DMSO presented similar dose response curves and IC50 values (Table 9). This
may due to the lack of ROS generation in 100% DMSO solvent, whereas the generation
of reactive species relies on the present of reactants in treated liquid (Tanaka et al., 2011),
and the DMSO may function as scavenger of OH radicals (Eberhardt and Colina, 1988).
Hence, 30 s and 10 min CAP-treated JW-04-061 DMSO solution demonstrated likely non
or weak synergistic cytotoxicity in combination with CAP treatment.
To further confirm the synergistic effects between JW-04-061 and CAP, JW-04-061 was
diluted in culture medium in different concentration then treated with CAP for 0-40 s.
The CAP-treated JW-04-61 culture medium solution was subsequently incubated with
U373MG cells for 48 h before Alamar Blue assay. As seen in Figure 25a, b, CAP 10-40
s treated JW-04-061 culture medium solution induced a pronounced decreasing of cell
viability with concentrations higher than 10 μM compared with CAP untreated group,
when CAP treatment alone had low cytotoxicity (~20% decrease of cell viability).
Table 8. IC50 values of JW-04-061 treated by CAP 0-30s in DMSO solution.

Untreated
JW-04-061
IC50 (μM)
95%
Confidence
Intervals
(μM)

120.3
85.37 to 169.4

CAP 30s
treated JW-04061 in DMSO
107.6
84.72 to 136.8

CAP 10 min
treated JW-04061 in DMSO
123
117.7 to 128.5

CAP 10 min
treated
DMSO
2279
1228 to 4233

Meanwhile, NAC was applied as antioxidant to further investigate the mechanism. 4 M
NAC solution was diluted in culture medium till final concentration 4 mM before adding
JW-04-061 and 40 s CAP treatment. As seen in Figure 25a, b, the NAC treated group
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presented much higher cell viability and relatively gentle decrease of dose response curve
compared to CAP treated group, which demonstrated that ROS generated by CAP
treatment played key roles in the activation of anti-cancer effects of JW-04-061. The
normalized isobologram also have been analysed and presented in Figure 25d, which
further confirm the synergistic effects between CAP treatment and JW-04-061 treated in
culture medium. Using CompuSyn software, the synergistic analysis was carried out and
combination index (CI) values have been calculated. The CI values of JW-04-061 with
10 s CAP were 0.31099, 0.33520 with 20s, 0.47561 with 30s, and 0.57796 with 40 s,
which were all less than 1.00 and confirmed the significant synergistic cytotoxicity
between CAP treatment and JW-04-061 (Figure 25d).
Taken together, we have demonstrated that JW-04-061 was mainly activated by the
reactive species generated during CAP treatment, therefore presented significant
synergistic cytotoxicity to U373MG cells in combination with CAP treatment.
Before the COVID-19 situation and closure of the research buildings, we acquired
additional preliminary results which have been included in Appendix V, which can be
used to further determine the detailed mechanism behind the synergistic cytotoxicity
between CAP treatment and prodrug JW-04-061. Overnight storage CAP-activated
medium, CAP-activated cells and catalase (hydrogen peroxide decomposition) have been
used to study the dose response of U373MG cells to JW-04-061.
As seen in Appendix V Supplementary Figure S3a, when cells were treated with
overnight storage CAP-activated medium and prodrug, no synergistic cytotoxicity was
observed. Meanwhile, the U373MG cells have been activated and incubated for 0-5 hours
after CAP treatment, then incubated with fresh medium containing prodrug. There was
no significant synergistic cytotoxicity observed between CAP-activated cells and prodrug
comparing to direct combination of CAP treatment and prodrug, but the CAP-activated
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cells presented relative lower cell viability at low prodrug concentration comparing to
direct combination of CAP treatment and prodrug (as seen in Appendix V Supplementary
Figure S3b). On the other hand, as seen in Appendix V Supplementary Figure S3c, there
was no significant synergistic effects between CAP treatment and prodrug JW-04-061 to
catalase treated cells.
Table 9. IC50 values of JW-04-061 treated by CAP 0-40s in culture medium solution.
IC50

95% Confidence

(μM)

Intervals (μM)

JW-04-061 Control

270.9

218.6 to 335.6

JW-04-061 CAP10s treated medium +drug

54.37

47.56 to 62.15

JW-04-061 CAP20s treated medium +drug

31.05

26.71 to 36.10

JW-04-061 CAP30s treated medium +drug

39.21

31.27 to 49.16

JW-04-061 CAP40s treated medium +drug

37.06

31.18 to 44.04

95.65

79.08 to 115.7

JW-04-061 CAP40s treated medium +drug
+NAC
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Figure 25. Dose responses of U373MG cells to JW-04-061 treated by CAP in culture
medium solution or DMSO stock solution.
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JW-04-061 has been added into culture medium to corresponding concentrations then
treated with CAP for 0-40 s with or without NAC. Then the CAP treated medium
containing JW-04-061 was added in 96-well plates to incubate with U373MG cells for
48 hours and the dose response was presented using nonlinear regression (a) and bar
chart (b). (c) JW-04-061 was prepared in DMSO stock solution and treated with CAP for
30s and 10 min, then series diluted in fresh culture medium and incubated with U373MG
cells for 48 hours and compared with control groups (Untreated JW-04-061 and vehicle
(equivalent volume of pure DMSO) treated with CAP for 10 min).(d) Isobologram
analysis of the combinational effect of JW-04-061 and CAP. The single doses CAP on yaxis and JW-04061 on x-axis were used to draw the line of additivity. Four combination
points were indicated in the isobologram (CAP 10-40s and corresponding IC50 values
of CAP-treated JW-04-061). The localisation of combined JW-04-061 and CAP at
different time exposures can be translated to synergism CI ＜ 1, additivity CI=1 or
antagonism CI>1.

4.4

Discussion

With development of technique and revolution of knowledge, we are capable of
performing precise surgery, targeted and focused chemotherapy and radiotherapy after
quick and accurate diagnosis of tumours. However, current treatments still present several
side effects, including poor patient experience, secondary malignancy and a variety of
long-term sequelae (Triesscheijn et al., 2006; Tachibana, Feril and Ikeda-Dantsuji, 2008;
von Woedtke et al., 2013; Murray and Robinson, 2016). Meanwhile, researchers are
exploring novel therapies based on different techniques, including sonodynamic therapy
(Maeda et al., 2017), photodynamic therapy (Kawczyk-Krupka et al., 2015), CAP therapy
(Ratovitski et al., 2014), gene therapy (Naldini, 2015) and immunotherapy (Pardoll, 2012)
and some of them have achieved great outcome in clinical trials and even been
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successfully applied in practice. However, novel therapies are also very limited with the
high requirement of technique, expensive cost and unknow side effects. In this case,
combination therapy has been considered as a promising way to solve the problem in a
short time while generating less side effects. Usually patients are treated with
combination of surgery, radiotherapy and chemotherapy based on the type and progress
of the tumours. However, those treatments usually present no synergistic therapeutic
effects but increase additive anti-cancer effects to improve the survival of patients along
with more side effects. The purpose of investigating combination therapy in this chapter
is to improve the anti-cancer effects synergistically and therefore to reduce the dose and
side effects of the treatment.
We have tested a total of 47 prodrug candidates from 4 collaborators, including
aminoferrocene-based prodrugs provided by Prof. Andriy Mokhir (Marzenell et al.,
2013), ferrocene, [3] ferrocenophane and ferrocifen derivatives provided by Prof. Gérard
Jaouen (Jaouen, Vessières and Top, 2015), matrix metalloproteinase pro-inhibitors and
thiazolidinone-based prodrugs provided by Prof. Seth M. Cohen (Perez et al., 2015), and
a series of pyrazolopyrimidines derivatives provided by Prof. John Stephens (Kelada et
al., 2018), in combination with low dose CAP treatment using culture medium without
pyruvate. We have identified only two leading candidates with synergistic cytotoxicity in
combination with CAP treatment, which are JW-04-061 and JW-04-057a provided by
Prof. Stephens.
As seen in Figure 19, 20, 21 and 22, all candidates provided by Prof. Andriy Mokhir, Prof.
Gérard Jaouen and Prof. Seth M. Cohen which contain typical ROS-trigger groups
presented no significant synergistic cytotoxicity in combination with low dose CAP
treatment. However, there were few prodrug candidates which presented significant anticancer effects just themselves. This might be due to the relatively high ROS level in
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U373MG cancer cells caused by their rapid proliferation and altered metabolism.
Subsequently, the relatively high cellular ROS level in U373MG cells was already rich
enough to trigger the activation of those prodrug candidates without extra ROS generated
by low dose CAP treatment. Therefore, the CAP treatment didn't activate those prodrug
candidates in U373MG cells and thus presented no synergistic cytotoxicity in
combination with those prodrugs. However, those high cytotoxic prodrug candidates,
including P286, P686, P53, P722, P258, P257 (as seen IC50 values in Table 6, dose
response curves in Figure 20 and 21), can be used in future projects to test their
cytotoxicity and specificity in healthy cells and cancer cells, which may contribute to the
discovery of novel efficient anti-cancer prodrugs.
Furthermore, as seen in Figure 25, we have investigated the synergistic effects between
JW-04-061 and CAP treatment. To distinguish the effects induced by CAP to cells and to
prodrugs, we have investigated the cytotoxicity of CAP-treated prodrugs without direct
and immediate effects from CAP treatment to cells.
To remove the direct and immediate effects from CAP to U373MG cells, we first treated
JW-04-061 in DMSO for 30 sec or 10 min then series diluted the CAP-treated JW-04061 DMSO solution in fresh medium to corresponding final concentrations, subsequently,
U373MG cells were incubated with CAP treated JW-04-061 culture medium solution
(from CAP-treated DMSO solution) to investigate if the CAP treatment induced direct
changes to prodrugs in DMSO solution. However, there's no significant synergistic
cytotoxicity observed when the CAP treatment was performed to prodrug DMSO solution
(Figure 25c). We have realized that 100% DMSO contains no H2O in the solution,
therefore it could be one of the reasons that the CAP treatment could not induce enough
generation of ROS in JW-04-061 DMSO solution without substrate (Lu et al., 2017).
DMSO has been demonstrated to be a scavenger of OH radicals (Eberhardt and Colina,
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1988). Therefore, alternatively, JW-04-061 was first diluted in fresh culture medium to
corresponding concentrations, then was exposed to CAP treatment for 10-40 s at 75 kV.
The CAP-treated JW-04-061 culture medium solution was subsequently incubated with
U373MG cells for 48 h before Alamar Blue assay. As seen in Figure 25a, b, significant
synergistic effects were observed in combination of CAP treatment and JW-04-061
treated in culture medium solution. The synergistic cytotoxicity was also analysed using
isobologram (Figure 25d). Meanwhile, we have applied NAC as antioxidant to
investigate the roles of ROS. As seen from Figure 25a, b, with protection from NAC, the
cytotoxicity of CAP-treated JW-04-061 in culture medium was significantly decreased.
Although, the NAC may decrease the intracellular ROS level of U373MG cells then lead
to the decreased cytotoxicity. The lower dose of CAP treatment induced less increasement
of cytotoxicity of JW-04-061, which supported that the ROS generated in culture medium
played the main role in the activation of drug. Taken together, we can determine that,
without direct and immediate effects from CAP to U373MG cells, JW-04-061 still has
significant synergistic cytotoxicity in combination with CAP treatment when there is
normal generation of ROS in culture medium. However, we could not fully determine the
roles of CAP-induced ROS played in the synergistic effects yet. The high level of ROS
in culture medium may affect U373MG cells via a variety of activities, including lipid
peroxidation, oxidation of protein/DNA/RNA, and intracellular ROS signalling pathways,
then trigger the synergistic cytotoxicity with JW-04-061. We acquired additional
preliminary results which may explain more mechanism behind the synergistic
cytotoxicity between JW-04-061 and CAP treatment.
Overnight storage CAP-activated medium, CAP-activated cells and catalase (hydrogen
peroxide decomposition) have been used to study the dose response of U373MG cells to
JW-04-061 and investigate the mechanism behind the synergistic cytotoxicity between
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JW-04-06 and CAP treatment. As seen in Appendix V Supplementary Figure S3a, JW04-061 was added into overnight storage CAP-activated medium just before incubation
with cells, no synergistic cytotoxicity was observed when cells were treated with
overnight storage CAP-activated medium containing JW-04-061 compared to control
groups. Yan et al. reported that short-lived reactive species were removed by overnight
storage as well as most of long-lived reactive species, such as hydrogen peroxides in the
CAP-activated medium (Yan et al., 2016). However, the DIT-120 system investigated in
this project has been shown to generate high concentrations of hydrogen peroxides which
were stable in various liquids over storage time (Boehm et al., 2017). Therefore, this is
yet to be further determined for prodrug treatment. So far, we can determine that the
oxidised components in CAP-activated medium have no effect on the synergistic
cytotoxicity between CAP-treatment and prodrug JW-04-061. For the record, the fresh
CAP-activated medium should have been used to compare with the overnight storage
CAP-activated medium for prodrug series dilutions and treatment. As seen in Figure 25,
the fresh CAP-treated medium containing prodrugs presented significant synergy, which
may be comparable with overnight storage CAP-activated medium. Meanwhile, as seen
from Appendix V Supplementary Figure S3c, catalase has been used to decompose
hydrogen peroxides, and the prodrug only has been exposed to other reactive species
generated by CAP, which demonstrated no significant synergistic cytotoxicity. It
demonstrated that the hydrogen peroxides generated by CAP in culture medium may play
a main role in the activation of JW-04-061 during and after CAP treatment.
On the other hand, CAP-activated U373MG cells have been applied to investigate the
possible synergy between prodrugs and cellular responses to CAP treatment, such as
peroxidised cellular membrane, accelerated cellular uptake and oxidation stress response
(He et al., 2020). U373MG cells were activated together with medium by CAP for 30 sec
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and then incubated for 0-5 hours. Afterwards, fresh medium containing prodrug JW-04061 was used to test cellular dose response and the possible synergistic effects. As we
can see in Appendix V Supplementary Figure S3b, there was no significant synergistic
cytotoxicity observed between CAP-activated cells and JW-04-061 compared to direct
combination of CAP treatment and prodrug. However, it presented lower cell viability
(around 25% decrease) in CAP-activated cells, which may be due to changing of culture
medium 0-5 hours after CAP treatment causing extra loss of cells. However, it
demonstrated that the synergistic cytotoxicity is mainly from CAP-activated prodrug
instead of CAP-activated cells. The experiments discussed above, including treating cells
with CAP only, incubating cells with prodrugs only, treating cells and prodrugs with CAP
at the same time, incubating CAP-untreated cells with CAP-treated prodrugs (prodrugs
were treated with CPA in culture medium solution or DMSO stock solution), incubating
CAP-untreated cells with prodrugs dissolved in overnight storage CAP-activated medium,
incubating CAP-treated cells with CAP-untreated prodrugs, were performed with same
volumes, same concentrations of prodrugs and same types of culture medium without
pyruvate. NAC and catalase were used as scavengers of reactive species in inhibiting
study. The preliminary conclusion is that the JW-04-061 presents significant synergistic
cytotoxicity against U373MG cells after being activated by low doses of CAP treatment
in culture medium, whereas the ROS, specifically hydrogen peroxides, may play a main
role in the activation of JW-04-061.
All in all, investigating combination therapy is a promising way to develop efficient anticancer therapies with as little as possible side effects, especially if there are significant
synergistic anti-cancer effects which can be specifically and precisely targeted to tumour
tissue. Various compounds and nanoparticles were investigated as sensitizers for
radiotherapy, photodynamic therapy and others. However, the majority of sensitizers only
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promote the efficiency of the therapy itself or present extra diagnosis function but have
no extra therapeutic effect. Therefore, in this chapter, we discovered and demonstrated
new compounds that can synergistically kill cancer cells in combination with low dose
CAP treatment, which have not been reported before. The JW-04-061 and JW-04-057a
can be further investigate for future trials. This research has contributed to the foundation
of CAP/ROS-trigger prodrugs research and will inspire the development of more efficient
prodrugs that can be combined with targeted and precise CAP treatment for cancer
therapy.
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5.

GENERAL DISCUSSION
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In the development of successful interventions to cure cancer, nanomaterials have played
key roles. In last two decades, a variety of nanomaterials have been greatly expanded as
well as highly diversified and multi-functionalized. Some of these nanomaterials were
determined as lead candidates to delivery chemotherapeutics to tumours and have passed
preclinical trials and successfully applied to the clinic. Enhanced permeation and
retention-based tumour targeting and then, especially, active targeting was introduced,
which highly increased the efficiency and specificity of drug delivery into tumours. Due
to the excellent loading capacity of nanocarriers and multifunctionality of their ligand or
themselves, nanoparticles can be applied in cancer treatments, as both carriers, sensitisers
and imaging agents, which can provide advanced diagnosis as well as diversified
treatments.
AuNPs, as one of the most commonly investigated and used nanomaterials for cancer
treatment, can be readily manufactured in a variety of specific shapes, size and
monodispersity with different functions, therefore can be used as diagnostic agents,
carriers and/or sensitizers for cancer therapy. The AuNPs we used in this project were
synthesised by trisodium citrate (Na3C6H5O) reduction of auric acid (HAuCl4) and
therefore were not functionalized and only capped with citrate and manufactured in
spherical shape and ~20 nm diameter by controlling the ratio between Na3C6H5O and
HAuCl4. Non-functionalized AuNPs have shown selective cytotoxicity to cancer cells,
are generally consider nontoxic to healthy cells whereas small AuNPs usually elicit
higher cytotoxicity than larger AuNPs (Connor et al., 2005; Patra et al., 2007; Alkilany
and Murphy, 2010). The AuNPs of ~20 nm diameter we used have been demonstrated to
have elicit relatively low cytotoxicity in both normal and cancer cells and are optimal for
permitting BBB compared with non-functionalized AuNPs of other sizes (Pan et al., 2007;
Shilo et al., 2015). Therefore, 20 nm citrated capped spherical AuNPs were applied in
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this study for investigation of the combination therapy with CAP treatment, which also
can be the optimal candidate for drug delivery across BBB.
As emerging technology, it has been clinically shown that cold atmospheric plasma can
be safely and directly applied on patients for disinfection and promoting the healing of
wounds and ulcerations (Weltmann et al., 2008; von Woedtke et al., 2013; Mai-Prochnow
et al., 2014; O’Connor et al., 2014). CAP is showing strong potential in cancer treatment
as well. Recently, it has been repetitively demonstrated that CAP have significant and
selective cytotoxicity to multiple tumour lines in vitro and in animal models (Walk et al.,
2013; Ratovitski et al., 2014; Park et al., 2015; Recek et al., 2015; Yan et al., 2015;
Conway et al., 2016; Zhu et al., 2016). Moreover, as additional treatment, a prospective
clinical trial for head and neck cancer treatment has been carried out, Metelmann et al.
presented that CAP treatment not only reduced contamination of ulcerations caused by
head and neck cancer and may have inhibited tumour growth and caused visible local
destruction after two weeks of treatment. Meanwhile, during the trial, CAP treatments
presented low side effects and benefits to patients in various aspects, such as easy to
handle treatment, easing cancer pain, gain of weight and likely prolonged survival.
(Metelmann et al., 2015). Most recently, for the first time, a CAP device, Canady
HeliosTM Cold Plasma Scalpel, has been approved for human clinical cancer treatment
trials by the FDA to evaluate its safety in patients with solid tumours with carcinomatosis
scheduled to undergo surgical resection for cytoreduction (‘Canady Helios Cold Plasma
Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites’, 2020). In this
study, cold plasma is sprayed in the area of the resected tumour margins after removing
gross solid tumour via surgery (‘Canady Helios Cold Plasma Scalpel Treatment at the
Surgical Margin and Macroscopic Tumor Sites’, 2020). Cold plasma also has been
successfully evaluated in many non-cancer related trials (e.g. Chronic wounds treatment
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(Isbary et al., 2012), symptomatic knee osteoarthritis treatment (Sánchez et al., 2012),
herpes treatment (Isbary et al., 2014), treatment of lesions in Hailey-Hailey disease
(Isbary et al., 2011)). For instance, for chronic wounds treatment, a randomized
controlled trial presented a significant reduction in bacterial load in plasma-treated
wounds (Isbary et al., 2012). The CAP treatment for patient with chronic wounds was
well tolerated and no side-effects occurred (Isbary et al., 2012).
A promising synergistic anti-cancer effect between CAP and AuNPs which we observed
was that the uptake of AuNPs into U373MG cells was significantly enhanced with CAP
treatment, and the cytotoxicity of the AuNPs to U373MG cells was also significantly
increased combined with CAP treatment. There have been reports that CAP treatment can
induce pore formation on cell membrane that may increase delivery of agents into cells,
and had synergistic cytotoxicity combined with nanoparticles especially gold
nanoparticles. Jinno et al. has described that the electrical effects of CAP combined with
reactive species helped the gene transfection into L-929, mouse fibroblast cells (Jinno et
al., 2016). Krassowska et al., simulated that strong electric fields, which exist during CAP
treatment, can induce formation of large pore in spherical cell membranes (i.e. 15-25 nm)
(Krassowska and Filev, 2007). Cheng et al., observed that uneven membrane and
membrane pores were induced in U87 cells after treatment of CAP (Cheng et al., 2015).
Nina et al., also described the unrecoverable partial cell membranes and cell components
damage induced by CAP treatment in U87 cells. The direct membrane damage and pore
formation induced by CAP treatment described in these studies may explain that we
observed low levels of non-active uptake of AuNPs during the first few hours after CAP
treatment, which was not inhibited by NaN3 or low-temperature (4 ℃) incubation. NaN3
was used as metabolic inhibitor to inhibit the energy-dependent endocytosis, and lowtemperature incubation was used to inhibit endocytosis as a standard experiment.
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However, we mainly observed that active uptake of AuNPs was stimulated after low dose
CAP treatment which was inhibited by NaN3 and low-temperature incubation. This has
not been reported before. Furthermore, we also observed the significant enhancement of
AuNPs uptake with indirect CAP treatment which removes the direct physical effects. It
confirmed that pore formation and direct membrane damage plays only a minor role in
the increased uptake of AuNPs induced by low dose CAP treatment compared to previous
studies. It should be noted that each of these studies were carried out using different
cancer cell lines and various dose of CAP generated by different devices with distinct
input voltage, frequent, current and therefore cause different response of cancer cells to
CAP treatment.
On the other hand, several studies to date have reported the synergistic anti-cancer effect
between CAP treatment and AuNPs. Kim et al., first demonstrated that cytotoxicity of
CAP to G361 human melanoma skin cancer cells was significantly increased (near fivefold) by combining with anti-FAK antibody-conjugated AuNPs (FAK-AuNPs) (Kim et
al., 2008). In this study, the adopted 30nm AuNPs didn’t present any observable cytotoxic
effect on the proliferation of G361 cells while applied alone, but increased the cell death
rate from 14% (CAP only) to 36% (CAP and unconjugated AuNPs) and 74% (CAP and
FAK-AuNPs) (Kim et al., 2008). It is interesting that Kim et al., noted that the cell
morphology was maintained, even in dead cells, after combination treatment of CAP and
FAK-AuNPs, whereas cells dying from CAP usually undergo anoikis. (Kim et al., 2008).
In another study, fluorouracil, a DNA synthesis inhibitor chemotherapeutic that has been
widely used in clinical treatment of breast, gastrointestinal and gynaecological cancers,
was loaded in core (gold)-shell (PLGA) nanoparticles for combination treatment with
CAP against human breast cancer MDA-MB-231 cell line (Zhu et al., 2016). Synergistic
cytotoxicity between the drug loaded core-shell AuNPs and CAP treatment and enhanced
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cellular internalization of the drug loaded core-shell AuNPs by CAP treatment were
observed (Zhu et al., 2016). Similarly, X. Cheng et al., described that 100 nm uncoated
AuNPs presented synergistic cytotoxicity to U87 cells combined with CAP treatment,
which was also dose dependent (Cheng et al., 2014). At the optimal concentration, AuNPs
induced U87 cell death up to a 30% overall increase compared to the control group with
the same plasma dosage only (Cheng et al., 2014). Highest intracellular ROS intensity
induced by CAP was measured at this optimal concentration as well (Cheng et al., 2014).
The exact mechanism has yet to be discovered but they concluded that the AuNPs in the
medium may accelerate the absorption of exogenous ROS and RNS generated by CAP
into cells (Cheng et al., 2014). A study was carried out by Irani et al. which demonstrated
that the cell death of HCT-116 cells (human colorectal cancer cells) was increased
significantly by CAP treatment in the present of ~55 nm citrate-capped AuNPs (Irani et
al., 2015). However, despite all the evidences for the synergistic anti-cancer effects
between CAP treatment and AuNPs, the underlying mechanism of this synergistic
cytotoxicity was yet to be well understood.
To date and to the best of our knowledge we are the first to demonstrate the detailed
mechanism behind the synergistic anti-cancer effects between CAP treatment and AuNPs
and gave a strong hypothesis with regards to CAP facilitated permeability of drugs. As
described in Chapter 2, we have successfully determined that CAP treatment promotes
the uptake of AuNPs into U373MG cells via ATP-dependent active pathway and
eventually accumulated in lysosomes, and published a peer-reviewed paper based on this
work (He et al., 2018). The enhanced accumulation of AuNPs in U373MG cells was first
observed under optical microscope. Then we have tracked the accumulation and uptake
of AuNPs into cells with or without CAP treatment using a variety of technique and
devices, including AAS, confocal microscope, flow cytometry, electron microscope and
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Zetasizer, combined with a panel of inhibitors and fluorescent probes, including ATP
inhibitor sodium azide, antioxidant NAC, lysosomes tracker. Using AAS, we have
successfully tracked the accumulation of AuNPs inside U373MG cells and demonstrated
that the uptake of AuNPs enhanced by CAP treatment was an active pathway. Using
confocal microscope, the majority of intracellular AuNPs has been confirmed to located
in lysosomes which presented significant greater accumulation with CAP treatment. It
should be noted that antioxidant NAC didn’t significantly decrease the stimulated uptake
of AuNPs by CAP, which may demonstrate that short-lived species or NAC-insensitive
reactive species played the main role in the stimulation of cellular uptake. Using indirect
CAP treatment also demonstrated that physical effects induced by CAP also didn’t play
main role in the increased uptake of AuNPs into U373MG cells.
However, we didn’t fully answer the questions behind the synergistic cytotoxicity
between CAP treatment and AuNPs. It is worth to understand the mechanism behind the
synergy which will be useful for developing more efficient deliveries of nanoparticles
and pharmaceuticals into cancer cells for tumour therapy and diagnosis and other relevant
cancer therapies that induce an increase in extracellular ROS. Therefore, we continued
the investigation of the synergistic effects between CAP treatment and AuNPs and tried
to precisely identify the CAP-affected cellular pathways involved in the enhanced uptake
of AuNPs.
The current study of Chapter 3 demonstrated, for the first time, that the synergistic effects
of nonfunctionalised AuNPs combined with CAP, to glioblastoma cancer cells, is via the
clathrin-mediated endocytosis stimulated by CAP-induced membrane repair processes.
In Chapter 3, numerical modelling of the uptake of gold nanoparticles into U373MG
glioma cells predicted that CAP may introduce a new uptake route. We have
demonstrated that cell membrane repair pathways play the main role in the stimulated
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new uptake route, following non-toxic doses of CAP treatment (30 s, 75 kV). CAP
treatment induced cellular membrane damage, mainly via lipid peroxidation as a result of
ROS and RNS generation. Membranes rich in peroxidised lipids were then trafficked into
cells via membrane repairing endocytosis. We confirmed that the enhanced uptake of
nanomaterials is clathrin-dependent using a batch of specific chemical inhibitors and
silencing of gene expression. Therefore, we have hypothesised that CAP-stimulated
membrane repair increases endocytosis and accelerates the uptake of gold nanoparticles
into U373MG cells after CAP treatment. In Chapter 3, our data has demonstrated the
utility of CAP to model membrane oxidative damage in cells and characterised a
previously unreported mechanism of membrane repair to trigger nanomaterial uptake.
This research article has been published in the peer-reviewed journal ‘Scientific Report’
(He et al., 2020).
Although there has been study hypothesis that after uptake via receptor-mediated
endocytosis, epidermal growth factor (EGF)-conjugated AuNPs combined with CAP
induced DNA damage and selective apoptosis of A549 human alveolar basal epithelial
cancer cells (Kim et al., 2017). This hypothesis was based on the decreased uptake of the
EGF-conjugated AuNPs when incubated at 29.5 ℃ compared to 37 ℃, and that the EGF
ligand usually triggers recruitment of the EGF receptor to clathrin-coated pits which has
been demonstrated to be the endocytosis pathway of uptake of EGFR-ligand complex, as
well as that AuNPs are mainly internalized via clathrin/ caveolar-mediated endocytosis,
phagocytosis, macropinocytosis, and pinocytosis (Kim et al., 2017). However, this study
didn’t directly demonstrate that the increased uptake of AuNPs was via receptor-media
endocytosis and also used ligand-conjugated nanoparticles which is different compared
to our study. There is another study demonstrating that iron-dependent cold plasmainduced oxidative stress can stimulate significant increase in fluid-phase endocytosis,
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lysosome biogenesis and autophagy, therefore inducing highly selective anti-proliferative
activity against rat SM2 (sarcomatoid subtype) malignant mesothelioma cells (Shi et al.,
2017). However, the study presented that the CAP treatment decreased transferrin
receptor-1 which is in contrast with our study. We used transferrin conjugated with Alexa
Fluor™ 546, an early endosome marker, and confocal microscope to investigate the
endocytosis enhanced by CAP treatment and demonstrated that the quantification of
transferrin uptake was significantly increased within 5 min after CAP treatment compared
to control group. The contrast may be due to the variety of different cell lines and different
dose of CAP generated from distinct devices.
As seen in Chapter 2 and 3, the ROS and RNS induced lipid peroxidation played an
important role in the CAP-induced endocytosis and oxidization stress. It should be noted
that ROS and RNS play important roles in many other anti-cancer interventions, including
phototherapy (Zhou et al., 2016), ultrasonic therapy (Yu, Wang and Mason, 2004), as
well as some types of chemotherapy (Kasiappan and Safe, 2016), as especially in this
most common cancer treatment, radiotherapy (RT) (Manda, Nechifor and Neagu, 2009).
As mentioned in Chapter 1, the reactive species is a double-edged sword for cancer cells
and can be utilised for developing efficient therapeutic strateges against cancer cells.
ROS-inducing chemotherapy agents and radiation therapy are now the most common
anti-cancer innovation involved with reactive species.
Radiation therapy is one of the primary treatments for neoplasm using high-energy
ionizing radiation (IR). The acting mechanisms of RT include the generation of free
radicals or the direct deposition of energy by IR. Due to photoelectric effects and
Compton effects, the energy track of IR is composed by electrons in matters, which
induce ionization and excitation (Rehman et al., 2015). In cells, the electrons interact with
water and generate free radicals, including ROS and RNS (Mikkelsen and Wardman,
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2003). Damage is induced by the ROS/RNS-caused oxidative stress and lesions of
cellular macromolecules, including DNA, protein and lipids (Nikitaki et al., 2016).
Meanwhile, the cell killing effect is also related to the direct deposition of energy by IR,
which is highly penetrating and able to cause irreparable damage to genetic materials
even at low dose (Rothkamm and Löbrich, 2003). However, due to the high cytotoxicity
and non-targeted effects of radiation, the radiation must be accurately delivered to tumour
tissue while sparing normal tissue to improve PFS, OS and life quality of patients
(Nikitaki et al., 2016). Although ionizing radiation induces the generation of intracellular
ROS and free radicals (Magnéet al., 2006; Graves, 2012), the cytotoxicity of radiation is
mainly owing to the photons-directly-caused DNA damage (Mikkelsen and Wardman,
2003; Graves, 2012), even at low doses, resulting in irreparable damage to cellular genetic
material and cell death (Rothkamm and Löbrich, 2003). Compared to radiation, CAP can
produce longer lived reactive species, selectively inducing apoptosis to cancer cells
through signalling pathways, generating low-energy species which is relatively low-toxic
to normal cells. Due to the regular ROS level in normal cells, the antioxidant system in
normal cells present higher resistant to CAP treatment compared with cancer cells.
However, it has been demonstrated that CAP treatment can induce proliferation arrest,
DNA damage and a senescence phenotype to healthy cells without killing them.
Therefore, the dose of CAP treatment should be carefully controlled on targeted
cancerous tissue.
CAP devices are low cost, easy to control and the field is undergoing a rapid pace of
innovation and advancement (Ishaq, Evans and Ostrikov, 2014). Therefore, the potential
of CAP for developing more efficient and lower side-effects human healthcare is
significant and promising. On the other side, there are many research questions related
with CAP treatment awaiting to be solved for the clinical application of CAP for cancer
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therapy. For instance, there are a variety of CAP devices which have been investigated in
research. Due to high diversity (voltage, currency, frequency, gas types, various
components and designs of devices), the comparability between CAP devices is yet to
be further improved. Meanwhile, the doses of CAP generated from disparate devices are
difficult to be precisely identified by time of treatment. The identification of exact
reactive species, especially short-lived reactive species, have not been solved yet. CAP
only has been investigated for cancer therapy recently, thus the long-term effects of CAP
treatment are yet to be fully explored. Those are the challenges facing the field of plasma
medicine and require more efforts to eventually implement the CAP therapy in the clinic.
In Chapter 2 and 3, the focus of the project was investigation of the synergy between
AuNPs and CAP to understand the mechanism behind CAP and AuNPs synergy. In
Chapter 4, the focus was brought to prodrugs and CAP treatment. We first screened all
prodrug candidates using culture medium with pyruvate but didn’t observed leading
candidates with significant synergistic cytotoxicity. We have realized that pyruvate, a
common component of culture medium, may present negative effects in our experiments
as antioxidant (Ramos-Ibeas et al., 2017). Therefore, in Chapter 4, we screened all 47
prodrug candidates again and successfully identified that two compounds, JW-04-061
and JW-04-057a, provided by Prof. John Stephen, have significant synergistic
cytotoxicity in combination with low dose CAP treatment, using culture medium without
pyruvate. The synergistic effects between JW-04-061 and CAP treatment was further
investigated and will be published as peer-reviewed article in collaboration with Prof.
John Stephen. Other prodrugs, provided by Prof. Andriy Mokhir, Prof. Gérard Jaouen
and Prof. Seth M. Cohen, all contain typical ROS-trigger groups but presented no
significant synergistic cytotoxicity in combination with low dose CAP treatment, which
may be due to the natural ROS level in U373MG cancer cells being high enough for
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prodrug activation without CAP treatment. But we still have identified that few prodrug
candidates, including P286, P686, P53, P722, P258, P257, present high anti-cancer
effects on their own. Thus, those candidates can be used in future research to test their
cytotoxicity and specificity in healthy cells and cancer cells to discover new prodrugs.
In conclusion, we investigated the mechanism behind the synergistic anti-cancer effect
between CAP and AuNPs and provided solid evidence that the membrane oxidation
damage induced clathrin-dependent endocytosis played main role in the accelerated
uptake of AuNPs into U373MG cells by CAP treatment. In Chapter 4, we screened all
prodrug candidates and have identified two leading candidates that possess most
significant synergistic cytotoxicity to U373MG cells in combination with CAP treatment.
We also have provided preliminary evidence that reactive species generated in CAPtreated culture medium did play the main role in the activation of the leading prodrug
candidate JW-04-061, which leads to the synergistic cytotoxicity. This thesis provides
evidence to understand how CAP treatment induces a variety of responses of glioma cells,
especially stimulated endocytosis, which can be also applied in enhancing permeability
and tumour accumulation of other therapeutic and diagnostic agents for development of
efficient cancer therapies and diagnosis. Meanwhile, two novel prodrugs that have
synergy with CAP treatment have been identified and investigated. However, new
research questions have been brought to light by this study. Further studies are required
to fully elucidate what cell death pathways are involved in the synergistic cytotoxicity of
AuNPs and CAP. Investigation of this novel combination therapy using prodrug-loaded
AuNPs and CAP treatment in vitro, in 3-dementional cancer sphere model, and in vivo
also can be investigated in future projects for development of practical innovations in
clinical therapy. For in vivo treatment, alternative CAP devices, such as plasma jet or
plasma needle, are required to deliver CAP to targeted area. The cell death pathways
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involved in the anti-cancer effects of prodrug leading candidates combined with CAP
have yet to be explored.
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7.3 Appendix III Supplementary Information for Chapter 2

Figure S1. UV-vis absorption spectrum of 100 μg/ml AuNPs dispersed in water. The
AuNPs solutions were treated with CAP at 75 kV for 30 s, or untreated.

Table S1. Raw dataset of the Alamar Blue assay. U373MG cells were treated with
different concentrations of AuNPs (0-800 μg/ml). After incubated for 48 h, cell viability
was analysed using the Alamar Blue assay. The table presented the raw date produced by
the Microplate Reader, Synergy HT (BioTek).
Raw dataset of the Alamar Blue assay
AuNPs

Treatment：AuNPs+CAP 30s,75

Treatment：AuNPs only

Concentration
800 μg/ml
400 μg/ml
200 μg/ml
100 μg/ml
50 μg/ml

kV
22

20

28

28

30

3

9

9

3

1

29

28

31

32

33

2

7

2

1

6

30

32

33

33

32

7

5

4

1

0

30

33

33

33

34

0

6

7

6

4

33

35

35

35

34
209

113

86

79

81

103

175

122

172

171

183

177

140

219

206

219

164

136

150

184

178

232

210

206

207

238

25 μg/ml
12.5 μg/ml
6.75 μg/ml
3.375 μg/ml

0
Negative control

5

1

3

2

9

32

34

35

35

34

9

6

2

2

6

35

35

34

36

37

8

6

7

6

4

33

35

36

36

37

0

6

3

5

9

33

34

36

35

36

8

8

3

8

0

33

35

35

35

36

5

4

2

6

0

13

14

13

14

13

210

182

200

198

192

177

167

192

210

186

200

204

246

277

247

276

284

299

269

292

280

242

280

354

292

276

7.4 Appendix IV Supplementary Information for Chapter 3

Supplementary Figure S1. (a) Electro energy distribution function (EEDF) of CAP; (b)
Fluorescence level of intracellular oxidised H2DCFDA was measured via Flow cytometry,
the analysed average of mean FL1-A value.

Supplementary Figure S2. The fluorescent integrated density of non-oxidised BODIPY
was quantified using ImageJ. The statistical significance was assessed by one-way
ANOVA with Tukey’s multiple comparison post-test (*P<0.05, **P<0.01, ***P<0.001,
****p<0.0001), n≥50, see Appendix IV Supplementary Table S1 for original data

211

Supplementary Figure S3. The U373MG cells were loaded with C11-BODIPY (green),
then co-stained with and LysoTracker™ Deep Red (red) after CAP treatment (30 s, 75
kV) and observed under confocal microscope, three images are presented in the figure.
White arrows point out examples of co-localisation between oxidised C11-BODIPY and
lysosomes.

Supplementary Figure S4. After incubation with various inhibitors as indicated,
U373MG cells were treated CAP for 0, 30 s at 75 kV and then loaded with transferrin for
5 min or 100 μg/ml AuNPs for 3 h respectively before observing under confocal
microscope, then the fluorescence integrated densities were quantified using ImageJ. The
statistical significance was assessed by one-way ANOVA with Tukey’s multiple
212

comparison post-test (*P<0.05, **P<0.01, ***P<0.001, ****p<0.0001), n≥50.

Supplementary Figure S5. Oxidized C11-BODIPY emission was measured with same
threshold to highlight vesicle-like condensed area. (a) Sample of CAP treated cells; (b)
Sample of untreated cells; (c) With same threshold, the fluorescence integrated densities
were quantified using ImageJ. The statistical significance was assessed by unpaired Ttest. (*P<0.05, **P<0.01, ***P<0.001, ****p<0.0001), n≥50.
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Supplementary Discussion:
The intensity of O3 production may explain why there was no detectable emission of NO,
O, NOx and low intensities of •OH and N2+ in Figure 12a, as the free electrons were likely
quenched before reaching higher energetic states by the interaction and formation of O3.
Reaction mechanisms (1-4) can further explain how the formation of NO, NOx, and O
was hindered. In these reactions, M is a third body atom or molecule that, in this case,
may be N2* or O2.
O + O2 + M ∗ → O3 + M

(1)

M∗ + NO → M + N + O

(2)

O + H2 O → 2 •OH

(3)

2N + M → N2 + M

(4)
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Supplementary Figure S6. Uptake and subcellular localization of AuNPs observed by
confocal microscopy. After CAP treatment (0, 30 s), U373MG cells were incubated with
100 μg/ml AuNPs for 3 h. Early, late endosomes and lysosomes were stained using
CellLight™ Early/Late Endosomes-RFP (Marked as orange channel in images) and
215

LysoTracker™ Green DND-26, respectively. The far-red emission of AuNPs (Red) was
excited using 633 nm laser.
Supplementary Table S1.
Control.
Non-oxidized
(Supplementary
825441
Figure
9989492)
1060462
859260
530275
829356
665668
1278050
2038367
936308
1259645
1573896
1019896
963641
862036
812204
1113481
748271
1165023
764072
1232175
1007005
982070
1320705
946150
1342500
653886
499775
875556
1037540
906223
1097569
1207059
718964
559771
475472
747381
807312
707968
840742
777642
1022745
1228769
2064986
697882
1220345
775782
1182171
812884
940440
555395

Integrated Density of BODIPY
CAP 30s.
Control. Oxidized (Figure
Non-oxidized
13b)
764257
232430
(Supplementary
760580
310618
Figure
6658792)
327636
1089862
179182
765581
307326
360915
176954
551518
499637
264406
510195
596517
356545
760052
292490
332197
407417
866259
281113
499450
227051
296252
181733
846493
189916
881837
248568
861837
300329
778087
273441
524382
211968
867958
282522
508610
317893
595270
161873
610424
155628
445595
458594
1463426
399135
708723
462811
888079
196388
373856
190853
1477152
153302
653049
163432
1078557
142877
675892
206789
402444
37404
1083730
109317
930197
236604
898191
142135
331716
270552
532198
82436
817839
84652
414865
168778
749632
364207
879071
100734
1084756
114519
412708
49002
884861
273032
566726
58729
667011
169249
895365
184585
497905
198073
603690
154684
684168
441372
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CAP 30s.
Oxidized
417629
(Figure
3428743b)
495228
477016
426428
448261
293395
325466
273752
464481
167146
394278
302926
221856
454239
374735
373363
505987
292939
388750
597744
295272
306654
390399
890896
741382
524934
306468
390161
651081
187065
906811
312273
617780
468648
296259
389688
195602
506283
451699
303635
431292
701205
444981
223330
423576
569403
660069
227918
478087
254274

1327438
718786
642920
1050097
834466

371186
502118
415450
1489285
250668
247114
460969
345379
325823
342280
694899
607436
821919
1413574
729336

274210
245082
228162
437520
350830
199513
184087
260743
234688

Supplementary Table S2.
Integrated Density of Transferrin
Untreated
110807
66999
125539
25907
18663
36431
55003
58136
108838
203364
38237
106023
153065
46973
231021
126260
58261
53516
28616
169818
119425
69592
24623
126382
109035
251395
90739
76501
76803
71061
70167
71700

CAP30s
57027
112562
86679
97764
210017
151799
82789
180386
219322
120825
109507
181812
232475
103867
165690
189547
145942
216243
175271
79758
197285
173238
207385
137586
103140
55164
287846
49045
75313
76832
89317
116572

217

362961
398478
325251
346672
479690
1122291
191401
335414
346672
303883
306629
1149608
150280
456893
283002
269830
234559
524097
372300
626520
889340
691489

29972
28606
87132
33269
95125
80060
64769
106737
74147
79054
25151
40603
72073
124198
77852
103302
109488
58064
75705
27911
86282
117192
32705
120661
129909
106761
90118
39569
164849
84330

81825
205643
134411
101051
355132
57270
73021
108349
88346
56330
115220
109490
124859
218535
134532
71167
71050
60830
58081
63689
181942
170011
89790
71784
163049
107358
132343

Supplementary Table S3
Untreated
108598
43443
77433
94477
86584
98793
102070
129770
112724
60643
70525
110091
139093
98220
133442
143649
75022
123196
70338
55592
71972
168227
93020
129316

CAP30s
295322
only
108782
251156
84583
65841
91549
163102
156221
81989
207294
80463
86986
145578
63260
69745
110816
123363
134115
228112
140503
121850
158303
121401
70365

Integrated Density of Transferrin
Pitstop
Pitstop+CAP
64736
100433
38572
31750
47517
76352
25591
100240
35782
71304
39735
28401
100772
44936
40368
22378
30864
12836
74733
17119
76017
26816
75272
97123
91199
43380
29856
83012
115762
17713
105188
49522
43457
54983
50026
18278
7877
59622
69660
29797
99571
77787
62211
74743
89301
78765
98921
47823

218

CPZ
38802
24310
39598
294486
68324
51158
53180
72708
68844
131656
72856
62814
119252
26884
51452
28458
71198
74608
26936
3384
7454
34034
19250
15276

CPZ+CAP
56788
83128
45220
19690
13416
9444
16446
29576
5404
7596
4568
21856
2280
7814
129394
117634
30926
77612
68470
88596
30684
75958
95484
103746

110653
88591
122648
75639
131539
157044
163738
78925
111987
125506
125495
120301
105738
48458
68317
36999
72117
89229
45164
77146
88215
91529
80253
63880
120907
86245

146501
129369
82011
98961
112977
76354
94709
51942
177314
94675
129185
127507
90869
119518
113258
247984
277862
184301
167793
317787
213580
72160
60324
97864
156754
125687

86540
84316
80932
76763
188739
30436
46748
34317
59776
35976
57772
56559
90776
32429
58616
18765
67164
72684
38795
49816
12847
56799
26547
15265
56795
23657

32383
42288
52147
42159
101745
28371
63526
91475
41096
56949
69132
99148
41119
59855
47787
73103
27352
37608
41806
72871
87006
66654
49931
46675
29802
64467
12833
28102
38183
29502
37891
61498
51505
35668
24266
51119

219

49392
15354
19722
51914
54704
41096
36212
23016
19956
17996
31342
19040
56680
24088
42838
18410
9752
22664
21144
63528
15258
18400
64260
20094
18770
27556
17776
69252
19000
34386
8592
11670
37184
8968
21180
90982
22680
42116
7278
6646
59824
8114
19838

9158
4520
25244
17308
50974
16284
5584
19136
7634
30856
84574
30892
9672
12082
37932
4872
61354
29434
36554
27876
69646
59842
23916
14374
79040
61076
14866
85876
15354
8102
38704
34414
78286
16564
71468
10220
19342
16544
9582
77040
30404
54566
48010
7918
16944
6710
7116
34934
7930
67322
8512
5804
8342
26376
33834
2612
17928
20240
9364
22084
53872

38896
26456
15434
43858
11738

MβCD

MβCD+C

131419
124614
69503
75277
76750
18178
81444
88041
57794
51151
76552
86342
40633
97243
36007
79613
79863
115776
47129
36055
87390
62452
93547
74815
65652
90255
71303

66932
AP
93007
97275
46598
77640
92103
24984
95210
98855
89031
75078
85701
59098
91913
93666
93835
73324
69286
35314
46718
83701
56757
68512
43701
38500
46948
102306

Integrated Density of Transferrin
Filipin
Filipin
Genistei Genistein

Amilori

Amiloride

97900
129504
110897
90356
104776
73574
159303
124298
108271
72235
33351
30163
62316
65030
109848
95871
106984
157208
109433
27594
79618
89721
194085
36909
50967
159055
165479

196235
de
138704
29079
72203
64304
72146
83737
54808
33708
31934
64961
56665
48094
30674
97877
99403
60424
76203
37386
81334
29538
65159
79248
34570
101412
40862
30034

124569
+CAP
135077
51297
88474
112269
45995
14594
47209
144728
49935
123415
114787
163106
99006
104122
145760
131902
117916
43884
139639
137618
73523
115470
38530
214459
55017
72765

163871
+CAP
187302
280194
105230
76422
85766
113291
90004
232008
76414
137916
116268
77831
77608
134224
82976
164104
74697
78977
83753
146374
152046
135891
127681
92144
91692
64158

220

101792
n
133971
65462
147728
147365
68864
72395
101640
96453
174993
271282
221595
83503
145251
99669
72559
202898
51052
58917
112259
140919
163308
67768
69400
52293
74286
119649

133841
+CAP
118480
127431
283770
103548
51402
55713
94243
244560
104571
93475
142366
113373
94037
83792
161527
247658
82664
65763
87005
179148
75257
260961
94462
252478
71411
159244

50020
76361
61373
72042
89546
94135
70875
46285
74820
64908
49964
25266
12030
68275
24230
48315
56293
46775
53149
61754
18804
23564
46598

90653
105447
48421
14139
27184
58249
29039
118411
60569
69129
19395
97511
99651
94682
53849
77480
124595
125449
67036
101836
127051
78954
56597

48369
39814
82143
117174
96452
61675
152249
51630
178335
58091
109739
122864
62501
115067
89403
144868
133432
143229
50177
60733
147230
74873
64963
173794

Untreated

CAP 30s

Pitstop

5516
3581
27847
15965
2647
3198
6305
5788
3919
17942
4457
18099
5395
10992
16843
7621
17892
21501
2455
8796
11688
3500
13317
4841
2679
17626
1669
8186

22261
12306
10762
3480
10667
4966
8758
20948
8903
10360
17401
50518
21642
9222
11587
14788
13311
20808
12197
8593
10932
15539
20754
8846
4831
16624
10846
16627

6083
4177
1746
3011
4032
4808
3805
7747
7417
1322
2229
4509
5231
2962
2971
2567
6843
1608
10176
6170
1970
3286
8646
2766
1331
5692
4185
5613

143926
83297
93936
100813
101386
144732
50729
72558
116879
92915
150147
126267
88480
70907
87317
91462
158029

121836
157275
100709
268448
96458
200374
133156
123251
66756
148409
156027
116189
131616
145548
64925
99657
129320
126041
113392
69885
81771
256252
185763
90235
87308
34485
64651
116152
160153

Integrated Density of AuNPs
Pitstop+CAP
3792
6099
2099
1812
1975
6106
2532
1728
3160
3273
2863
4671
5348
2937
4733
3325
5923
7813
2810
2574
9692
2373
4150
8823
4191
1857
3482
4884

221

167913
103238
117632
56085
122851
244874
172584
93479
99088
156027
139595
127740
188948
247489
129827
129957
108170
113664
224130
249655
112130
137488
246213
99266
88875
121148
215831

78864
21499
87521
32872
86774
108724
99005
91400
162496
59966
83504
79816
70233
54977
20755
87959
113851
9751
195704
205460
71758
60650
102646
104360
72262
62646
106858

82769
145664
103887
96235
107471
73740
138795
109758
97441
55005
122417
96430
105109
82412
137153
62907
62485
139596

CPZ

CPZ+CAP

7990
1863
1486
1434
5801
4778
7212
5556
5631
4089
2949
4297
2607
5111
2967
8772
5787
5110
3289
2880
7444
9698
3923
5399
2188
5285
4443
4856

8366
1957
8966
6266
1452
3468
2421
2566
3101
4259
2871
3558
3562
7809
7133
4191
3747
8074
5436
3060
2601
3402
3123
2857
5444
6896
3207
4577

9202
9836
8877
10929
8565
7736
2356
2851
23594
14115
5866
25137
11108
9864
16203
11111
9532
8395
11415
11279
11099
13153
12553
13217
17633
4742
11052
15608
5281
15270
12153
14067
13005
6557
14369
28194
4478
7769
15100
14411
5912
9159
10064
22400
15100
3145
5178
16426
27029
8473
6730
4345
9773

19013
18567
12700
10548
6980
12991
15723
29901
7900
24781
12827
11509
31897
4429
5919
7653
14639
13590
8222
15100
26498
14704
5136
17050
9468
7312
4848
13345
10442
17738
10179
7909
12894
10555
29626
9385
13564
26029
18355
8849
6822
10362
12428
9474

Filipin

Filipin

14925
13177
6253

+CAP
45932
6400
6224

6779
5571
3958
3951
2132
2702
1284
2677
5960
4984
7586
4864
9875
5750
6359
6231
4619
1388
4931
2072
3939
3847
2878
5958
6171
9188
3643
1471
8934
7551
2156
9601
15586
7303
3134
3070
6450
4504
1676

10185
4395
2648
1977
4485
5126
4665
5481
2430
4714
3752
4573
1779
2711
4560
3132
1628
6677
12145
22026
5527
2204
2964
3948
7410
2197
1465
5365
4764
1713
2552
2816
1916
6227
7636
16947
2184
5572
2971
4198
3081
8244
6451
2825
733

3336
7300
2034
2889
5657
3539
3242
7771
3372

Integrated Density of AuNPs
Genistein
Genistein
MβCD
7861
3124
7004

+CAP
8525
8659
+CAP
17234

222

10364
3826
5294

3296
3899
3728
2222
3424
6041
3298
8405
4964
4473
1527
3776
4807
2822
4205
3023
10408

MβCD

Amilori

Amiloride+C

+CAP
5563
6803
2748

de
4919
6343
8187

AP
12384
8314
5489

4841
17947
4950
5319
11753
8816
3601
4623
14331
3477
10509
6237
7240
7500
3569
3443
17505
11009
14142
12541
10120
6846
7556
8475
15018
24729
6180
8662
16450
9587
11228
11317
5662
16028
9972
9829
13112
14690
14599
3840
8961
7528
5024
10471
4401
9953

21801
15017
6373
9478
17365
10640
12295
5898
6364
26822
18101
15876
13389
33586
10446
12871
6565
10467
5683
14049
17180
7140
13706
14675
18780
9029
9180
7303
17269
5057
14892
11273
3751
6097
7096
14357
5305
4870
6517
6081
10141
14356
10728
4837
12326
11511
8079
20982
9719
6663
16067
9929
26445
13543
13793
12121
13008
7982

8737
12423
6463
6621
9855
9297
15754
2416
8974
26687
13251
3005
3677
1610
21888
16131
12798
10002
20026
4944
8411
17666
7391
9217
14439
10800
10289
4240
5030
5329
4067
27835
21257
5817
5579
19417
1497
5149
6111
9586
8745
9156
14895
10299
10661
3269
3960
6973
11519
6567
3955

11437
6792
11330
12569
29753
5810
9558
10012
12247
4487
11413
24979
26444
20449
11668
9829
22269
7997
21671
4504
10937
14563
14822
19264
39774
12115
9980
10558
10707
7643
18347
10790
9966
10412
11849
11330
7456
10368
8107
12417
16088
18577
25898
16529
9265
13413
7929
9668
10979

223

8912
14276
9686
8051
8871
5919
4132
29822
9759
12254
10175
4763
20656
5935
8371
11152
4376
12687
7365
5930
17596
8740
15900
4593
2451
3554
3791
13315
5436
10356
1700
5436
3554
2462
15179
6384
6338
10377
4391
9562

3850
17048
4090
8453
4153
5268
5229
13267
8702
6550
8515
9959
8809
4552
3501
7595
10268
6862
5081
12182
7779
6003
5778
18306
13608
17698
2271
8238
6113
3952
8427
5052
11620
6685
5245
5810

3139
5059
1863
4450
2650
2781
13092
1360
1107
2166
3635
5746
12468
7872
2171
4149
13666
4572
9826
8787
5460
14653
16330
7051
28750
12822
7980
2636
4535
4568
2574
2969
2219
3242
2159
5537
20414
4421
9412
11953
5431
2471
34529

4808
13403
8839
13091
24387
14911
6714
11432
7042
8005
7039
10338
5008
8225
8509
5992
8063
9861
11328
11552
13135
9408
5093
12713
7968
4766
5260
8735
12229
7559
13070
12427
15870
8116
13472
6946
7951
19438
9825
5042
8533
24524

Supplementary Table S4.
CAP30s Control
540329
317286
366683
118864
389856
260748
255370
143714
254835
241522
173393
437882
301708
283998
529897
132739
325045
256487
225093
459960
242832
102314
274004
319820
144878
313094
215681
426863
169499
449778
207286
600642
191247
175692
167735
195195
195351
131726
328548
212497
453971
318022
335974
135597
226104
136796
168061
530325
310895
156015
118700
122974
133195
267536
200762
299249

CAP 0s
172547
Control
431535
78334
227289
182028
95261
67797
155367
143994
409060
91173
98606
372871
42174
192966
43429
171486
155863
218957
332020
163495
178575
43099
116779
33679
281964
474462
78871
25139
157231
25451
105195
124412
128267
312896
129867
127963
352128
257630
116701
134485
113204
203686
81301
258075
117997
189202
354143
179360
249807
104282
189066
84785
141462
345977
77114

Integrated Density of AuNPs
CAP 0s
71657
Clathrin
Silenced
52885
50113
98205
58882
213664
32246
84077
18060
130518
82556
20741
42321
50000
22797
32307
111229
165385
243576
115717
32769
134059
91085
96918
42816
92220
163157
107430
78092
44965
46103
99071
169342
80229
36048
76657
117916
22666
66817
53062
35270
33485
37665
39651
18179
56467
26238
16544
42583
10222
19974
53493
27174
21953
148609
73347

224

CAP 30s
81386
Clathrin
Silenced
26174
83853
62198
113274
176140
90214
155663
167904
52593
22219
19181
16830
36912
11897
67489
22481
45392
12669
14759
59857
29691
36894
46448
24724
41174
12320
42693
54199
26720
68806
50186
18736
16030
55855
106951
17979
39283
17452
34551
10871
43176
6543
20391
9906
43154
33298
6978
10313
7391
18762
56664
8288
72528
24130
13301

94514
293151
176776

47361
43665
9389
270307
31190
257884
155736
345060
43585
81386
23622
75993
65180
568575
318601
174400
52373
23718
59279
38939
75419
98606
24077
75776
41710
22592
70125
45832
98998
114681
126842
72896
161663

62139
54334
4625
6653
46708
50733
49224
17503
15541
3876

225

18333
20520
17705
38519
28687
15938

7.5 Appendix V Supplementary Information for Chapter 4

Supplementary Figure S1. The average reading of Alamar Blue assay performed within
the plates treated with CAP and Cmpd 6. The control and CAP 30s treated groups
presented in this figure were incubated with just culture medium without compounds for
48 h before Alamar Blue assay, demonstrated that this CAP treatment decreased around
50% of cell viability.

Supplementary Figure S2. The dose response curves of JW-04-061 and JW-04-057a
with or without 30 s CAP treatment have been repeated to further confirm the synergistic
cytotoxicity.
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Supplementary Figure S3. Determine the synergistic cytotoxicity between CAP
treatment and prodrug JW-04-061.
(a) The culture medium was treated with CAP for 30 s and storage overnight. The
U373MG cells were then incubated with prodrug JW-04-61 in overnight storage CAPactivated medium for 48 hours. (b) U373MG cells were treated with CAP and then
incubated in the culture medium that has CAP-treated together for 0-5 h, and then
incubate with fresh medium containing prodrug JW-04-061. (c) The culture medium was
227

supplemented with 0.1 mg/ml catalase and then added into the 96-well plate during CAP
treatment and incubated with U373MG cells for 48 hours.
Supplementary Table S1. Structures of compunds provided by Prof. Andriy Mokhir,
Friedrich Alexander University, Germany (Marzenell et al., 2013).

1e

2a

228

Supplementary Table S2. Structures of compunds provided by Prof. Seth M. Cohen,
University of California San Diego, US (Perez et al., 2015).

1,2PY-2
HOPO-2

1,2PY-2HOPO-2Benzyl
Boronic

PY-2Cmpd1
Boronic

Cmpd2

229

Supplementary Table S3. Structures of compunds provided by Prof. Gérard Jaouen,
Chimie ParisTech, France (Gormen et al., 2010; Görmen et al., 2010).

P5

P581

P686
DP1

P286

P722

DP6

P721

230

P240

P292

P284

P283

P15

P256

P257

P208

P258

P85

231

P53

P388

CG20

P228

P316

232

Supplementary Table S4. Structures of compunds provided by Prof. John Stephens,
Maynooth University, Ireland (Kelada et al., 2018).

JWMK2

04061

JW04MK6
057a

JWMK7

01072

JWMK8

01009

JWMK9

01037
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JW-

JW-

04-

01-

037

033

JW-

JW-

04-

04-

039

017

JW04012

Supplementary Table S5. List of compounds that have been published.
Code

Publication

P5

1. Metal carbonyl tracers and the ferrocifen family: Two facets
of bioorganometallic chemistry

DP1

moiety on the expression of a cytotoxic effect on breast cancer
cells

P286

Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene
and [3] Ferrocenophane Tetrasubstituted Olefin Derivatives
against Human Cancer Cells

DP6

Comparative toxicity of [3] ferrocenophane and ferrocene
moieties on breast cancer cells

P284

P15

P257

Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene
and [3] Ferrocenophane Tetrasubstituted Olefin Derivatives
against Human Cancer Cells
A ferrocenyl derivative of hydroxytamoxifen elicits an estrogen
receptor-independent mechanism of action in breast cancer cell
lines
Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene
and [3] Ferrocenophane Tetrasubstituted Olefin Derivatives
against Human Cancer Cells

234

Source
Prof.
Gérard
Jaouen
Prof.
Gérard
Jaouen
Prof.
Gérard
Jaouen
Prof.
Gérard
Jaouen
Prof.
Gérard
Jaouen
Prof.
Gérard
Jaouen
Prof.
Gérard
Jaouen

P258

P53

CG20

P686

P292

P283

P256

P85

P388

P228

P316
1,2HOPO2
1,2HOPO2Boronic
PY-2
PY-2Benzyl
PY-2Boronic

Prof.
Comparative toxicity of [3] ferrocenophane and ferrocene
Gérard
moieties on breast cancer cells
Jaouen
Prof.
Ferrocifen type anti-cancer drugs
Gérard
Jaouen
Prof.
A new series of ferrocifen derivatives, bearing two aminoalkyl
Gérard
chains, with strong antiproliferative effects on breast cancer cells
Jaouen
Prof.
Phthalimido–ferrocidiphenol
cyclodextrin
complexes:
Gérard
Characterization and anticancer activity
Jaouen
Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene Prof.
and [3] Ferrocenophane Tetrasubstituted Olefin Derivatives Gérard
against Human Cancer Cells
Jaouen
Prof.
A new series of ferrocifen derivatives, bearing two aminoalkyl
Gérard
chains, with strong antiproliferative effects on breast cancer cells
Jaouen
Prof.
Comparative toxicity of [3] ferrocenophane and ferrocene
Gérard
moieties on breast cancer cells
Jaouen
Prof.
Comparative toxicity of [3] ferrocenophane and ferrocene
Gérard
moieties on breast cancer cells
Jaouen
THE FERROCIFEN FAMILY AS POTENT AND SELECTIVE Prof.
ANTITUMOUR COMPOUNDS: MECHANISMS OF Gérard
ACTION
Jaouen
Atypical McMurry Cross-Coupling Reactions Leading to a New Prof.
Series of Potent Antiproliferative Compounds Bearing the Key Gérard
[Ferrocenyl-Ene-Phenol] Motif
Jaouen
Prof.
Comparative toxicity of [3] ferrocenophane and ferrocene
Seth M.
moieties on breast cancer cells
Cohen
Prof.
Emerging Trends in Metalloprotein Inhibition
Seth M.
Cohen
Prof.
Seth M.
Cohen

Emerging Trends in Metalloprotein Inhibition

Prof.
Seth M.
Cohen
Prof.
Emerging Trends in Metalloprotein Inhibition
Seth M.
Cohen
Prof.
Hydrogen Peroxide Activated Matrix Metalloproteinase
Seth M.
Inhibitors: A Prodrug Approach
Cohen
Hydrogen Peroxide Activated
Inhibitors: A Prodrug Approach

235

Matrix

Metalloproteinase

Cmpd1

Cmpd2

1e

2a

MK2

MK6

MK7

MK8

MK9

JW-04037

JW-04039

JW-04061

JW-04057a

Prof.
Exploring hydrogen peroxide responsive thiazolidinone-based
Seth M.
prodrugs
Cohen
Prof.
Exploring hydrogen peroxide responsive thiazolidinone-based
Seth M.
prodrugs
Cohen
Prof.
Aminoferrocene-based prodrugs and their effects on human
Andriy
normal and cancer cells as well as bacterial cells
Mokhir
Prof.
Aminoferrocene-based prodrugs and their effects on human
Andriy
normal and cancer cells as well as bacterial cells
Mokhir
Prof.
Synthesis of pyrazolopyrimidinones using a “one-pot” approach John
under microwave irradiation
Stephen
s
Prof.
Synthesis of pyrazolopyrimidinones using a “one-pot” approach John
under microwave irradiation
Stephen
s
Prof.
Synthesis of pyrazolopyrimidinones using a “one-pot” approach John
under microwave irradiation
Stephen
s
Prof.
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9. List of Employability Skills and Discipline Specific
Skills Training
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Modules

EC
TS

Reasons for choosing

10

This module introduced knowledge
in research methods and especially
statistical analysis of data, which
benefited my research work.

10

This module provided many
knowledges of biological advanced
diagnostic methods, which will be
beneficial for my future research
carrier.

5

This module provided me great
concept
about
knowledge
management and innovation which
benefited for my PhD carrier and
will be useful for my future work.

5

I’m highly interested in molecular
medicine, which wasn’t highly
related with my current project but
can be helpful for research work in
near future.

5

Food science is as important as
medicine, and this module inspired
me a lot with the variety of the hot
topics in food science and
healthcare fields.

5

Research integrity is necessary for
every researcher. By taking this
module, I understood the integrity
better, as a research, and keep it in
my mind all the time to not make
mistake.

BIOL 9223: Research
Discipline
Specific
Modules

Methods and Biostatistics
BIOL 9220: Advanced
Diagnostic Methods and
Bioinformatics
MECH 9002: Innovation
and Knowledge
Management
CRDI Techniques &
Strategies in Molecular

Employabi

Medicine

lity Skills
Modules

AFGDP Hot Topics

GRSO 1012 Research
Integrity
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